The development of model systems to explore mechanisms of chemical stress by Sison, Rowena Louise C
THE DEVELOPMENT OF MODEL SYSTEMS 
TO EXPLORE MECHANISMS OF 
CHEMICAL STRESS
Thesis submitted in accordance with the requirements of the University 
of Liverpool for the degree of Doctor of Philosophy
Rowena Louise C. Sison
DECLARATION
This thesis is the result of my own work. The material contained within this thesis has not 
been presented, nor is currently being presented, either wholly or in part for any other 
degree or qualification.
Rowena Louise C. Sison
This research was carried out in the Department of Molecular and Clinical Pharmacology, 
Institute of Translational Medicine, University of Liverpool
CONTENTS
ABSTRACT.......................................................................................................................................... j
ACKNOWLEDGEMENTS................................................................................................................ iv
PUBLICATIONS................................................................................................................................ ..
ABBREVIATIONS...........................................................................................................vi
CHAPTER 1: General introduction............................................................................. 1
CHAPTER 2: Evaluation of the THLE-2E1 cell line as an in vitro model of chemical
stress.........................................................................................  31
CHAPTER 3: The Nrf2t"/'} mouse model as an in vivo model of chemical stress:
effect of acute and chronic exposure to paracetamol.......................60
CHAPTER 4: Qualification of ophthalmic acid as a potential biomarker of chemical
stress in vitro and /r? vivo................................................................... 106
CHAPTER 5: Investigating the potential of ophthalmic acid as a translatable
biomarker of chemical stress in the clinic........................................ 129
CHAPTER 6: Final discussion................................................................................. 148
APPENDIX ...........................................................................................................................161
BIBLIOGRAPHY..........................................................................................................167
ABSTRACT
Adverse drug reactions (ADRs) continue to be a major public health issue, accounting for a 
high incidence in patient morbidity and mortality. Mechanisms of ADRs are complex, 
therefore drugs often undergo rigorous assessment for their clinical safety, utility and 
efficacy in man. In doing so, model systems are often employed to simulate the body's 
response to a particular drug under a certain condition, such as that of a particular disease, 
for example. However, research in this area is often hampered by the limitations posed by 
model systems that are currently available, resulting in a gap in predicting the drug's 
pharmacotoxicoiogy which determines its use man. To bridge this gap, continued research 
in the development of better model systems is required in order to reduce and manage the 
clinical consequences of ADRs.
In light of the problem that is currently faced in drug safety research, the purpose 
of this PhD project was to identify the development of new model systems for investigating 
the consequences of chemical stress. In particular, this project focussed on investigating the 
suitability of two independent model systems and a potential biomarker for studying drug- 
induced liver injury (DILI), given the role of the liver in drug metabolism. The non- 
tumourigenic human liver epithelial cell line, THLE-2E1, engineered to overexpress the 
cytochrome P-450 2E1 enzyme was investigated because of the role of CYP2E1 in the 
toxicological profiles of a number of clinically relevant compounds, including that of alcohol 
and paracetamol (APAP), as well as its ability to generate oxidative stress through its 
interaction with NADPH-cytochrome P450 reductase (CPR). The second model evaluated 
was the nuclear factor erythroid 2-related factor 2 (Nrf2) null mouse (Nrf2(V')) due to the 
regulatory role of the transcription factor Nrf2 in a wide array of cy to protective genes 
including glutamate cysteine ligase (GCL), the enzyme responsible for the rate limiting step 
in the synthesis of the antioxidant glutathione (GSH). Having been recently reported as a 
potential biomarker of GSH consumption, the GSH analogue, ophthalmic acid was also 
assess for its utility as a translatable biomarker of oxidative stress across in vitro and in vivo 
systems, and in man.
The THLE-2E1 cells along with the THLE-Null which contains an empty vector were 
characterised for morphological difference, CYP2E1 protein content and activity as well as 
for toxicity in response to paracetamol treatment. These experiments demonstrated no 
morphological difference but a slower growth rate (42 h) in the THLE-2E1 compared with 
the THLE-Null cells (29 h). CYP2E1 overexpression and activity (0.67 nmol/mg/protein) were 
only observed in the THLE-2E1 cell line. Furthermore, GSH content was observed to be 
higher in the THLE-2E1 (74.89, 50.62 and 37.91 nmol/mg/protein at 24, 48 and 72 h 
respectively) compared with the THLE-Null (41.98, 35.17 and 29.74 nmol/mg protein at 24, 
48 and 72 h respectively), suggesting an up-regulation of cell defence in these cells. 
Interestingly, treatment with paracetamol did not demonstrate a difference in toxicity 
between the THLE-2E1 and THLE-Null cells, despite the CYP2E1 activity observed in the 
THLE-2E1 with the substrates chlorzoxazone (CHZ) and APAP, which was distinctly absent in 
the THLE-Null. Both the high GSH level and absence of CYP2El-mediated toxicity in the
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THLE-2E1 cells suggests an up-regulation of cellular defence as a consequence of high 
oxidative stress in these cells generated by the interaction between CYP2E1 and CPR. As 
well as insufficient CYP2E1 activity, despite overexpression and CYP2E1 activity measured in 
the THLE-2E1 cells compared with the THLE-Null, demonstrated a similar toxicity profile to 
the THLE-Null cells. The THLE-2E1 cell line is therefore a potentially useful model of 
oxidative stress, and to some extent in CYP2El-mediated metabolism studies, however, this 
cell line is not suitable for toxicity based investigations.
Nrf2(+/+) and Nrf2('A) animals were treated with either an acute dose (350 mg/kg) 
across a 5 h time point, an escalating chronic dose (0 - 600 mg/kg) for 8 days or an 
escalating chronic dose (0 - 600 mg/kg; 8 days) with a further toxic dose challenge (1000 
mg/kg; day 9) of paracetamol to determine the role of Nrf2 in the regulation of the GSH 
system, which comprises the GSH synthetic pathway and several other metabolic pathways 
that are closely linked to GSH synthesis. Under the three dosing regimens with 
paracetamol, the Nrf2('A) mice were highly susceptible to paracetamol-induced toxicity as 
demonstrated by a marked increase in serum alanine transaminase (ALT) activity as well as 
fatalities in the Nrf2*'A) group that were chronically-treated and subsequently challenged 
with a toxic dose of paracetamol. However, this enhanced susceptibility in the Nrf2('A) to 
toxicity was only observed upon reaching a certain threshold of stress as demonstrated in 
the acute study where a progressive increase in serum ALT was observed at 5 h whilst levels 
remained the same in the Nrf2(+/+), suggesting the abrogated ability of the Nrf2('A) to up- 
regulate cellular defence. This was further demonstrated by the delay in GSH recovery in 
the Nrf2('A) animals compared with the Nrf2(+/+) under all three dosing regimens. 
Autoprotection against a toxic dose of paracetamol was demonstrated in the Nrf2(+/+) with 
lower levels of serum ALT compared with animals that only received the toxic dose. This 
was also demonstrated in the equivalent Nrf2('A) animals but to a lesser extent as more 
fatalities occurred in this group compared with the wild type. No significant differences 
were observed in the metabolites measured in the GSH system between the Nrf2(+/+) and 
Nrf2('A1 mice. However, a delay in the synthesis of GSH and its analogue, ophthalmic acid 
(OA), both of which share the same synthetic enzymes, glutamate cysteine ligase (GCL) and 
glutathione synthetase (GS), and which are both under Nrf2 regulation was observed, 
therefore providing further support in the abrogated ability of the Nrf2('A) mice to up- 
regulate cellular defence in response to chemical stress. This piece of work demonstrates 
that the Nrf2('A) mouse is a useful model of chemical stress as Nrf2 is clearly an important 
determinant in cytoprotection against chemical stress. However, the similarities in response 
observed between the two strains also suggest that other mechanisms are involved 
particularly in the acquirement of autoprotection against a toxic APAP dose. Due to the role 
of Nrf2 in cellular defence, work carried out here have focused on cytoprotection against 
chemical stress, however, other changes in metabolic activity should also be investigated in 
these animals as they are responsible for the production of chemical stress in the first 
instance.
Mouse and rat treated with APAP and diethyl maleate (DEM) respectively were 
measured for liver and/or serum ophthalmic acid, GSH and ALT levels to determine if OA is 
a direct biomarker of GSH consumption. The mouse hepatoma cell line Hepalclc as well as 
the human THLE-Null and THLE-2E1 cells were treated with either DEM, the APAP reactive
metabolite, N-acetyl-p-benzoquinoneimine (NAPQI) or paracetamol, and were also 
measured for cellular GSH and OA levels to determine the translatability of OA as an 
oxidative stress biomarker across in vitro and in vivo systems using a variety of GSH 
modulators. This was further explored in man where basal OA in human serum was also 
assessed. A significant increase in liver and serum OA over time in response to APAP was 
observed in the APAP-treated mice but was not concurrent with GSH depletion. 
Furthermore, although a statistically significant depletion in GSH was observed in rats 
treated with DEM, no corresponding increase in hepatic or serum OA was observed. None 
of the experiments carried out in vitro demonstrated a correlation between GSH depletion 
and ophthalmic acid increase, suggesting that OA is not a direct marker of GSH depletion. 
However, where an increase in ALT was observed in any of these experiments, OA levels 
were also consistently elevated, suggesting that OA may be a general marker of chemical- 
induced toxicity. The ability to detect and quantify extremely low levels of basal OA in 
human serum was demonstrated, and was observed to exhibit both intra- and inter­
individual variation, similar to that observed with ALT. Ophthalmic acid is not a direct 
biomarker of GSH consumption but its potential as a general marker of toxicity should be 
further explored. The ability to detect and quantify basal OA in human serum are important 
attributes of a biomarker, particularly in man, therefore the role of OA in chemical stress 
should be further investigated as OA may have the potential as a marker of chemical stress 
in man.
To conclude, the models investigated in this project have the potential as models 
for use in the preclinical evaluation of chemical stress. However, none provides all the 
attributes needed to address all toxicological issues. As such, this reiterates the difficulty in 
the development of better model systems, therefore continued research in this area should 
be encouraged.
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Chapter 1
1.1 INTRODUCTION
Adverse drug reactions (ADRs) are major contributors to the high incidence of patient 
morbidity and mortality (Park et ai, 2005a, Pirmohamed et afw 2004), and as a 
consequence, numerous drugs have been withdrawn either at the development or post 
marketing stage (Jefferys et ai, 1998). Drug-induced liver injury (DILI) in particular, is the 
most prevalent type of ADR due to the role of the liver in drug metabolism (Park et al., 
1995). Indeed, APAP-induced liver injury accounts for a significant proportion of acute liver 
failure (ALF) in the US (Lee, 2004, Larson etal., 2005) and in Europe (Davern etal., 2006). As 
such, significant effort has been made by various groups to fully elucidate the mechanism(s) 
of ADRs. Information obtained so far from these investigations has in turn been utilised for 
the design and development of better drugs through:
• Continued improvement and development of model systems to gain a better insight 
into the toxicological nature of xenobiotics and the role of metabolism and 
transporters, as well as the protective mechanisms adopted by various species to 
combat against such insults.
• The identification of biomarkers that could be utilised both in research and in the clinic 
to predict or even prevent the onset of ADRs.
• The identification of structural chemical alerts that have the potential to cause ADRs.
The constant exposure of cells to stress of varying origin has led to the evolution of 
a multi-faceted system of cytoprotection within the cell, levels of which can be regulated 
depending on the gravity of stress present. Cell defence has therefore evolved into a set of 
highly intricate and tightly regulated response mechanisms against cellular stress of varying 
magnitude. One such mechanism involves the transcription factor Nrf2, which is involved in 
the transcriptional up-regulation of a variety of cy to protective genes including glutamate 
cysteine ligase (GCL), the enzyme responsible for the rate limiting step in the synthesis of 
the antioxidant glutathione (GSH), when cellular stress is elevated as a consequence of 
xenobiotic-induced injury for example.
The knowledge obtained from mechanistic investigations on ADRs can therefore be 
highly valuable in developing model systems such as the identification of novel biomarkers 
that could be used for the design and development of safer drugs amongst other 
applications, offering great benefit to both the public and pharmaceutical industry. The 
continuous development and improvement of model systems should therefore be
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encouraged as it is an important aspect in understanding the cause of APRS and in the 
design and development of safer drugs.
The focus of this thesis is on the development of novel experimental models in 
which to investigate the mechanistic basis of DILI and the adaptive response to chemical 
stress, and the use of such model systems in the pursuit of more sensitive and earlier 
biomarkers of chemical stress.
1.2 ADVERSE DRUG REACTIONS
Adverse drug reactions, as defined by Edwards and Aronson (2000), are 'an appreciably 
harmful or unpleasant reaction, resulting from an intervention related to the use of a 
medicinal product, which predicts hazard from future administration and warrants 
prevention or specific treatment, or alteration of the dosage regimen, or withdrawal of the 
product.' In the US, a total of 249, 633 suspected ADRs, based on administrative data, were 
reported for both ambulatory care and hospitalised patients between 2002 and 2005 
(Kane-Gill et al.r 2010). Analysis of these data revealed antineoplastic and anticoagulant 
agents to be the highest risk, followed by antihypertensives, antiarteriosclerotic and 
antirheumatic agents, being the more common cause of ADRs. ADRs have also proven a 
costly impediment in drug development and even in the success of those already approved 
for public administration (Smith and Schmid, 2006). As such, a collaborative effort from 
drug and health-based organisations of both public and private sectors must therefore be 
pre-requisites, if the ongoing problem posed by ADRs is to be successfully managed and 
eventually solved.
Due to the complex nature of ADRs, stringent classification of these reactions is not 
possible, however, for the sake of general reference, they have been grouped into six main 
categories as summarised in Table 1.1 (Edwards and Aronson, 2000, Park et aL, 2000). 
Alternatively, ADRs are also regarded as either 'on target' or 'off target' reactions. 'On 
target' adverse reactions refer to those that could be predicted from the known 
pharmacology of the drug and in most cases, are resolved with the adjustment of drug 
dosage. 'Off target' adverse reactions on the other hand, are unpredictable and although 
occur less frequently, may be life threatening in their severity. One factor that is currently 
under investigation is differences in inter-individual susceptibility to ADRS as a consequence
4
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of our unique individual genetic make-up (Park et ai, 2005a, Wijnen et al., 2007, van 
Schaik, 2008, Pirmohamed, 2010). In particular, polymorphisms in both phase I and phase II 
metabolising enzymes such as the cytochrome P450 (CYP450) and UDP-
glucuronosyitransferase (UGT) enzyme families have been well documented as important 
influencing factors in our susceptibility to ADRs (Guillemette, 2003, Carlini et al., 2005, 
Bauman et al., 2006, Falzoi et al., 2010, Tohkin et al., 2010).
Table 1.1. Classification of adverse drug reactions. Adapted from Park et al., 2005a and 
Edwards and Aronson, 2000.
Reaction type Description Examples
A (augmented) Predictable from the known 
pharmacology of the drug. It is 
commonly observed but with a 
low mortality rate.
Digoxin toxicity; serotonin 
syndrome with serotonin- 
selective reuptake inhibitors 
(SSRIs).
B (bizarre) Unpredictable from the known 
pharmacology of the drug 
(idiosyncratic). It is less common 
but proves to be serious and fatal.
Penicillin hypersensitivity; 
malignant hyperthermia 
(exposure to general 
anaesthesia); pseudoallergy 
(ampiciilin rash).
C (chemical) Their biological activities can often 
be predicted or rationalised from 
their chemical structure.
APAP toxicity.
D (delayed) Adverse effects are not apparent 
until after a certain period of drug 
use.
Carcinogenicity, teratogenicity.
E (end of 
treatment)
Occurs upon the withdrawal of a 
drug either at the end or as an 
abrupt termination of a treatment 
plan.
Withdrawal of phenytoin and 
paroxetine; opiate withdrawal 
syndrome; myocardial ischaemia 
((3-blocker withdrawal).
F (failure) Dose-related and often caused by 
drug interactions.
Inadequate dosage of a 
contraceptive particularly when 
used with specific enzyme 
inducers.
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1.3 THE LIVER
AN drugs have the potential to cause toxicity (Halegoua-De Marzio and Navarro, 2008). The 
liver, rich in metabolising enzymes, is the main organ where biotransformation and 
subsequent detoxification of xenobiotics including drugs take place. As such, the liver is 
constantly exposed to high levels of parent drugs and metabolites (chemically stable and/or 
reactive) produced during drug bioactivation. As a consequence, the liver is a primary 
target for drug-induced toxicity. Indeed, DILI is the most common ADR, resulting as a major 
burden in patient health (Kaplowitz, 2005, Davern et al., 2006) and a costly obstacle in the 
pharmaceutical industry (Park et al., 2005b, Antoine et al., 2008). As such, the liver is an 
important focal point in the study of ADRs.
1.4 DRUG METABOLISM
Essentially, the role of drug metabolism is to eliminate drugs from the body. This is 
achieved through the conversion of non-polar, lipophilic compounds to polar, hydrophilic 
entities, via enzymatically-driven reactions, reducing their ability to penetrate tissues and 
renal tubular reabsorption. Drug metabolism is more commonly divided into two distinct, 
often sequential phases, phase I and phase II as summarised in Table 1.2. However, a more 
recent category referred to as phase III, which is concerned with the transport of parent 
drugs and their respective metabolites across cell membranes has been included and is also 
summarised in Table 1.2.
6
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Table 1.2 Phases I, II and III of drug metabolism.
Phase I Phase II Phase III
Function(s) Addition of functional Addition of Provide barrier
groups for phase II endogenous molecules against drug
reactions. (glucuronic acid, GSH, penetration. Key
Activating sulphate, amino acid player in drug
intermediary process and acetate) to absorption.
employed by increase the distribution and
prodrugs. hydrophilicity of 
drugs/metabolites.
excretion.
Reaction(s) Oxidation, reduction Sulfation, ATP-dependent
and hydration. glucuronidation, 
acetylation and GSH 
conjugations.
substrate transport. 
Sodium- and ATP- 
independent 
transport.
Key Cytochrome P450 Sulfotransferase P-glycoprotein (P-gp)
proteins (CYP) microsomal (SUIT), UGTs, GSTs and Multidrug resistance-
enzymes. N-acetyltransferases associated protein
IMAD(P)H:quinone
oxidoreductases
(NQOl), Epoxide
hydrolases (EPH),
Flavin-containing
monooxygenase
(FMO),
cyclooxygenase (COX), 
monoamine oxidases 
(MAO) and 
hydrolases.
(NAT). (MRP)
Organic anion 
transporting 
polypeptide 2 
(OATP2).
Despite the intended benefit of drug metabolism to the body, accumulation of the 
parent drug and/or highly reactive species (reactive oxygen species (ROS) and electrophiles) 
produced as a consequence of drug bioactivation can sometimes overwhelm the cell's 
defence system, after a drug overdose for instance (unintended or not), or due to inter­
individual pharmacogenetic susceptibility to a drug (Tohkin et al.t 2010). Such a situation 
could lead to unmanageable levels of ROS and electrophiles increasing the potential for 
protein adduct formation and oxidation. This in turn may result in the accumulation of 
protein damage, cell death, organ toxicity and even death (Figure 1.1).
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DRUG
Phase I/ll metabolism 
Phase III transport
Phase III transport
Cellular accumulation
Phase I metabolism
Stable Reactive
metabolites metabolites
Quinone
Quinoneimine
Epoxide
Hydroxylamine
Furan
Thiophene
Nucleic acids 
Protein —
Elimination *— Detoxification
Figure 1.1 The role of drug metabolism in adverse drug reactions. Under normal circumstances, 
drugs undergo phases I, II and III metabolism, all of which aim to convert lipophilic molecules into 
more hydrophilic entities facilitating their safe elimination from the body. Drug metabolism often 
involves drug bioactivation which results in the production of reactive metabolites, which are 
normally deactivated through conjugation with GSH. However, when levels of these reactive species 
surpass the cell's ability to detoxify them at a sufficient rate, macromolecules become at risk of 
becoming targets for covalent binding and oxidation, damages which if unrepaired and accumulate, 
could lead to toxicity. Adapted from (Park et al., 2000, Copple et a!., 2008b).
1.5 DRUG-INDUCED LIVER INJURY
Drug-induced liver injury is a rare event with its true incidence still remaining 
undetermined, however, its clinical importance as the most prevalent cause of acute liver 
failure signifies its relevance as an important safety issue in public health (Ostapowicz et al., 
2002). Furthermore, DILI has led to the withdrawal of 800 drugs to date, a major burden 
which carries great cost to the pharmaceutical industry (Antoine etai, 2008).
DILI is regarded as either predictable or idiosyncratic (Pachkoria et al., 2007), 
although the majority manifest as the latter, attributing to 13 - 17 % of acute liver failure 
(Bjornsson and Olsson, 2005). Idiosyncratic DILI may also have a dose-dependent 
component and often occurs after a latent period of up to one year (Lee, 2003, Abboud and 
Kaplowitz, 2007), reiterating the unpredictability of this disease. Whilst statin-induced DILI 
are often resolved and have been rarely associated to cause idiosyncratic DILI, antibiotics 
and NSAIDS are the most common causative drugs along with antiretroviral therapy which 
is reported to cause DILI in 10 % of patients under therapy (Blinkova et al., 2007). APAP is a
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classic example of predictable DILI (section 1.5.1), where its toxicity is induced in a dose- 
dependent manner, usually after an overdose (Laine et a!., 2009). Susceptibility to the 
development of DILI encompasses a combination of both environmental and intrinsic 
factors including age, sex, genetic polymorphisms in metabolising enzymes and pre-existing 
liver disease as summarised in Table 1.3.
Table 1.3 A summary of factors that influence the susceptibility of an individual to 
develop DILI.
Factor Example
Age Co-amoxiclav and isoniazid hepatotoxicities are more common in older 
individuals whilst sodium valporate and erythromycin hepatotoxicities 
are more prevalent in young people (Maddrey, 2005).
Sex Female patients accounted for 76 % of liver transplant recipients for 
the treatment of drug-induced acute liver failure between 1990 and
2002 (Morgan etal., 1984, Ostapowicz etal., 2002, Russo etal., 2004). 
Sex hormones and pro-inflammatory cytokines can alter liver 
metabolism which influences the susceptibility between gender to 
acute DILI (Flynn and Ferguson, 2010).
Genetic
polymorphism
CYP2D6 deficiency has been reported to be the cause of perhexiline 
hepatotoxicity (Morgan et al., 1984, Alvan et al., 1990). Variants within 
the HLA complex have been associated with flucoxaciilin-induced (Daly 
et al., 2009), lumiracoxib-induced (Singer et al., 2010) and 
ximelagatran-induced (Kindmark etal., 2008) liver injuries.
Disease Pre-existing liver disease increases the susceptibility of HIV and 
tuberculosis (TB) patients co-infected with hepatitis B or C to the 
development of DILI (Kontorinis and Dieterich, 2003, Sulkowski, 2003, 
Sulkowski, 2008).
DILI can either lead to hepatocellular, cholestatic or mixed liver injury. 
Hepatocellular injury is characterised by marked elevations in alanine-aminotransaminase 
(ALT) and aspartate-aminotransaminase (AST) enzymes, both of which are highly abundant 
in the liver and are therefore believed to be hepatic leakage products during liver injury 
(Boyd, 1983, Sherman, 1991, Dufour et al., 2000a, Dufour et ah, 2000b). Other markers of 
liver injury are also observed including increases in total plasma bilirubin and alkaline 
phosphatase (ALP), although for hepatocellular-specific injury, they are preceded by ALT
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and AST elevations in the serum. Cholestatic injury on the other hand is characterised by 
the opposite, with a significant rise in ALP preceding elevations in both ALT and AST 
(Halegoua-De Marzio and Navarro, 2008). Mixed DILI represents cases that show 
characteristics of the former two. Although rare, DILI can also manifest as immune- 
mediated and is characterised by fever, rash, eosinophilia, auto antibodies and antihapten 
antibodies. Another rare DILI that leads to mitochondrial injury is characterised by 
significant levels of lactic acid and microvesicular steatosis in liver biopsies.
1.5.1 APAP hepatotoxicity
APAP is a clinically relevant model of DILI (Ostapowicz et al., 2002). It is tolerated at 
therapeutic doses but is often fatal when taken at an overdose. APAP is primarily 
metabolised through conjugation reactions with SULT and UGT enzymes. However, a small 
proportion can also undergo CYP450-mediated oxidation, in particular, by CYP2E1, CYP1A2 
and CYP3A4 isoforms, to the reactive intermediate, N-acetyl-p-benzo-quinoneimmine 
NAPQI (Raucy etal., 1989). At therapeutic doses, NAPQI can be deactivated by conjugation 
with the antioxidant GSH via the activity of glutathione^-transferases (GSTs). However, 
when I eve ispf.N A PQI oyerwhe I m s the rate of detoxification resulting in the depletion of 
GSH store, NAPQI becomes free toj^ind to cellular nucleophiles causing cell damage and 
even cell death (Jollow et al., 1973, Mitchell et al., 1973a, Mitchell et al., 1973b, Potter et 
al., 1973, Dahlin et al., 1984, Lee etal., 1996). The production of NAPQI combined with the 
inability of the cell to sufficiently deactivate overwhelming levels of this reactive 
intermediate, during an overdose for example, are two main determinants of APAP-induced 
toxicity. Indeed, reports of APAP toxicity have been made from a therapeutic dose (Moling 
et al., 2006, Dart and Bailey, 2007), however, this is often in conjunction with other 
underlying conditions which predisposes an individual to APAP toxicity, including chronic 
alcohol consumption (Whitcomb and Block, 1994, Prescott, 2000, Schmidt et al., 2002, 
Krahenbuhl etal., 2007) and malnutrition (Whitcomb and Block, 1994).
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Figure 1.2 The metabolic fate of APAP. APAP (paracetamol) is primarily metabolised by 
sulfotransferases (SULTs) and UDP-glucuronosyl transferases (UGTs) and subsequently excreted in 
the urine. A small proportion can also undergo phase I metabolism via CYP2E1, CYP1A2 or CYP3A4 
oxidation into the reactive intermediate N-acetyl-p-benzo-quinoneimine (NAPQI), which can be 
deactivated through GSH conjugation mediated by glutathione-S-tranferases (GST), forming a 
mercapturate which is also excreted in the urine. However, bioactivation of high levels of APAP to 
NAPQI, during an overdose for instance, may overwhelm cellular defence, resulting in the depletion 
of GSH therefore allowing NAPQI to bind to macromolecules causing cell damage and cell death.
1.6 CELLULAR DEFENCE
To protect against the constant exposure to hazardous, potentially toxic molecules from 
both endogenous and exogenous origin, the liver has evolved a multi-layered defence 
system that is designed to combat cellular stress in a variety of situations as detailed in 
sections 1.6.1 - 1.6.3 and summarised in Figure 1.4. However, although such defence 
system exists, an overwhelming increase in cellular stress as a consequence of exposure to 
high levels of drugs for example may lead to insufficiency in the safe clearance of drugs as 
described in section 1.5.1, disrupting the balance between cellular stress and defence 
(Figure 1.3). Reactive species that could not be deactivated are therefore free to cause 
cellular damage through protein covalent binding and oxidation potentially resulting in 
toxicity.
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Figure 1.3 The disruption of balance between cellular stress and cell defence as a consequence of 
significant elevations in cellular stress.
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Figure 1.4 Classification of cellular defence. The level of cellular defence is determined according to 
the severity of cellular stress present. Stage I refers to basal cytoprotection against intrinsic, low 
levels of oxidative stress. Transcriptional up-regulation of antioxidants and detoxifying enzymes 
constitutes stage II and is induced upon a considerable increase in cellular stress, often as a result of 
a combination of internal and external factors (such aas genetic polymorphism and smoking 
respectively for example). The transcription factor Nrf2 plays an important role in the transcriptional 
up-regulation of cell defence genes both at stages I and II as detailed further in section 1.6.2.1. Stage 
III involves cell death which can be classified into four stages, apoptosis, oncotic necrosis, necrosis 
and autophagy. For a more detailed description of each of these cell death mechanisms, please refer 
to (Edinger and Thompson, 2004, Duprez et a!., 2009, Malhi et a!., 2010). The cell enters stage III 
when the extent of cell damage is so great that the sacrificial death of one or a small population of 
cells proves the best strategy in keeping the integrity of neighbouring cells and the organism as a 
whole. Adapted from (Net et a!., 2006).
1.6.1 Stage I: Basal antioxidants and detoxifying enzymes
Reactive oxygen species (ROS), although potentially toxic, are inherently produced through 
various aerobic metabolic reactions in the cell (Yu, 1994). Furthermore, ROS are now 
becoming more accepted to have an essential role in a variety of normal cell functions 
including intracellular signalling, regulation of transcription factor activities, gene 
expression and redox status (Palmer eta!., 1987, Furchgott, 1995, Sundaresan eta!., 1995, 
Finkel, 1998, Kamata and Hirata, 1999, Rhee, 1999, Patel et o/., 2000, Bogdan, 2001). 
However, they can also readily react with macromolecules including DNA (Mates et a!., 
1999, Marnett, 2000), lipids (Halliwell, 1993, Steinberg, 1997, Frei, 1999, Yla-Herttuala, 
1999) and proteins (Butterfield et al., 1998, Stadtman and Berlett, 1998) that may lead to 
cellular damage and eventually cell death. As such, ROS levels are tightly regulated by 
closely coupling their utility in various cellular processes with their detoxification to prevent
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uncontrollable levels to escalate. Protective antioxidant mechanisms have therefore 
evolved to combat against basal oxidative stress and are grouped into non-protein and 
protein molecules.
1.6.1.1 Non-protein antioxidants
Non-protein antioxidants deactivate both ROS and electrophiles in a sacrificial manner by 
donating an electron to radical species, thus deactivating the reactive nature of such 
species. Such antioxidants include ascorbic acid {Sies etai, 1992, Buettner, 1993, Meister, 
1995), a-tocopherol (Chopra and Thurnham, 1999, Yla-Herttuala, 1999), p-carotene and 
bilirubin (Yu, 1994).
1.6.1.2 Glutathione
Glutathione (GSH) is a non-protein thiol that is ubiquitously found in mammalian cells with 
a particular abundance in hepatocytes (5 - 10 mM). It is a tripeptide (y-glutamyl-cysteinyl 
glycine) that is synthesised in a two step process (Figure 1.5). The first step, which involves 
the conjugation, oi-giut.amate and cysteine, catalysed by glutamate-cysteine ligase (GCL) to 
fonTLy-glutamyl cysteine (y-GC), is also the,iale-limitjng step of this pathway. Subsequent 
(PonJ4§^^Qj9Ly^^^SLi!yciggj^rough the catalytic activity of glutathione synthetase 
(GS) completes the synthesis of GSH (Bloch and Anker, 1947, Meister and Anderson, 1983).
Under physiological conditions, its principal role is to maintain the cell's redox 
status by undergoing thiol-disulfide exchange reactions catalysed by thiol-transferases 
(Carlberg and Mannervik, 1985). This reversible reaction allows oin equilibrium to be 
reached, so that the oxidised form, GSSG, is kept to a minimum, with levelsjriajntained to 
approximately 1 % of its reduced (G.SH) counterpart. GSH plays an important role in cellular 
defence in that ROS produced either from normal aerobic metabolism or chemical stress, as 
well as electrophiles, are deactivated by GSH directly or through enzymatic reactions 
catalysed by various detoxifying enzymes including glutathione sulfotransferases and 
peroxidises (Awasthi et al., 1975, Sies et al.t 1997). The resulting GSH conjugates are either 
exported from the cell into bile or blood where they may undergo subsequent cleavage of 
the y-glutamyl moiety by y-glutamyl transpeptidases (GGT) and the cysteinyl-glycine bond 
by dipeptidases. The resulting cysteinyl conjugate undergoes N-acetylation and forms a
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mercapturate that is excreted in the urine (DeLeve and Kaplowitz, 1991). In addition, GSH is 
also implicated in other cellular activities including DNA and protein syntheses, enzyme 
activity, transport, cell proliferation and as a store of the highly important amino acid, 
cysteine (Cho et al., 1981, Meister and Anderson, 1983, Wu et al., 2004, Townsend, 2007).
As a consequence of its multiple roles, maintenance of GSH levels is crucial for the 
survival of the cell both physiologically and during cellular stress. As such, various
mechanisms have been employed by the celt for . regulating the.GSH pooj. One such
mechanism is the rate-limiting step in GSH synthesis where GCL activity is up-regulated 
when cellular GSH is severely depleted. Conversely, high levels of cellular GSH negatively 
regulate GCL activity thereby preventing further GSH synthesis (Richman and Meister, 1975, 
Griffith and Meister, 1979, Maede et al., 1982, Reed and Fariss, 1984, Russo et al., 1986, 
Tsutsui et al., 1986, Furukawa et al., 1987, Coursin and Cihla, 1988, Meister, 1988, Sun et 
al., 1988). GCL is a heterodimer that is made up of the subunits, glutamate cysteine ligase 
catalytic (GCLC) and glutamate cysteine ligase modulator (GCLM). GCLC is responsible for 
the enzyme s catalytic activity (binds the substrates) whilst GCLM is involved in regulating 
this catalytic activity (enhances the binding activity by lowering the Km for glutamate and 
increasing the Ki to GSH feedback inhibition) (Meister, 1983, Griffith, 1999, Yang et al., 
2007). The interaction of these two subunits is therefore an influencing factor on the 
activity of GCL, hence GSH synthesis (Meister and Anderson, 1983, Griffith, 1999, Yang et 
al., 2007). Another factor that influences the synthesis of GSH is the availability of its 
precursors. Although GSH is made up of the three amino acids, cysteine, glutamate and 
glycine, its role in cellular defence heavily relies on the thiol group of cysteine (Liu et al., 
1996, Griffith, 1999, Griffith and Mulcahy, 1999). As such, the availability of cysteine is 
essential for the synthesis of a fully functioning GSH.
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Figure 1.5 The glutathione biosynthetic pathway.
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1.6.1.3 The glutathione system
Due to the multi-functional role of GSH in various cellular processes including cell defence, 
its synthetic pathway is closely linked to several metabolic pathways, some of which are 
important sources of precursors required for GSH synthesis. Perturbations in these 
pathways may therefore significantly affect mechanisms by which GSH levels are regulated. 
Metabolic pathways that are directly linked to the GSH biosynthetic pathway are 
summarised in Figure 1.6 and individually illustrated and described in Appendices 1-4. 
Ophthalmic acid biosynthesis is introduced in more detail in section 1.6.1.4 and illustrated 
in Figure 1.7.
Spermidine Spermine
Methionine
adenosyl
transferase
S-adenosyl-
homocysteine Serine ThreonineMethionine
Adenosyl
homocysteinase
Homocysteine
Cystathionine
p-synthase
a-aminobutyrate-pyruvate
aminotransferase
2-Ketobutyrate ^y"Cystathionine
Glu imate
Cysteine
GlutamateCystine/glutamate
antiporter
Cysteine
sulfinate
y-Glutamyl cysteine y-Glutamylaminobutyrate
GSH
synthetase
Glycine
Hypotaurine GSSGGlutathione Ophthalmate
Taurine
Glutathione (conjugate)
Figure 1.6 The GSH system. A schematic diagram describing the relationship between the GSH 
synthetic pathway with other closely related metabolic pathways including ophthalmic acid, 
methionine, transsulfuration, taurine and polyamine pathways as well as the cystine/glutamate 
transport. Labels in blue box represent enzymes responsible for the catalysis of the reaction in which 
they are labelled in the system. For a more detailed description of each pathway, refer to 
Appendices 1-4. Labels including GSH, GSSG and GCL are abbreviations used for glutathione, 
oxidised glutathione and glutamate cysteine ligase respectively.
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1.6.1.4 Ophthalmic acid pathway
The functional role of ophthalmic acid is poorly defined. As an analogue of GSH, its use in 
research has predominantly been for determining the significance of the thiol group within 
the cysteine moiety of GSH (absent in ophthalmic acid) in the vast number of cellular 
processes that GSH is involved in. Coincidentally, it is also through these studies that 
potential roles of ophthalmic acid have been proposed. Such roles include its use as an anti­
coenzyme that prevents the use of GSH as a co-factor by various detoxifying enzymes 
(Waley, 1953), a competitive inhibitor for the extracellular transport of GSH (Ballatori and 
Dutczak, 1994) and as a facilitator for the MRPl-mediated transport of glucuronide 
conjugates (Leslie et al.f 2001, Leslie et a/., 2003). Alt these functions, although requiring 
further investigation suggest that ophthalmic acid may act as a surrogate molecule for GSH 
during cellular stress where intracellular conservation of GSH may become an increasing 
priority. In a recent study where changes in the hepatic metabolome of mice treated with 
APAP were investigated, the level of ophthalmic acid was observed to increase during 
which GSH and cysteine were significantly decreased. It was therefore proposed that the 
decrease in cysteine which complemented the decrease in GSH may have triggered the 
increase in ophthalmic acid (Soga et al, 2006) as a consequence of sharing the same 
synthetic machinery (Figure 1.8).
Ophthalmic acid is a tripeptide consisting of 2-aminobutyrate, glutamate and 
glycine. Its synthesis starts with the conjugation of 2-aminobutyrate and glutamate to form 
y-gl uta my l-2-a mi nobutyrate (y-Glu-2AB) via the catalytic activity of GCL This is then 
followed by the conjugation between y-Glu-2AB and glycine to form ophthalmic acid, 
catalysed by GS (Figure 1.7) (Cliffe and Waley, 1958, Cliffe and Waley, 1961). As GSH and 
ophthalmic acid share the same enzyme for their synthesis (Figure 1.8), it has been 
suggested that levels in precursors, in particular cysteine, may influence the activities of 
these enzymes, which are either catalysing the synthesis of GSH, or ophthalmic acid. 
Through enzyme kinetic studies, GCL has been reported to have a greater affinity for 
cysteine than 2-AB suggesting that the GSH pathway is unsurprisingly, considering its 
multiple cellular functions, the more dominant pathway (Seelig and Meister, 1985). 
However, when cysteine levels are low, during oxidative stress for example, GCL activity 
may switch to the ophthalmic acid pathway. As such, ophthalmic acid has been proposed to 
be a potential biomarker of oxidative stress (Soga et al., 2006).
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Figure 1.7 Ophthalmic acid synthetic pathway.
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Figure 1.8 Similarities and differences between GSH and ophthalmic acid biosynthesis. GSH and
ophthalmic acid use the same biosynthetic machinery for their synthesis, including the enzymes GCL 
and GS as well as the substrates glutamate and glycine. However, GSH and ophthalmic acid differ in 
in that in addition to glutamate and glycine, GSH synthesis also requires cysteine but in its place, 2- 
aminobutyrate is used during ophthalmic acid synthesis.
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1.6.1.5 Detoxifying enzymes
In addition to non-protein antioxidants, phase I defence system also constitutes a number 
of enzymes that catalyse the deactivation of a variety of reactive species as summarised in 
Table 1.4.
Table 1.4 A summary of detoxifying enzymes and their respective activities in 
deactivating reactive species.
Enzyme Function
Superoxide
dismutase
Catalyses the formation of H2O2 from two molecules of superoxide 
(02"). Particularly important in the detoxification of high levels of 02'' in 
the mitochondria during respiration.
Catalase Catalyses the dismutation of H2O2 to water and 02 using substrates such 
as phenols and alcohols.
Peroxiredoxin
(Prx)
Directly reduces peroxides {H2O2 and lipid peroxides) and peroxynitrite. 
The active site thiol can be regenerated by thioredoxins (Trx), 
sulforedoxins and peroxiredoxins.
Glutathione
Peroxidases
(GPx)
Catalyses the reduction of FI2O2 using GSH and other peroxides as 
substrates to alcohols.
Thioredoxins
(Trx)
Specific donors of electron to many Prxs. Reduced Trx prevents 
apoptosis via an inhibitory binding to apoptosis signal-regulating kinase
1 (AKS-1) which is lost when Trx is oxidised.
1.6.2 Stage II: Up-regulation of antioxidants and detoxifying enzymes
When levels of cellular stress are enhanced and basal defence mechanisms can no longer 
detoxify reactive species sufficiently, an adaptive response is employed by the cell in which 
transcriptional up-regulation of cytoprotective genes is induced. This response is 
predominantly mediated by transcription factors, proteins that recognise and bind to 
certain DNA sequences upstream of the genes concerned, and in doing so, recruit both 
transcriptional and translational machineries for the expression of target genes. Key 
mediators include nuclear factor kB (NF-kB), activator protein 1 (AP-1), hypoxia-inducible 
factor 1 (HIF-1), aryl hydrocarbon receptor (Ah receptor or AHR) and nuclear factor
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erythroid 2 (NF-E2)-reiated factor 2 (Nrf2), all of which are summarised in Table 1.5 except 
for Nrf2 which is discussed in more detail in section 1.6.2.1.
Table 1.5 A summary of transcription factors involved in the up-regulation of 
cytoprotective genes.
Transcription factor Binding/recognition
site Stimuli for induction Target genes
Nuclear factor-KB kB elements Bacterial and viral Cyclooxygenase
(NF-kB) infections, oxidative 2 (COX2),
and endoplasmic inducible
reticulum stress. intrinsic oxide
proinfiammatory synthase (iNOS),
cytokines (INFa, IL- GST subunit PI-
10, IL-1B interleukin 1 (GSTP1-1),
1-B and chemical GCL, SOD, p53,
agents Bcl-xL and FasL.
Activating protein-1 12-o-tetradecanoate- Bacterial and viral GSTs, GCL,
(AP-1) 13-acetate (TPA) - infection, cytokines, COX2, iNOS and
responsive element cellular and chemical various
{IRE) or stress. apoptotic
Cyclic adenosine 
monophosphate 
(cAMP) - responsive 
element (CRE)
regulators.
Hypoxia-inducible 
factor 1 (HIF-1)
Hypoxia Growth factors
Heat shock factors High temperature Heat-shock
(HSF) proteins
Aryl hydrocarbon Dioxin response Ligan mediated. CYP450
receptor (Ah receptor element (DRE) Chlorinated dioxins, enzymes
orAHR) related halogenated (Hillegass et al.,
aromatic 2006),
hydrocarbons, constitutive
dibenzofurans, 2, 3, androstance
7, 8- receptor (CAR)
tetrachlorodibenzo- (Patel etal.,
para-dioxin (TCDD) 2007). For other
(Bradshaw etal., target genes,
2002, Barouki etal., refer to
2007, Peng et ai, (Hankinson,
2009). 1995, Nebert et 
al., 2000,
Petrulis and 
Perdew, 2002).
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1.6.2.1 Regulation by Nrf2 in cell defence
The role of Nrf2 in cell defence was first demonstrated by Itoh and colleagues (1997) in the 
Nrf2 null mice wherein these animals were observed to have a decreased ability in 
maintaining and up-regulating levels of a wide array of cytoprotective genes. This was 
further explored by various groups and have also reported this effect in a variety of tissues 
including the liver (Itoh et al., 1997, Chan and Kwong, 2000, Kwak et aL, 2001, Ramos- 
Gomez et al., 2001, Chanas et al., 2002, Rangasamy et al., 2005), lung (Chan and Kan, 1999, 
Cho et al., 2002, Ishii et al., 2005, Rangasamy et al., 2005), skin (Xu et al., 2006), brain (Lee 
et al., 2003, Shih et al., 2005, Kraft et al., 2006) and the gastrointestinal tract (Itoh et al., 
1997, McMahon et al., 2001, Khor et al., 2006). Furthermore, these animals were also 
observed to demonstrate an enhanced susceptibility to xenobiotic and environmentally- 
induced stresses, one of the first examples having reported by Itoh and colleagues with 
butylhydroxyanisole (BHA) which resulted in a significant increase in the mRNA levels of 
NAD(P)H:quinone oxidoreductase (NQOl) and glutathione S-transferases (GST) in the Nrf2 
wild type animals but not in their knock out counterparts. This effect was also 
demonstrated by various groups using a variety of chemical stress inducers including AFAR 
(Chan et al., 2001, Enomoto et al., 2001), pentachlorophenol (Umemura et al., 2006), 
carbon tetrachloride (Xu et al., 2008) and arsenic (Jiang et al., 2009). Common in the 
promoter region of these Nrf2 target genes is a consensus sequence 
(5'GAGTCACAGTGAGTCGGCAAAAATT-3') known as the antioxidant response element (ARE) 
that is recognised and bound to by Nrf2 along with a small musculo-aponeurotic factor 
(Maf) protein which in turn inititates gene transcription (Itoh et al., 1997, Nguyen et al., 
2009).
Independently, investigations carried out by Reisman and colleagues on the 
therapeutic mechanism of oleanolic acid against liver injury also demonstrated the 
protective role of Nrf2 (Reisman et al., 2009a). Oleanolic acid pre-treatment has been 
demonstrated to protect against a wide array of hepatotoxicants including acetaminophen, 
carbon tetrachloride (CCI4), furosemide, bromobenzene and cadmium chloride (Liu et al., 
1993a, Liu et al., 1993b, Liu et al., 1994a, Liu et al., 1994b, Klaassen and Reisman, 2010). 
Furthermore, oleanolic acid has also been shown to protect from various diseases including 
anaphylactic shock (Zhang and Ma, 1995) and diabetes (Gao et al., 2009). However, it was 
only recently through work with paracetamol that Reisman and colleagues were able to 
demonstrate the ability of oleanolic acid to activate Nrf2 (Reisman ei al., 2009a).
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Since the discovery of the protective role of Nrf2, cumulative research from various groups 
revealed Nrf2 as a master regulator of a wide array of cytoprotective genes including 
NAD(P)H:quinone oxidoreductase or NQOl (Li and Jaiswal, 1992, Itoh et ai, 1997, Kwak et 
al., 2001, McMahon etal., 2001), glutathione S-transferases or GST (Itoh etal., 1997, Knight 
et al., 2008, Reisman et al., 2009d), glutamate-cysteine ligase or GCL (Moinova and 
Mulcahy, 1999, Reisman etal., 2009b), haem oxygenase-1 or HO-1 (Alam et al., 1999) and 
multidrug resistance-associated proteins or MRPs (Maher et al., 2005, Maher et al., 2007). 
Furthermore, its protective role has also been implicated in various diseases such as cancer, 
inflammatory, neurodegenerative and cardiovascular diseases (Cho et al., 2004, Cullinan et 
al., 2004, Yu and Kensler, 2005, Leonard et al., 2006, Kensler et al., 2007, Johnson et al., 
2008, Yoon et al., 2008, Kanninen et al., 2009, Reddy et al., 2009, Zakkar et al., 2009, 
Boutten et al., 2010, Jiang et al., 2010, Cheng et al., 2011) which as a consequence, has 
been exploited in the development of therapeutic interventions.
Although the protective role of Nrf2 has been well established, the mechanism(s) 
that regulate its activity is not, as is the topic of discussion in a paper published by Nguyen 
and colleagues (Nguyen et al., 2009). However, one of these proposed mechanisms has to 
date been widely utilised and certainly exploited in the experimental work of many groups 
including that of our department and will be described in further detail below. Also, this 
particular mechanism will be referred to in the regulation by Nrf2 in cell defence.
One proposed mechanism in which Nrf2 activity is regulated is via its interaction 
with the cysteine-rich cytosolic protein, Kelch-like ECH-associated protein also known as 
Keap 1 as illustrated in Figure 1.9 (Itoh et al., 1999, Dhakshinamoorthy and Jaiswal, 2001). 
In the absence of cellular stress, Keapl plays a dual role, as a repressor by anchoring Nrf2 in 
the cytosol and as a facilitator of Nrf2 degradation (Itoh et al., 1999, Dhakshinamoorthy and 
Jaiswal, 2001). The latter fate of Nrf2 is mediated by Cullin 3 (Cul3), an E3-based ligase that 
targets Nrf2 for ubiquitination and subsequent proteasomai degradation (Kobayashi etal., 
2004a). Consequently, this highly efficient and spontaneous degradation mechanism limits 
Nrf2 to a half-life of between 10 - 30 minutes (Furukawa et al., 1987). Nrf2 up-regulation 
requires oxidative and/or electrophilic stimuli, resulting in the disruption of the Nrf2/Keapl 
interaction (Itoh et al., 1999) . This abolishes the ability of Keapl to bind to newly 
synthesised Nrf2 allowing its translocation into the nucleus. Nuclear Nrf2 requires 
heterodimerisation with small Maf proteins in order to bind to the antioxidant response 
element (ARE), a DNA sequence motif (5'GAGTCACAGTGAGTCGGCAAAAATT-3') that is 
conserved amongst Nrf2 target genes (Itoh et al., 1997). Nrf2, which is a member of the cap
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'n' collar (CNC) family of transcription factors (Itoh et a!., 1995), is by far the most potent 
activator of the ARE (Kobayashi et al., 1999). The binding of the Nrf2/Maf heterodimer to 
the ARE leads to the recruitment of transcriptional co-activators including the cAMP 
responsive element protein (CREB)-binding protein or CBP (Katoh et al., 2001) which 
eventually initiates the transcription of a large battery of Nrf2-regulated genes.
BASAL Proteasomal 
---------------- 1> proteolysis
Figure 1.9 Regulation of Nrf2 activity. A schematic diagram describing the regulation of Nrf2 activity 
basally and upon induction by an increase in chemical stress as described in section 1.6.2.1.
1.6.3 Stage III: Programmed Cell Death
When phase I and phase II levels of cell defence become insufficient in protecting against 
extreme levels of cellular stress, the cell may resolve to the induction of programmed cell 
death through apoptosis for the containment of damage therefore preventing the spread of 
damage to surrounding healthy cells. Hallmarks of apoptosis include membrane blebbing, 
cell shrinkage, chromatin condensation and DNA fragmentation (Robertson and Orrenius, 
2000).
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1.7 BIOMARKERS
In addition to model systems that are used to investigate ADRs, biomarkers are also 
invaluable tools for use both in research and in the clinic to indicate the therapeutic 
threshold of drugs, which in turn could influence the application of drugs already in the 
market and in deciding whether those currently in the pipeline should be withdrawn.
A biomarker is a measurable indicator of either a natural biological process, a 
pathogenic process or a pharmacological process in response to a therapeutic intervention 
(Biomarkers Definitions Group, 2001). It is therefore a highly useful tool in a wide array of 
research and clinical applications including DILI. Ideally, a biomarker should be organ 
specific, sensitive for a particular type of injury, transferable across species, have low inter- 
and intra-individual variability, biologically relevant, present in biological samples that can 
be accessed in a non-invasive manner, stable, reduced when the insult or injury is resolved 
and amenable to testing. Years of research have led to the discovery of many biomarkers of 
DILI, however none of these have successfully fulfilled all the criteria outlined above.
1.7.1 Biomarkers in DILI
Biomarkers which are commonly used both in pre-clinical and clinical research and in the 
clinic to detect DILI include alanine transaminase (ALT), aspartate transaminase (AST), 
alkaline phosphatase (ALP) and total plasma bilirubin, all of which are endorsed by the US 
Food and Drug Administration (FDA). In particular, ALT and AST are more commonly 
referred to as the gold standard markers of hepatotoxicity. ALT and AST are leakage 
products of liver injury that are deposited into the blood. ALT displays higher sensitivity 
than AST and although both suffer from a lack of specificity, the more widespread 
expression of AST in extrahepatic tissues compared with ALT makes it a less specific marker 
(Ozer et oi, 2008, Yang et al.t 2009). ALT elevations may also prove to be false-positive 
(Edgar et ai, 1998, Thulin et o/., 2008) or false-negative (Solter et al., 1998, Solter et o/., 
2000). However, the problem with regards to the specificity of ALT could be resolved when 
taking into consideration the two isoenzymes, ALT1 and ALT2, each of which have different 
tissue specificity during DILI. However, at present, this approach could not be readily 
adopted as current commercially available and validated tests do not have the ability to 
differentiate between the two isoenzymes. Indeed, work is already underway in the 
development of a more sensitive and robust assay that will allow the specific detection and
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quantification of these isoenzymes. Cytosolic AST and mitochondrial (mAST) have also been 
identified as two isoenzymes of AST that may add further specificity as a marker of liver 
injury, in particular for mAST, as a specific marker of alcohol-induced liver injury (Macchia 
et al, 1997), however, further work is still required. ALP when used in conjunction with 
other markers such as ALT can be used as a specific marker of cholestatic DILI 
(Ramachandran and Kakar, 2009) however, ALP elevations may also be observed in other 
conditions such as bone disease and pregnancy (Reust and Hall, 2001) therefore its utility as 
a DILI biomarker is highly dependent on its use as a combination with ALT or AST. The liver 
is responsible for the clearance of bilirubin from the plasma. As a direct indicator of liver 
function (Senior, 2009), total plasma bilirubin is a more specific marker of liver injury in 
comparison to ALT, AST and ALP. However this advantage is still hampered by the ability of 
other conditions (Fabris et al., 2009) to trigger elevations in total plasma bilirubin therefore 
measurement of other parameters is still required.
Although a common practice has now been adopted where several markers are 
measured during the study of DILI, continued effort is still made by various groups in search 
for biomarkers that may offer better sensitivity and specificity compared with the current 
standards. At present, several promising biomarkers have been reported that offer better 
sensitivity and specificity for predicting liver injury, although may still require confirmation 
with other biomarkers. A summary of potential markers of DILI that are currently under 
investigation is presented in Table 1.6.
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Chapter 1
1.7.2 Ophthalmic acid as a potential biomarker of chemical stress
Hepatic GSH depletion is a common feature of DILI and as such is routinely used as a 
marker of chemical stress in pre-clinical studies. However, its use is limited to pre-clinical 
applications as it is rapidly degraded in the blood by y-GGT therefore analysis in humans is a 
challenge. Recently, as described earlier in this chapter, ophthalmic acid has been proposed 
as a potential surrogate marker of GSH depletion (Soga et al., 2006). Although GSH 
depletion is not necessarily a marker of hepatotoxicity, an alternative marker that reflects 
GSH status in addition to the current panel of markers could contribute to the level of 
sensitivity and to some extent, specificity, in the prediction of DILI. Indeed, drugs that have 
the potential to cause hepatotoxicity exert this ability through different modes, one of 
which could be oxidative stress. GSH depletion would therefore play a significant role 
considering its importance in maintaining the cell's redox status as discussed in section 
1.6.1.2. A biomarker of GSH depletion may therefore aid in elucidating the hepatotoxic 
potential of drugs. Further investigation into the potential of ophthalmic acid as a marker of 
GSH consumption is required as very little work on its biological function has been 
undertaken so far. Furthermore, Soga and colleagues (2006) suggested that the increase in 
ophthalmic acid in APAP-treated mice was due to a combination of cysteine and GSH 
depletion. Determination of the exact trigger of ophthalmic acid increase therefore needs 
to be elucidated as the depletion in GSH observed may just be a consequence of cysteine 
depletion, cysteine being a precursor of GSH which contains the thiol group that is essential 
for the wide array of biological activity in which GSH is involved in.
1.8 AIMS OF THE PROJECT
In light of the problem still posed by ADRs, despite the vast body of knowledge that is 
available on the toxic mechanisms of ADRs as well as the defence systems deployed to 
combat it, the aim of this thesis was to develop novel model systems to allow investigations 
in the mechanisms of DILI and to facilitate the development of novel biomarkers of drug- 
induced chemical stress. In particular, the human liver epithelial cell line, THLE-2E1, which 
has been engineered to overexpress the CYP2E1 enzyme, the Nrf2(V') mouse and the 
endogenous metabolite ophthalmic acid were assessed for their potential as models of 
chemical stress.
The THLE-2E1 cell line was assessed to determine its utility as a model of oxidative 
stress in the absence or upon induction of a metabolic substrate. The THLE-2E1 cell line
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would be an ideal model for investigating oxidative stress as overexpression of the CYP2E1 
enzyme has been shown to be pro-oxidant due to the incomplete coupling between this 
enzyme and NADPH-cytochrome P450 reductase. The Nrf2^ mouse was investigated for its 
potential use in determining the extent of the role of Nrf2 in DILI, in particular, the extent 
of its regulatory role in cellular defence. Work carried out in this model specifically looked 
at the role of Nrf2 in the regulation of the GSH system. Finally, ophthalmic acid was 
investigated as a biomarker of oxidative stress as it has been demonstrated to significantly 
increase upon depletion of hepatic GSH as a result of APAP treatment. As described in 
section 1.6.1.2 and discussed further in chapter 3, GSH plays a central role in cellular 
defence in addition to other physiological processes within the cell. A biomarker that could 
reflect the behaviour of GSH during a toxic insult is therefore valuable in determining the 
susceptibility of a cell to toxicity in response to a particular drug treatment. As such, as part 
of the work carried out on ophthalmic acid, perturbations right across the GSH system were 
also investigated.
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Chapter 2
Evaluation of the THLE-2E1 cell line as an in vitro model of chemical
stress
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2.1 INTRODUCTION
The use of primary human hepatocytes continues to be the preferred in vitro route for 
determining and extrapolating the metabolic and toxicity profiles of a drug to a clinical 
setting (Guillouzo et a!., 1993, LeCluyse, 2001, Bjornsson etal., 2003, Gomez-Lechon etai, 
2004). However, such systems have a limited life-span, are highly variable with regards to 
cytochrome P450 (CYP450) contents and activity and dedifferentiate rapidly following 
isolation (Bjornsson et al. 2003; Cross et al. 2000; Guillouzo et al. 1993). It is also difficult to 
access a consistent supply of freshly isolated cells, which are preferable to the 
cryopreserved alternatives. Consequently, many groups have opted for using immortalised 
human cell lines as an alternative as they have proven easier to maintain, are long-lived and 
readily available. One major disadvantage however, is the absence of metabolic activity as a 
consequence of transformation (Rowe et al., 2010). In order to address this deficit, cell lines 
have been developed which are engineered to overexpress individual CYP450 isoforms 
constitutively or through the use of an inducible promoter (Dai et al., 1993, Chen and 
Cederbaum, 1998, Goldring eto/., 2006).
Recently, a panel of SV40 T-antigen-immortalised human liver epithelial cells (THLE) 
has been stably transfected with specific CYP450 isoforms (CYP-1A2, 2C9, 2D6, 2E1 or 3A4), 
with expression transcriptionally driven by a cytomegalovirus (CMV) promoter and selected 
for by the G418 selective gene (Pfeifer et al., 1993, Mace et al., 1997). These cells were 
derived from the THLE-5B parental immortalised human hepatocyte cell line which exhibits 
hepatocyte-like phenotype, with high levels of reduced GSH and phase II enzyme activities 
except for UGTs (Pfeifer et al., 1993, Dambach et al., 2005). In conjunction with work within 
the Molecular Toxicology group at AstraZeneca (Alderley Park, UK), all THLE-CYP cell lines 
were characterised and assessed for their utility in drug toxicity studies. The focus of this 
chapter was to characterise and evaluate the THLE-2E1 cell line for its potential as an in 
vitro tool for studying chemical stress.
The significance of a CYP2E1 cell line for the study of chemical stress stems from 
the intrinsic ability of this CYP450 isoform to elicit oxidative stress in the absence of an 
inducer. Compared with other CYP450 isoforms, CYP2E1 has the ability to constitutively 
produce high levels of ROS (Gorsky et al., 1984, Dai et al., 1993) due to its weak coupling 
with CPR as demonstrated in isolated microsomes and reconstituted enzyme systems 
(Gorsky et al., 1984, Ekstrom and Ingelman-Sundberg, 1989). This unique feature of CYP2E1
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was also reported in a human hepatocarcinoma cell line developed to overexpress this 
enzyme (HepG2-2El) (Dai et a!., 1993). The authors of this study associated the increased 
level of oxidative stress observed in these cells with the up-regulation of glutathione (GSH) 
synthesis (Mari and Cederbaum, 2000).
Electrophiles
CYP-2E1 Chemical substrate
Mitchondrial damage/ 
Protein arylation
Oxidative stress Oxidative stress Chemical stress
Apoptosis/Necrosis
Figure 2.1 A schematic diagram summarising the pathways by which CYP2E1 elicits cellular stress.
CYP2E1 exhibits enhanced NADPH oxidase activity compared with other CYP450 isoforms due to its 
poor coupling with CPR; resulting in the constitutive production of free radicals/ROS including 
superoxide anion (02 ), H202 and hydroxyl radicals ( OH), all of which lead to oxidative stress (Gorsky 
et al., 1984, Ekstrom and Ingelman-Sundberg, 1989). This can be further potentiated through 
CYP2El-mediated metabolism of a chemical substrate such as APAP, which can be bioactivated into 
the chemically reactive metabolite (electrophile) NAPQJ (Raucy et ai, 1989). Cellular damage such as 
that in the mitochondria and protein arylation caused by both ROS and electrophiles that can no 
longer be managed by the cell's defence system may lead to the dysfunction of various cellular 
processes, potentially resulting in cell death (apoptosis/necrosis).
The ability of CYP2E1 to produce a state of oxidative stress can be potentiated 
through the addition of chemical substrates. In particular, the CYP2El-mediated toxicity 
elicited by ethanol (Morimoto et al., 1994, Nanji et al., 1994, Lieber, 1999, Bradford etal., 
2005, Gonzalez, 2005, Cederbaum, 2006) and APAP (Mitchell et at., 1973b, McClain et al., 
1980, Morgan et al., 1983, Raucy etal., 1989, Lee etal., 1996, Zaher eta/., 1998, Manyike et 
al., 2000, Cheung et al., 2005) are well documented and continue to have a significant 
impact on public health. Furthermore, CYP2El-mediated metabolism has also been
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implicated in the carcinogenicity of certain compounds such as nitrosamines and 
azocompounds (Yang et a!., 1990, Guengerich et al., 1991, Sohn et aL, 1991, Sohn et oi, 
2001). As APAP is a well documented substrate for CYP2E1 bioactivation to the electrophile 
NAPQI (chapter 1 section 1.5.1), where at overwhelming levels consequently causes toxicity 
to the human population even to this day (Ostapowicz et al., 2002), APAP has been chosen 
as the chemical model for evaluating the potential of THLE-2E1 as an in vitro model of 
chemical stress.
Although CYP2E1 overexpressing ceils have been previously developed and are in 
current use (Dai et al., 1993, Chen and Cederbaum, 1998, Goldring et al., 2006), the THLE- 
2E1 cell line is unique for being a member of a panel of CYP overexpressing cells that 
originate from one parental immortalised cell line. Furthermore, this panel of cell lines also 
include the THLE-Nulls which have been transfected with an empty vector, providing a 
direct control during studies that utilises the CYP overexpressing cells, such as those 
described in this chapter. As inter- and intra-species variability in the metabolic and toxicity 
profiles of drugs is a common problem (Turpeinen etal., 2007), the availability of the THLE- 
CYP cells could potentially provide the capability to elucidate the metabolic and toxic 
profiles of a drug candidate within a specific model system at the pre-clinical stage. As such, 
the aims of the work described in this chapter were:
1. To characterise the THLE-2E1 cell line which have not been previously assessed in 
terms of viability, growth characteristics, CYP2E1 expression levels and metabolic 
capacity using the CYP2E1 model substrate chlorzoxazone.
2. To assess the THLE-2E1 cells as a model system for exploring oxidative stress in the 
absence of metabolic substrates using the THLE-Null cells as a comparator.
3. To assess the THLE-2E1 cells' capacity for the metabolic activation of a known 
CYP2E1 substrate (APAP) as a model of oxidative stress.
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2.2 MATERIALS AND METHODS
2.2.1 Materials
All chemicals and media supplements were purchased from Sigma-Aldrich (Poole, Dorset, 
UK) and Invitrogen (Paisley, UK) unless otherwise stated. Cell culture media (Basal PMFR-4) 
was purchased from Millipore (Billerica, Massachusetts, USA). Sterile Biocoat™ cell culture 
flasks and plates were purchased from Becton Dickinson (Oxford, UK). Nunclon A cell 
culture dishes were from Nalge-Nunc International (c/o VWR International, Lutterworth, 
Leicestershire, UK). All other plasticware were sourced from Fisher (Loughborough, 
Leicestershire, UK). CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay (MTS assay) 
was purchased from Promega (Southampton, Hampshire, UK). Precision Plus Protein 
Kaleidoscope standards and non-fat dry milk were from Bio-Rad (Hemel Hempstead, 
Hertfordshire, UK). RIPA buffer and Protease Cocktail Inhibitor were purchased from 
Thermo Scientific (Basingstoke, Hampshire).
THLE-CYP cells (Null and CYP2E1) were obtained under license from Nestec Ltd, 
Switzerland. Briefly, the non-tumourigenic human liver epithelial cell line SB (THLE-5B) was 
immortalised by transfection with a simian virus 40 large T antigen. The THLE-5B was used 
as the parental cell line for establishing the THLE-CYP cell line panel by transfection with 
individual cytochrome P450 cDNA (including CYP2E1 and an empty vector for THLE-Nul!) 
driven by a cytomegalovirus (CMV) promoter (Figure 2.2) (Pfeifer et al., 1993). The THLE- 
CYP cells have been demsontrated to retain characteristics of the parental THLE-5B cells, all 
of which express both phase I and phase II enzymes with the exception of UGTs (Mace et 
al., 1997).
36
Chapter 2
Figure 2.2 A generalised plasmid construct used to transfect the THLE-5B cells into specific THLE- 
CYP and THLE-Null cell lines. The THLE-Null cell line was established using a plasmid construct that 
doesn't contain a CYP450 cDNA. The high expression of each CYP450 isoform is driven by a CMV 
promoter and maintained and selected for by the G418 resistance gene (Pfeifer et a!., 1993).
2.2.2 Cell culture
2.2.2.1 Media preparation
THLE-CYP cells were maintained in complete media (CM) which comprised Basal PMFR-4 
media supplemented with 2 mM GlutaMAX, 1.75 pM insulin transferrin selenium (ITS), 1 
nM hydrocortisone, 0.5 ng/ml epidermal growth factor (EGF, reconstituted at 0.1 mg/ml in 
10 mM acetic acid/0.1 % bovine serum albumin (BSA)), 35 pg/ml bovine pituitary extract 
(BPE), 0.33 nM retinoic acid, 3 % fetal bovine serum (FBS) and 150 ng/ml G418. Serum free 
media (SFM) which has the same composition as CM less ITS and FBS was used for drug 
incubations.
2.2.2.2 Growing of cryopreserved cells
Cryopreserved cells (1 x 106cells/ml and prepared as detailed below in section 2.2.2.5) were 
subjected to a quick thaw step in a pre-heated 37 °C water bath and immediately 
transferred into a sterile Biocoat ™ T75 flask with 15 ml complete media (CM). The cells
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were allowed to attach to the surface of the flask for a minimum of 4 hours (h) in a 
humidified chamber at 37 °C under 5 % C02. This was followed by the removal of the media 
and replacement with a further 15 ml fresh CM for cell growth. Media was routinely 
replaced every two days until growth reached 80 % confluency at which point the cells 
were passaged. Cells used were between passages 13 - 20.
2.2.2.3 Cell passaging
Passaging of the cells involved a wash step with Hank's balanced salt solution (HBSS, -Ca2+/- 
Mg2+), followed by treatment with 0.025 % trypsin-EDTA (1 ml) for 3 minutes at room 
temperature to allow the detachment of cells from the surface. Further trypsinisation was 
prevented by the addition of 10 ml CM which was also used to collect the detached cells in 
a suspension.
2.2.2.4 Cell counting
A mixture of cell suspension as acquired in section 2.2.2.3 and 0.2 % Trypan Blue at a 1:1 
ratio was prepared. Using a haemocytometer (Mods-Fuchs Rosenthal BS748 depth 0.2 mm, 
0.0625 mm2), 20 \x\ of this mixture was counted to calculate the number of cells/ml using 
the equation below:
Cells/ml = ((a + b + c + d)/4) x CF x DF
Where CF is the Conversion Factor = 5000, DF is the Dilution Factor = 2 and a, b, c and d are 
the number of cells per square on the haemocytometer.
2.2.2.5 Cryopreservation of cells
Cells were harvested as detailed in section 2.2.2.3 and collected in a pellet by centrifugation 
at 1200 revolutions per minute (rpm) for 3 minutes at room temperature. The media was 
carefully aspirated and the cell pellet reconstituted in freezing media (1:1 ratio of Basal 
PMFR-4 media (without supplements):FBS containing 10 % DMSO). The cells were counted 
as detailed in section 2.2.2.4 and divided into sterile Nunc cryopreservation tubes at 1 x 106 
cells/ml. The cells were slowly frozen down in an isopropanol containing cryopreservation
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chamber at -80 °C for 24 h and were subsequently transferred into a liquid nitrogen 
chamber for long term storage.
2.2.3 Cell morphology
Comparison of cell morphology was carried out by microscopy (Leica DM IRB microscope 
and Leica CD 200 camera; Leica Microsystems, Milton Keynes, Buckinghamshire, UK) on a 
24 h culture of both THLE-Null and THLE-2E1 cell lines in CM.
2.2.4 Cell growth rate
THLE-Null or THLE-2E1 cells were seeded at 250 x 103 cells/well in a Biocoat ™ T25 flask and 
left to grow in 5 ml CM for 72 h. Media was replaced for both cell lines as and when 
required within the allocated growth period. Cells were harvested and counted as detailed 
in sections 2.2.23 and 2.2.2.4 and values were used to calculate the doubling time of each 
cell line.
2.2.5 Cell growth curve
Increasing number of THLE-Null and THLE-2E1 cells were seeded (1 x 103 - 40 x 103 
cells/well) in Biocoat ™ 96 well plates for 24 h in triplicate. Mitochondrial activity as a 
measure of ceil viability was determined as detailed below (section 2.2.6).
2.2.6 Mitochondrial activity determination
Mitochondrial activity was measured as an indicator of cell viability using a Promega 
CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay™ kit. MTS (3-(4,5- 
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) 
solution was diluted 1 in 5 with serum-free media (SFM). All treatment media in the 
incubation plates were removed and replaced with 120 pi of MTS solution. The reaction 
was allowed to take place in a humidified chamber at 37 °C under 5 % C02 for 1 h. MTS 
solution (100 pi) was removed from the incubation plate and transferred into a Costar 96-
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well plate where the absorbance was immediately read using a Wallac™ EnVision® 
spectrophotometer (PerkinEtmer; Seer Green, Buckinghamshire, UK) at 492 nm.
2.2.7 Protein content determination using the Bradford method
Protein concentration was measured based on the Bradford method (Bradford, 1976) using 
the Protein Assay Dye Reagent. The Bradford method relies on the binding of the 
Coomassie Brilliant Blue G-250 dye to basic and aromatic amino acids resulting in a colour 
change of the dye from red to blue with a resulting change in absorbance maximum from 
465 to 595 nm. The protein content was determined by measuring the increase in 
absorbace at 570 nm using an MRX microplate reader (Chantilly, VA) which is proportional 
to the amount of bound dye and therefore the amount of protein present. A standard curve 
prepared from bovine serum albumin fraction V (0 - 2 mg/ml) was used to calculate the 
protein content.
2.2.8 Protein content determination using the Lowry method
For samples with low protein content, protein concentration was measured using the Lowry 
method (Lowry et aL, 1951). Samples and protein standards (1 mg/ml stock solution of 
bovine serum albumin fraction V in dH20 diluted to concentrations between 0-0.2 mg/ml) 
were diluted as appropriate in 0.5 M NaOH. Prepared samples and standards were added 
with 50 p.1 Lowry Reagent (0.5ml 1% CuS04.5H20, 0.5ml 2% NaK Tartarte and 10ml 10% Na2 
Co3 in 0.5M NaOH) and allowed to incubate for 15 min at room temperature. This was 
followed by the addition of 150 pi Folins Reagent (diluted 1 in 10 with dH20) and samples 
and standards were left to react in the dark at room temperature for a further 30 min. The 
absorbance was measured on an MRX plate reader (Chantilly, VA) at 570 nm.
2.2.9 Determination of total GSH content
GSH content was measured according to the 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB)-GSH 
reductase recycling method (Vandeputte et al., 1994). Briefly, proteins prepared in section
2.2.10 were pelleted by centrifugation at 14 000 rpm for 5 min. A 1:1 ratio (at 20 pi of each, 
v/v) of the supernatant and GSH buffer (0.143 M NaH2P04, 6.3 mM EDTA, pH 7.4) were
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combined in a Nunclon A 96-weii plate to neutralise the pH. Samples were incubated with 
the assay reagent (200 \x\; 1 mM DTNB, 0.34 mM NADPH, in 0.143 M Na^PO^ 6.3 mM 
EDTA, pH 7.4) for 5 min at room temperature. The enzymatic reaction was initiated by the 
addition of 0.35 U GSH reductase and immediately read at 405 nm for 5 min using an MRX 
microplate reader (Chantilly, VA). GSH concentrations of the samples were calculated using 
a GSH standard curve ranging between 1-80 nmol/ml GSH. GSH content for each sample 
was normalised to total protein content measured as described in sections 2.2.7 and 2.2.8.
2.2.10 Preparation of protein extracts
THLE-Null and THLE-2E1 cells were seeded (250 x 103 cells/well) in a Biocoat ™ T25 flask in 
triplicate for 24 h in a humidified chamber at 37 °C under 5 % C02 and subsequently 
harvested as detailed in section 2.2.2.3. Cell suspensions were centrifuged at 1200 rpm for 
3 minutes at 24 “C after which the media was carefully aspirated. The cell pellets were 
washed with HBSS (-Ca2+/-Mg2+) and collected by a further centrifugation step. Cytosolic 
extracts were obtained through cell lysis with 200 pi RIPA buffer supplemented with 
protease cocktail inhibitor. The resulting supernatant and pellet samples were stored at -80 
°C until required. Determination of protein concentrations were performed as detailed in 
section 2.2.7 or 2.2.8.
2.2.11 Western blot
Whole cell lysates (30 pg) were mixed with 5pl NuPage Master Mix (3.5pl IDS sample 
buffer and 1.5pl reducing reagent). Proteins were denatured at 80 °C for 10 min. Samples 
were loaded onto pre-made 4-12% NuPage Novex Bis-Tris gels alongside full range 
molecular weight rainbow markers (Precision Plus Protein Kaleidoscope standards) and two 
cryopreserved human hepatocyte prepared as for the THLE ceils (HL-hep) and a human liver 
homogenate (HL-hom) as positive controls. The samples were separated by denaturing 
electrophoresis using 3-(N-Morpholino) propapane sulfonic add (MOPS)-SDS running buffer 
(lx) at 90 V for 10 min which was increased to 170 V for a further 1 h. The resolved 
proteins were transferred to nitrocellulose membrane for 1 h at 80 V using a lx transfer 
buffer (glycine 50mM; Tris 25mM; II) with 20 % methanol (v/v). An ice pack was included in 
the transfer apparatus with a magnetic stirrer to ensure even distribution of heat.
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Following protein transfer, the membrane was rinsed in 0.1 % Tween-Tris buffered saline 
(T-TBS; ISOmiVI NaCI, 3mM KCI, 25mM Tris, 0.1 % Tween 20) and stained with Ponceau red 
dye to ensure equal protein loading and transfer of protein extracts. The membrane was 
again rinsed with 0.1 % T-TBS and blocked (30 min, 10 % blotting grade non-fat milk in 0.1 % 
T-TBS) to reduce non-specific binding. For specific CYP2E1 protein detection, the 
membrane was incubated with a rabbit anti-CYP2El IgG antibody (Abeam, Cambridge, UK); 
1:3000 in 0.1% T-TBS containing 2 % milk; 10ml) for 1 h at room temperature. The 
membrane was repeatedly washed (4x5 min washes) with 0.1 % T-TBS and then further 
incubated with a secondary antibody, goat anti-rabbit (Sigma-Aldrich, Poole, Dorset, UK), 
1:3000) for 1 h at room temperature. The membrane was again subjected to a multiple 
wash step. CYP2E1 protein-antibody conjugate was visualised using Western Lightning Plus 
chemiluminescence reagent (PerkinElmer) and membranes were exposed to ECL film 
(Amersham; GE Flealthcare, Little Chalfont, Buckinghamshire, UK).
2.2.12 Coomassie stain
Proteins (section 2.2.10) were resolved as detailed in section 2.2.11. The resolved proteins 
were fixed in a solution of 7 % glacial acetic acid in 40 % (v/v) methanol for a minimum of 1 
h and were subsequently stained with Brilliant Blue G Colloidal Coomassie dye (diluted 4:5 
(v/v) with methanol) for 2 h. Excess Coomassie stain was removed by washing the gel with a 
solution of 10 % acetic acid in 25 % (v/v) methanol for 1 minute, followed by a further rinse 
step with 25 % methanol.
2.2.13 CYP2E1 activity
Chlorzoxazone was used as substrate for the determination of CYP2E1 activity (Figure 2.3). 
THLE-Null and THLE-2E1 were seeded at 250 x 103 cells/well on a Biocoat™ 6-well plate 
format overnight in a humidified chamber at 37 °C under 5 % C02. Cells were treated with 
increasing concentrations of chlorzoxazone (0 - 500 |iM) in SFM for 2 h. The reaction was 
stopped with the addition of equal volumes of ice-cold acetonitrile to the drug solution 
(v/v) which were collected and transferred into tubes and stored at -80 °C until analysis.
Cell debris from the samples was removed by centrifugation (14 000 rpm, 4 °C, 10 
min). Clean supernatants were transferred into new tubes and spiked with 1 pM
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phenacetin (PNC) in 50 % MeOH. The samples were dried down by centrifugation under 
vacuum (SpeedVac, manufacturer, address) and subsequently reconstituted in 50 % MeOH 
(400 pi). Concentrated samples were analysed for 6-hydroxy chlorzoxazone by LC-MS-MS.
All LC-MS-MS experiments were performed using a Perkin Elmer SC1EX API 3000 LC- 
MS-MS system with a Perkin Elmer Series 200 Autosampler and HPLC Pump 
(Massachusetts, USA). Analytes were separated using a Silica Uptisphere CIS column 5 p 
ODB, 100 x 2 mm length (Interchim c/o Cheshire Sciences Chester, UK). The flow-rate of 
200 pL/min was achieved with an elution gradient composed of solvent A (0.1 % formic acid 
in dH20) and solvent B (100 % MeOH). The gradient started with a linear gradient from 100 
- 85 % for 5 min, 85 - 40 % for 10 min, 40 - 100 % for 3 min and finished with an isocratic 
step at 100 % for 2 min with solvent A. The total analysis time and injection volume were 20 
min and 50 p! respectively. The autosampler syringe was subjected to three pre and post 
sample injection washes with solvent A. Analytes were detected in the positive ion mode 
using MS-MS with multiple reaction monitoring (MRM) which uses the unique 
fragmentation pattern of each compound for detection and quantification. The source 
temperature was set at 350 °C and nebuliser gas set at 12. Collision energies and transition 
ion pairs were optimised for each analyte using reference compounds (Figure 2.4). System 
control and data acquisition were performed using Analyst Version 1.4 software.
Chlorzoxazone 6-OH Chlorzoxazone
Figure 2.3 CYPZEl-mediated metabolism of chlorzoxazone to 6-OH chlorzoxazone
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Figure 2.4 LC-MS-MS chromatograms of Chlorzoxazone, 6-OH Chlorzoxazone and Phenacetin. A
mixture of chlorzoxazone, 6-OH chlorzoxazone and phenacetin (internal standard) was analysed by 
LC-MS-MS using the MRM technique (MRM transitions in brackets) (section 2.2.13). The same LC- 
MS-MS method was used to analyse CYP2E1 activity in the THLE-2E1 cells.
2.2.14 APAP metabolite identification
THLE-Null and THLE-2E1 cell lines were seeded at 250 x 103 cells/well in a Biocoat™ 6-well 
plate format for metabolite identification. Each cell line was treated with increasing 
concentrations of APAP (0 - 25 mM) prepared in SFM for 24, 48 and 72 h. After incubation, 
the media was collected and added with equal volumes of 100 % MeOH. Cell debris from 
the samples were removed by centrifugation (14 000 rpm, 4 °C, 10 min) and monitored for 
the APAP metabolites as described below.
All LC-MS-MS experiments performed in this section were carried out on 
instruments detailed in section 2.2.13. The flow-rate of 200 pL/min was achieved with an 
elution gradient composed of solvent A (0.1 % formic acid in dH20) and solvent B (100 % 
MeOH). The gradient started with a linear gradient from 100 - 96 % for 3 min, 96 - 20 % for 
22 min, an isocratic step at 20 % for 5 min, a gradient step from 20 - 100 % and finally an 
isocratic step at 100 % for 1 min with solvent A. The total analysis time and injection 
volume were 41 min and 50 pi respectively. The autosampler syringe was subjected to 
three pre and post sample injection washes with solvent A. Analytes were detected in the 
positive ion mode using MS-MS with MRM which uses the unique fragmentation pattern of 
each compound for detection and quantification. The source temperature was set at 450 °C
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and nebuliser gas set at 15. Transition ion pairs used for the glucuronide, cysteine, 
cysteinylglycine, glutathione and sulphate conjugates were 328>152, 271>140, 328>182, 
457>328 and 232>152 respectively and adopted from (Kostrubsky et al., 2005) which were 
validated by (Mutlib et al., 2000). System control and data acquisition were performed 
using Analyst Version 1.4 software.
2.2.15 APAP toxicity
THLE-IMull and THLE-2E1 cell lines were seeded at 15 x 103 cells/weil in a BiocoatTM 96-weli 
plate format for cytotoxicity analysis. Each cell line was treated with increasing 
concentrations of APAP (0 - 25 mM) prepared in SFM for 24, 48 and 72 h. APAP toxicity was 
assessed following the MTS assay detailed in section 2.2.6. GSH content was also measured 
following the protocol detailed in section 2.2.9.
2.2.16 Statistical analysis
Where applicable, all data were expressed as mean ± standard error of the mean (SEM). 
Values to be compared were analysed for normal or non-normal distribution using a 
Shapiro-Wilk test. Unpaired t-tests. o.r.one-way ANQVA~;were used -when normality~was 
indjc§fed. A Mann-Whitney U or Kruskall-Wallis test was used when the data were 
determined to be non-normal!y distributed. All statistical tests were performed using 
-StatsDirectand results.were considered to be significant when_p_< 0.05.
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2.3 RESULTS
In order to evaluate the utility of the THLE-2E1 cell line as an in vitro tool for investigating 
chemical stress, all experiments in this chapter were also performed on the THLE-Null cell 
line which contains the same plasmid less the CYP450 cDNA (section 2.2.1), as a control.
2.3.1 Comparison of cell morphology
The morphology of both cell lines in culture for 24 h was assessed by visual inspection using 
a microscope at xlOO and x200 magnification. Figure 2.5 demonstrated that both THLE-Null 
and THLE-2E1 were morphologically similar indicating that overexpression of the CYP2E1 
enzyme did not have an effect on the physical appearance of the THLE-2E1 cells compared 
with the THLE-Null.
2.3.2 Comparison of growth rate
The growth rates of both cell lines were also determined by calculating the length of time at 
which the cell population has doubled in 72 h (section 2.2.4). At 37 “C under 5 % C02, 
conditions under which both cell lines were incubated during culture and treatment, the 
THLE-Nulls were observed to have a faster growth rate with a doubling time of 29 h 
compared with a slower growth rate of 42 h observed in the THLE-2E1 cells. This could be 
indicative of a stress response due to CYP2E1 overexpression having a negative impact on 
cell growth in the THLE-2E1 cells.
2.3.3 Comparison of mitochondrial activity
Cell viability was chosen as one end-point for assessing the effect of chemical stress in both 
cell lines using the MTS assay (section 2.2.6). As such, correlations between cell density and 
mitochondrial activity measured as the change in absorbance at 492 nm (optical density) 
were also evaluated. As presented in Figure 2.6, both cell lines demonstrated a good 
correlation between cell and optical densities up to 15,000 cells/well. However, this 
correlation decreased at cell densities above 15,000 cells/well. Interestingly, this trend was 
observed in both cell lines suggesting that this effect was not CYP2El-mediated.
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Figure 2.5 Morphological comparison between THLE-Null and THLE-2E1. THLE-Null (A) and THLE- 
2E1 (B) cell lines were cultured for 24 h in a T25 flask at 250, 000 cells at time 0. Cells were observed 
under a microscope to determine differences in cell morphology at xlOO and x200 magnifications 
(section 2.2.3).
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Figure 2.6 Correlation between cell density and mitochondrial function in THLE-Null and THLE-2E1 
cells. THLE-Null and THLE-2E1 cells were cultured in a 96 well plate for 24 h at increasing cell 
densities (0 - 40,000 cell number/well) (section 2.2.5). Mitochondrial activity was determined as a 
measure of cell viability (section 2.2.6). Correlation was made by plotting the optical density at 492 
nm against the cell number per well. Error bars represent the standard error of mean of three 
independent incubations where each incubation was carried out in triplicate, n = 3.
2.3.4 CYP2E1 protein content in THLE-Null and THLE-2E1 cells
CYP2E1 protein levels were also assessed in both cell lines by western blot as described in 
section 2.2.11 to demonstrate overexpression of this enzyme by the THLE-2E1 cells. The 
abundance of CYP2E1 was also compared with cryopreserved human hepatocytes (HL-hep) 
and human liver homogenate (HL-hom) to determine relative differences in CYP2E1 protein 
levels between systems.
Figure 2.7-A clearly demonstrates that CYP2E1 was overexpressed in the THLE-2E1 
cells compared with the THLE-Null cells. Furthermore, levels of CYP2E1 were similar 
between the THLE-2E1 cell line and the cryopreserved human hepatocyte samples 
indicating that both systems were comparable with regards to CYP2E1 protein content. 
However, levels of CYP2E1 were markedly higher in human liver homogenate compared 
with the THLE-2E1 cells and cryopreserved human hepatocytes. Interestingly, Ponceau 
(Figure 2.7-B) and Coomassie (Figure 2.7-C) stains demonstrate marked differences in the 
protein profile of the THLE cells (CYP2E1 and Null) compared with the cryopreserved human 
hepatocyte, despite similar levels of CYP2E1. Furthermore, protein profiles were 
comparable between the cryopreserved human hepatocytes and human liver homogenates 
despite differences in CYP2E1 protein levels (Figure 2.7-C).
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Figure 2.7 CYP2E1 protein content in THLE-Null and THLE-2E1 cell lines. Protein samples (section 
2.2.10) were analysed by western blot (A, section 2.2.11) and Coomassie stain (C, section 2.2.12). 
Cryopreserved human hepatocytes (HL-hep) and human liver homogenate (HL-hom) were used as 
positive controls for human CYP2E1 protein (56.85 kDa) as well as comparators for differentiating 
the protein profiles of these three systems. Actin (A) and Ponceau stain (B) were used as controls for 
sample loading. Numbered lanes (1, 2 and 3) under HL/Hep, THLE-Null and THLE-2E1 represent three 
separate cultures. Asterisks (*) represent non-specific protein bands.
2.3.5 CYP2E1 activity in the THLE-2E1 cells.
To determine whether the increased CYP2E1 expression in the THLE-2E1 cell line (Figure 
2.7) correlated with an increase in activity, both THLE-Null and THLE-2E1 cell lines were 
incubated with increasing concentrations of chlorzoxazone, a substrate for CYP2E1 
metabolism (Figure 2.3) for 2 h (Peter et a!., 1990). Detection and quantification of the 
metabolic product, 6-OH chlorzoxazone was carried out by LC-MS-MS (section 2.2.13). 
Figure 2.8 shows the detection of 6-OH chlorzoxazone in the THLE-2E1 cells with a
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maximum activity of 0.67 nmol/mg/min at 500 pM chlorzoxazone. Higher concentrations of 
the substrate did not lead to further increase in activity indicating possible saturation of 
active sites within the CYP2E1 enzyme. Relative to the sensitivity of the assay, no 6-OH 
chlorzoxazone was detected in the THLE-Null, which is in agreement with the minimal CYP 
activity reported in these cells (Dambach eta!., 2005).
Figure 2.8 THLE-2E1 metabolism of chlorzoxazone to 6-OH chlorzoxazone. THLE-Null (-------- )
and THLE-2E1 ( --------- ) cells were incubated with increasing concentrations (0 - 1000 pM) of
chlorzoxazone for 2 h. 6-OH chlorzoxazone was detected and quantified by LC-MS-MS (section 
2.2.13). Data presented was from one incubation carried out in duplicate (n = 1).
2.3.6 APAP metabolite turnover by THLE-2E1 activity
THLE-2E1 and THLE-Null cells were challenged with APAP, a drug well known to exert its 
toxicity through CYP2E1 mediated bioactivation to the electrophile NAPQI (Chapter 1 
section 1.5.1, Figure 1.2), to assess the potential of THLE-2E1 as an in vitro tool for studying 
xenobiotic-induced chemical stress.
Prior to assessing the toxicological effect of APAP in both cell lines, identification of 
APAP metabolites was carried out to confirm metabolic turnover. Identification of 
metabolites was carried out in all samples generated in section 2.2.15 to identify the 
optimal conditions for APAP bioactivation. The same samples were also analysed for 
toxicity and GSH levels so that in doing so, correlation between drug bioactivation, drug- 
toxicity and chemically-induced oxidative stress could be made.
The metabolic profiles of APAP in the THLE-Null and THLE-2E1 cell lines were 
observed to be distinctly different with the GSH conjugate (P-GSH) detected only in the
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THLE-2E1 cells, indicating CYP2El-mediated bioactivation of APAP into the reactive 
metabolite NAPQI (Figure 2.9). Furthermore, this also demonstrated a time-dependent 
increase in CYP2El-mediated bioactivation of APAP as P-GSH was most abundant at 72 h in 
the THLE-2E1 cells with the maximum turnover achieved between 5 and 15 mM APAP. A 
decline in P-GSH conjugate was observed above 15 mM APAP at 72 h suggesting toxicity as 
a result of prolonged exposure to high concentrations of APAP, an effect not observed at 24 
and 48 h.
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Figure 2.9 THLE-2E1 bioactivation of APAP. THLE-Null and THLE-2E1 cells (15, 000 cells per well, 96 
well format) were treated with increasing doses of APAP (0 -25 mM) and incubated for 24, 48 and 72 
h, after which samples of the media were analysed by LC-MS-MS (section 2.2.14). Ratios between 
APAP-GSH conjugate (P-GSH) against the internal standard, phenacetin, were determined. The above 
data represents the ratio calculated for the THLE-2E1 cells only as no P-GSH conjugate was detected 
in the THLE-Null. Results presented here were from a single incubation carried out in triplicate (n=l).
2.3.7 APAP-induced toxicity in the THLE-2E1 cells
APAP toxicity was assessed by measuring mitochondrial activity of both THLE-Null and 
THLE-2E1 cell lines (section 2.2.15). Figure 2.10 represents the percentage survival of both 
cell lines at increasing concentrations of APAP incubated for 24 (Figure 2.10-A), 48 (Figure 
2.10-B) and 72 (Figure 2.10-C) hours. No marked differences in toxicity profiles were
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observed between the THLE-Null and THLE-2E1 cell lines, however, the IC5o values (Figure 
2.10-D) at all time points were lower in the CYP2E1 containing cells which may be 
suggestive of CYP2El-mediated APAP toxicity.
D.
IC50 (APAP mM)
Null 24 h 17.89
2E1 24 h 9.74
Null 48 h 2.34
2E1 48 h 1.24
Null 72 h 1.31
2E172 h 1.02
B.
120
10000
C.
120
Figure 2.10 APAP toxicity in THLE-Null and THLE-2E1 cell lines. THLE-Null (--------- ) and THLE-2E1
( ---------  ) cell lines were treated with increasing doses of APAP (0-25 mM) for 24 (A), 48 (B) and 72
(C) h (section 2.2.15). Mitochondrial activity was measured (section 2.2.6) to determine APAP- 
induced toxicity and represented as percentage of cell survival. IC50 values were calculated and 
summarised in D. Error bars represent standard error of mean of 3 independent experiments in 
triplicate (n = 3).
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2.3.8 Glutathione levels in untreated and APAP-treated cells
GSH content was assessed both before and after exposure to APAP in the THLE-Null and 
THLE-2E1 cells (section 2.2.9) to determine whether the increase in P-GSH observed in the 
THLE-2E1 cells at 72 h correlated with changes in GSH levels.
In the absence of APAP, GSH levels appeared higher in the CYP2E1 containing cells 
at all time points (74.89, 50.62 and 37.91 nmol/mg protein observed at 24, 48 and 72 h 
respectively) than in the THLE-Null cells (41.98, 35.17 and 29.74 nmol/mg protein observed 
at 24, 48 and 72 h respectively). The higher level of GSH in the THLE-2E1 cells was 
maintained at all time points up to a concentration of 15 mM APAP except for that 
observed at 72 h where GSH was lower in the CYP2E1 containing cells (4.01 nmol/mg 
protein) compared with the THLE-Null (11.36 nmol/mg protein). However, at 25 mM APAP, 
GSH was observed to be markedly lower in the THLE-2E1 cells (3.50 nmol/mg protein) than 
in the THLE-Null cells (31.66 nmol/mg protein) after incubation for 24 h. This marked 
difference between the cell lines gradually decreased as GSH in the THLE-Null cells 
decreased at 48 and 72 h (4.79 and 0.65 nmol/mg protein) whilst GSH levels in the THLE- 
2E1 remained low (0.03 and 1.76 nmol/mg protein observed at 48 and 72 h respectively).
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Figure 2.11 GSH levels in THLE-Null and THLE-2E1 cells after a dose and time-dependent treatment 
with APAP. THLE-Nulls and THLE-2E1 cells were treated with increasing doses (0 - 25 mM) of APAP 
for 24 (A), 48 (B) and 72 (C) h. Following treatment, GSH and protein contents were measured 
(sections 2.2.9 and 2.2.8 respectively). Mean GSH data was obtained from a triplicate of two 
independent experiments (n=2) and represented as nmol/mg protein.
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2.4 DISCUSSION
The difficulties in extrapolating toxicity and metabolic profiles of new and existing drugs 
from pre-clinical studies to the clinic, has led to significant efforts in the development of 
more accessible alternative test systems such as the THLE-CYP expressing cell lines 
(Turpeinen et ai, 2007). The THLE-2E1 ceil line is the main focus of this chapter because of 
the CYP2E1 enzyme's high capacity to produce ROS in the absence or presence of a 
metabolic substrate (Gorsky et ai., 1984, Ekstrom and Ingelman-Sundberg, 1989), making it 
an ideal tool for oxidative stress studies. Furthermore, as it is a member of a panel of CYP 
overexpressing cell lines all of which have originated from the same parental cell line, the 
THLE-2E1 has an advantage over other CYP2E1 overexpressing cells in having direct 
comparators against other cell lines expressing other CYP450 isoforms and control. The 
purpose of the work described in this chapter was therefore to determine whether the 
THLE-2E1 can provide additional value in the study of oxidative stress. Characterisation of 
the THLE-2E1 with regards to viability, growth, CYP2E1 expression and metabolic capacity 
were carried out. This was followed by assessing the THLE-2E1 cell line's potential as a 
model for studying oxidative stress in the absence or presence of metabolic substrates 
including chlorzoxazone and the hepatotoxicant APAP, using the THLE-Null as a comparator.
Characterisation of untreated THLE-Null and THLE-2E1 cells in culture 
demonstrated no differences between the two cell lines with regards to cell morphology 
(Figure 2.5) and mitochondrial activity (Figure 2.6). However, THLE-2E1 was observed to 
have a slower growth rate of 42 h compared with the THLE-Null cells of 29 h which may be 
indicative of a CYP2El-induced stress response. As mentioned earlier, CYP2E1 is known to 
have a high capacity for creating an oxidative environment due to its loose coupling with 
CPR as demonstrated in a variety of test systems (Gorsky et ai, 1984, Ekstrom and 
Ingelman-Sundberg, 1989) including the HepG2-2El cell line established in the laboratory of 
Cederbaum and colleagues, where they have reported levels of ROS to be between 40 - 50 
% higher than in the control (Dai et ai, 1993, Chen and Cederbaum, 1998, Mari and 
Cederbaum, 2000). Based on this, the increased protein expression (Figure 2.7) and CYP2E1 
activity (Figure 2.8) observed in the THLE-2E1 cells compared with the THLE-Null may have 
also resulted in higher levels of basal oxidative stress in these cells. In order to adapt to 
such conditions, cellular defence in the CYP2E1 containing cells may have been enhanced 
but consequently, bearing a negative impact on the growth of the THLE-2E1 cells. Indeed, 
this negative effect in cell proliferation was reported in the HepG2-2El cells (Chen and 
Cederbaum, 1998) where the authors associated this observation as a consequence of
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CYP2E1 overexpression and reduced levels of vitamin E and ATP. It would therefore be 
useful If the same measurements (ROS, vitamin E and ATP) were carried out on the THLE- 
Null and THLE-2E1 cells to determine whether these factors are also the cause of the slow 
growth rate observed in the THLE-2E1 cells.
CYP2E1 western blot analysis clearly demonstrated overexpression of this protein 
in the THLE-2E1 cells compared with the THLE-Null (Figure 2.7-A). Furthermore, levels of 
CYP2E1 were comparable between the THLE-2E1 and cryopreserved human hepatocyte 
(HL-hep) samples. However, both were lower compared with an equivalent amount of 
homogenate from a whole human liver (HL-hom). Interestingly, ponceau (Figure 2.7-B) and 
coomassie (Figure 2.7-C) stains revealed that the overall protein profiles between these 
three test systems were distinctly different from each other, signifying the importance of 
caution when utilising such test systems to predict or extrapolate the toxic and metabolic 
profiles of drugs to a normal human liver. Particularly with the THLE-2E1, being a 
transformed cell line brings with it the inevitable intrinsic changes required to abrogate the 
ability to trigger apoptosis and/or necrosis to acquire immortalisation. A feature that makes 
these cells more amenable for toxic and metabolic studies but it may also be this very 
feature that prevents direct extrapolation of the toxic and metabolic profiles of drugs to 
primary hepatocytes. Furthermore, the high oxidative environment as a consequence of 
CYP2E1 overexpression in the THLE-2E1 cells may have resulted in enhanced cellular 
defence. This has been demonstrated in the control and APAP-treated THLE-2E1 cells 
(Figure 2.11) where GSH levels were consistently higher across the three timepoints 
measured (24, 48 and 72 h) up to and including those incubated with 5 mM APAP 
compared with the equivalent null cells, a characteristic that would not normally be 
observed in a normal liver cell. Interestingly, for each APAP concentration used in this 
particular experiment, a time-dependent decrease in GSH levels was observed for both cell 
lines. Furthermore, the extent of GSH depletion increases at higher APAP concentration 
demonstrating an incubation time and APAP concentration effect on GSH levels that is 
independent to APAP bioactivation.
Despite differences in CYP2E1 expression and overall protein profiles between the 
THLE-2E1, HL-hep and HL-hom test systems, the distinct CYP2E1 metabolic capacity of the 
THLE-2E1 cells compared with the THLE-Null as demonstrated in Figure 2.8 with 
chlorzoxazone gives it potential as a model for investigating the metabolic profile of drugs. 
No direct comparison of CYP2E1 activity between the THLE-2E1 cells and primary human 
hepatocytes could be made due to time constraints however, Lahoz et at. (2007) have
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reported CYP2E1 activity in primary human hepatocytes treated under comparable 
experimental conditions to that carried out in the THLE-2E1 cells (2 h incubation time, 5 pM 
chlorzoxazone and similar protein concentration for analysis) and was determined to be 46 
pmol/min/mg protein compared with 240 pmol/min/mg protein in the THLE-2E1 cells 
demonstrating a 5-fold higher metabolic capacity. This to some extent agrees with reports 
regarding the other CYP-overexpressing THLE cells as they were reported to exhibit higher 
CYP450 activity compared with primary human hepatocytes (Dambach et al.f 2005) but the 
THLE-2E1 cells certainly do not compare with the magnitude of difference in CYP450 
activity (25 - 90 fold observed in other THLE-CYP cells compared with primary human 
hepatocytes) which could be due to a number of reasons.
Although there is a clear overexpression of the CYP2E1 protein in the THLE-2E1 cells 
compared with the THLE-Nulls, the level of CYP2E1 overexpression may be lower compared 
with the level of overexpression of CYP450 enzymes in the other THLE CYP-overexpressing 
cells. This difference may be a consequence of the high oxidative environment in the THLE- 
2E1 cells which as suggested earlier may have also affected cell growth, determined to be 
slower (42 h) compared with the THLE-Nulls (29 h). Cellular resources may have therefore 
been prioritised for detoxification and/or adaptation to oxidative stress rather than cell 
growth. CYP2E1 expression may have therefore been compromised. Certainly, this has been 
demonstrated in the HepG-2El cells which were also engineered to overexpress the CYP2E1 
enzyme. These cells exhibited significantly higher levels of basal GSH, consistent with 
observations made in the THLE-2E1 cells (Figure 2.11). Messenger RNA (mRNA) and 
western blot analysis revealed this elevated GSH in the HepG2-2El cells to be associated 
with the up-regulation of Nrf2 (Mari and Cederbaum, 2000, Nieto et a!., 2003), which as 
mentioned in chapter 1 is an important transcriptional regulator of GCL, the enzyme 
responsible for the rate-limiting step of GSH synthesis (Kaplowitz et al., 1985, Moinova and 
Mulcahy, 1999, Wild et al., 1999, Chan and Kwong, 2000, Jeyapaul and Jaiswal, 2000, 
Reisman et al., 2009c). The role of Nrf2 in this adaptive cell defence mechanism may have 
also resulted in the up-regulation of phase II and III metabolism as several detoxifying 
enzymes are also under Nrf2 regulation, including GSTs and MRPs, as detailed in chapter 1. 
This adaptive mechanism may have also been employed by the THLE-2E1 cells against 
oxidative stress. Measurement of several endpoints that are under Nrf2 transcriptional 
regulation in the THLE-2E1 cells compared with the THLE-Nulls would provide a starting 
point in clarifying the role of Nrf2 in the adaptive defence mechanism acquired by the 
THLE-2E1 ceils against basal and induced cellular stress. Furthermore, the use of another
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THLE-CYP overexpressing cell line in this work, such as the THLE-1A2 and/or THLE-3A4, both 
of which also metabolise APAP could be useful in delineating between CYP2E1 and APAP- 
induced cellular stress {Dahlin et al., 1984, Raucy et oi, 1989, Manyike et al, 2000). 
Comparisons can also be made in terms of growth, cell viability, CYP450 protein expression, 
activity and toxicity to determine if the difference seen in the CYP450 activity in the THLE- 
2E1 cells when compared with primary human hepatocytes (Lahoz et al., 2007) is indeed 
due to the high oxidative environment. Although the THLE-2E1 cells do not have a 
comparable CYP450 activity with the other CYP-overexpressing THLE cells, the 5-fold 
difference in activity compared with that reported in primary human hepatocytes (Lahoz et 
al., 2007) could still give the THLE-2E1 cell line the potential in predicting the metabolic 
profile of drugs in humans who exhibit unusual CYP2E1 metabolic activity as a consequence 
of genetic polymorphism or induction through alcohol exposure/consumption (Prescott, 
2000, Schmidt et al., 2002, Krahenbuhl et al., 2007). If indeed the lower' difference in 
CYP2E1 activity of the THLE-2E1 cells compared with the primary human hepatocytes is due 
to a high oxidative stress environment caused by CYP2E1 overexpression, the THLE-2E1 
cells may therefore be comparable with other CYP2E1 overexpressing cell lines such as the 
HepG2-2El cells and could still be a good model for predicting CYP2El-mediated ADRs in 
vitro.
The CYP2El-mediated metabolic capacity of the THLE-2E1 cells was further 
confirmed by the presence of the glutathione adduct (P-GSH) produced as a consequence 
of APAP bioactivation to the reactive metabolite, NAPQI (Figure 2.9). This gives the THLE- 
2E1 cell line the potential as a model for investigating not just the metabolic profile of drugs 
but also their toxic potential. However, when toxicity was measured in these ceils upon 
treatment with varying concentrations of APAP (0-25 mM) and incubation times (24, 48 and 
72 h), no significant difference in toxicity profiles was observed between the THLE-2E1 and 
THLE-Null cells (Figure 2.10). It is plausible that toxicity was not captured under the 
conditions used. Indeed, although not significant, there was a small but consistent 
difference in the IC5o values between the THLE-2E1 and THLE-Null and this difference was 
more evident at the 24 h time point. This suggests that although levels of the GSH-P adduct 
were highest at the 72 h time point, cellular stress/toxicity was more likely to have taken 
place at 24 h or even earlier. However, due to time constraints, this could not be explored 
further. The highly similar IC5o values between the THLE-Null and THLE-2E1 cells at 48 and 
72 h could indicate cellular stress/toxicity from a combination of CYP2El-mediated 
bioactivation and accumulation of APAP itself. Of course, this may also just be due to a lack
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of activity in the THLE-2E1 ceils to cause significant cellular stress and hence toxicity as 
discussed above.
Work described in this chapter has demonstrated the potential and limitations of 
the THLE-2E1 cell line as a model for chemical stress. These cells demonstrated comparable 
characteristics with other CYP2E1 overexpressing liver cel! lines such as the HepG2-2El 
cells, particularly in their growth rates, which were determined to be slower compared with 
their respective controls. Furthermore, the high level of GSH observed was likely to be a 
consequence of the CYP2El-mediated oxidative environment. Such feature increases the 
potential of the THLE-2E1 cell line as a tool for studying oxidative stress. However, these 
features as a consequence of CYP2E1 overexpression may also be the reason for the limited 
use of the THLE-2E1 cell lines in predicting the metabolic profile and toxic potential of 
drugs. Although there is a distinct difference in CYP2E1 activity between the THLE-Null and 
THLE-2E1 cells, as demonstrated upon incubation with APAP and chlorzoxazone, the level of 
CYP450 activity is lower compared with other CYP450 expressing THLE cells. This is further 
supported by the lack of difference in toxicity profiles between the THLE-2E1 and THLE- 
Nulls. As such, work described in this chapter demonstrated that the THLE-2E1 cell line 
could be useful in CYP2E1 based metabolism studies but not in elucidating the toxic 
potential of CYP2E1 substrates.
59
Chapter 3
The Nrf2( / I
Chapter 3
mouse as an in vivo model of chemical stress: effect of 
acute and chronic exposure to APAP
60
Chapter 3
TABLE OF CONTENTS
3.1 INTRODUCTION.....................
3.2 MATERIALS AND METHODS
3.2.1 Materials.....................
3.2.2 Animal dosing regimen
3.2.3 The effect of acute APAP treatment to the GSH
63 
70
70 
70
system in wild type and Nrf2(V'
mice 70
3.2.4 The effect of chronic APAP treatment at escalating doses to the GSH system in
wild type and Nrf2('/'1 mice............................................................ 71
3.2.5 The effect of chronic APAP treatment at escalating doses followed by a lethal
dose to the GSH system in wild type and Nrf2(V') mice................................................. 71
3.2.6 Determination of serum alanine transaminase (ALT) levels..........................72
3.2.7 Determination of hepatic GSH content........................................................... 72
3.2.8 Determination of protein concentration......................................................... 72
3.2.9 Metabolite analysis by LC-MS-MS....................................................................72
3.2.9.1 Homogenisation of liver tissue.....................................................................72
3.2.9.2 Preparation of metabolite standard stocks................................................. 73
3.2.9.3 Preparation of standard and sample mixtures for analysis........................73
3.2.9.4 LC-MS-MS...................................................................................................... 74
3.2.10 Statistical analysis..............................................................................................75
3.3 RESULTS............................................  76
3.3.1 Metabolic perturbations within the GSH system in response to an acute sub- 
lethal dose of APAP in Nrf2(+/+) and Nrf2<‘/')mice.............................................................76
3.3.1.1 Determination of hepatic injury by measurement of serum ALT.............. 76
3.3.1.2 Metabolite analysis by LC-MS-MS............................................................... 78
3.3.1.2.1 Metabolite profile of Nrf2(+/+1 and Nrf2('/‘) mice in response to an acute 
dose of APAP.............................................................................................................. 78
3.3.2 Assessing metabolite perturbations in the GSH system upon chronic treatment
of Nrf2l+/+) and Nrf2(‘/'1 mice with escalating doses of APAP (150 - 600 mg/kg).......... 83
3.3.2.1 Determination of hepatic injury by serum alanine transferase measurement 
83
3.3.2.2 Metabolite profile of Nrf2(+/+) and Nrf2("/'1 mice in response to chronic
treatment with escalating doses of APAP...................................................................84
3.3.3 Metabolite perturbations in the GSH system upon chronic treatment of Nrf2(+/+)
and Nrf2("/") mice with escalating doses of APAP (150 - 600 mg/kg) for 8 days followed by 
a lethal dose of 1000 mg/kg APAP on day 9...................................................................89
61
254020582559657
Chapter 3
3.3.3.1 Determination of hepatic injury by measurement of serum ALT.............. 89
3.3.3.2 Metabolite analysis by LC-MS-MS................................................................92
3.3.3.2.1 Comparison between Nrf2<+/+SS, Nrf2('/')SS, Nrf2(+/+)SA and Nrf2(V')SA 
treatment groups.................................................................................................... 92
3.3.3.2.2 Comparison between Nrf2(+/+)AS, Nrf2('/')AS, Nrf2(+/+)AA and
Nrf2('/')AA.................................................................................................................. 93
3.4 DISCUSSION...........................................................................................................................97
3.4.1 Acute time-course study with 350 mg/kg APAP.............................................97
3.4.2 Chronic study with escalating doses of (150-600 mg/kg) APAP....................99
3.4.3 Chronic study with escalating (150-600 mg/kg) doses of APAP and subsequently
challenged with a lethal dose..........................................................................................102
3.4.4 Overall conclusion.......................................................................................... 104
62
Chapter 3
3.1 INTRODUCTION
The transcription factor Nrf2 is a well established regulator of the expression of many 
cytoprotective genes, including NAD(P)H:quinone reductase 1 or NQOl (Li and Jaiswal 
1992a; McMahon etaL, 2001a; Ramos-Gomez et ai, 2001a; Venugopal et oL, 1996; Wang 
et al., 2006), heme-oxygenase-1 or HO-1 (Alam et ai, 1999; Ishii et ai, 2000), glutamate 
cysteine ligase catalytic subunit or GCLC (Wild etai, 1999, Chan and Kwong, 2000, Jeyapau! 
and Jaiswal, 2000), glutamate cysteine ligase modifier subunit or GCLM (Moinova and 
Mulcahy, 1999, Wild etai, 1999, Chan and Kwong, 2000), glutathione-S-transferases or GST 
(Hayes et ai, 2000; Knight et al., 2008; Chanas et ai, 2002; McMahon et ai, 2001) and 
multidrug resistance-associated proteins or MRPs (Aleksunes et ai, 2008b). This regulation 
is achieved through the binding of Nrf2 to the antioxidant response element (ARE) 
sequence defined as, 5' G AGT C ACAGT G AGT CG G C A A AA ATT-3', a cis-acting regulatory 
element common to the promoter regions of target cytoprotective genes, which in turn 
induces gene transcription. The importance of this regulatory role has been confirmed by 
studies carried out in the Nrf2(‘/“) mice, whereby various groups have demonstrated that the 
deletion of the Nrf2 gene leads to a reduction in the constitutive expression and the ability 
to up-regulate both detoxifying and antioxidant enzymes in response to a chemical insult, 
resulting in the enhanced susceptibility of these animals to hepatic injury (Chan et ai, 2001, 
Enomoto etai, 2001).
In particular, the two subunits, GCLC and GCLM, which make up glutamate cysteine 
ligase (GCL), the enzyme responsible for catalysing the rate limiting step of GSH synthesis, 
are both under the transcriptional regulation of the Nrf2/ARE pathway, as depicted in 
Figure 3.1. Indeed, it has been well established by our group (Kitteringham etai, 2010) as 
well as that of others (Klaassen and Reisman, 2010) that the basal level of cellular GSH is 
between 20-30 % lower in the Nrf2('/') mice compared with wild type which is consistent 
with a reduction in GCL protein activity.
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Figure 3.1 The role of Nrf2 in the transcriptional regulation of GSH biosynthesis. Pathways were 
identified using the MetaCore database describing the role of Nrf2 in amino acid metabolism, 
including those implicated in GSH synthesis. Abbreviations used in the illustration is summarised in 
Table 3.1. (MetaCore, GeneGo Inc. http://www.genego.com/metacore.php)
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Table 3.1 Abbreviations for Figure 3.1.
ABBREVIATIONS SPECIES
ALAS2 5-aminolevulinate synthase, erythroid 
specific, mitochondrial precursor Human, mouse and rat
AP-1 AP-1 Human, mouse and rat
AP-2A Transcription factor AP-2A alpha Human, mouse and rat
ASSY Argininosiccinate synthase Human, mouse and rat
c-Maf Transcription factor Maf Human, mouse and rat
DCOR Ornithine decarboxylase Human, mouse and rat
Erk{MAPKl/3) Erk (MAPK1/3) Human, mouse and rat
FECH Ferrochelatase Humand and mouse
Mitochondrial precursor ferrochelatase 
(predicted) Rat
GATA-1 Erythroid transcription factor Human, mouse and rat
GCL cat Glutamamte-cysteine ligase catalytic 
subunit Human, mouse and rat
GCL reg Glutamate-cysteine ligase regulatory 
subunit Human, mouse and rat
HMBS Porphobilinogen deaminase Human, mouse and rat
KEAP1 Kelch-like ECFI-associated protein 1 Human, mouse and rat
MafK Transcription factor MafK Human and mouse
Transcription factor v-maf 
musculoaponeurotic fibrosarcoma 
oncogene family, protein K (avian)
Rat
MAFG Transcription factor MAFG Human and mouse
Transcription facto v-maf 
musculoaponeurotic fibrosarcoma 
oncogene family, protein G (avian)
Rat
Max Protein Max Human, mouse and rat
NF-E2 (45 kDa) Transcription factor NF-E2 45 kDa subunit Human, mouse and rat
NFE2L1 Transcription factor nuclear factor 
erythroid 2-related factor 1 Human and mouse
Transcription factor nuclear factor, 
erythroid derived 2 -like 1 (predicted)
Rat
Nrf2 Transcription factor nuclear factor 
erythroid 2-related factor 2 Human, mouse and rat
P38alpha
(MAPK14) Mitogen-activated protein kinase 14 Human, mouse and rat
PKC PKC Human, mouse and rat
SP1 Transcriptional factor SP1 Human, mouse and rat
ZNF148 Zinc finger protein 148 Human, mouse and rat
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GSH plays a key role in maintaining the redox status of the cell as well as providing cellular 
defence against chemical stress through the detoxification of both electrophiles and ROS. In 
addition to the transcriptional regulation of GCL by Nrf2, several other important factors 
also influence the synthesis of GSH. One such factor is the negative feedback loop that is 
governed by the cellular concentration of GSH. This mechanism influences the up- or down- 
regulation of GCL activity and hence GSH synthesis {Richman and Meister, 1975). Another 
factor is the availability of precursors, in particular, of the thiol containing amino acid 
cysteine. The thiol group of this molecule is key in the detoxification mechanism employed 
by GSH therefore cysteine availability is crucial for both the synthesis and function of GSH 
(Kaplowitz et al., 1985; Richman and Meister 1975; Meister and Anderson 1983). 
Heterodimerisation of GCLC and GCLM is another factor that could influence GSH synthesis 
(Seelig et al., 1984, Huang et al., 1993a, Huang et al., 1993b).
As demonstrated in Figure 3.2, the supply of cysteine for GSH synthesis is 
dependent on a number of pathways involved in amino acid metabolism. These include the 
methionine, transsulfuration, polyamine and cysteine sulfinate pathways (Finkelstein 1998; 
Lu 1999; Tarver and Schmidt 1939). As cysteine is used by GCL as substrate for the 
production of y-glutamylcysteine (y-GC), these pathways are also implicated in the 
transcriptional regulation of GCL by IMrf2. Furthermore, polyamine metabolism has been 
reported to induce directly the transcription of phase II detoxifying enzymes through the 
activity of H202 and aminoaldehydes which are products of spermidine oxidation, on the 
Nrf2/ARE pathway (Kwak eta!., 2003).
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Figure 3.2 The glutathione metabolome. A schematic diagram illustrating the GSH biosynthetic 
pathway including peripheral pathways implicated in this process. For a more detailed version, refer 
to chapter 1, Figure 1.6 and Appendices 1-4.
As mentioned earlier, in addition to the regulatory role of Nrf2 in the constitutive 
expression of various detoxifying and antioxidant genes, it is also responsible for the 
adaptive response of these genes against chemical stress. Due to its nucleophilic nature, 
high levels and cellular disposition, GSH is at the forefront of the detoxification of both 
electrophiles and ROS produced during chemical stress. However as GCL is regulated by 
Nrf2, this cytoprotective role is highly dependent on the response of Nrf2 to chemical 
stress. Amongst many hepatotoxicants, APAP is a well known modulator of GSH. It is widely 
available as an over-the-counter antipyretic analgesic that is safe for use at normal 
therapeutic doses. However, it is also the leading cause of drug-induced liver injury in the 
UK (Davern et al.f 2006) and United States (Larson et al., 2005; Lee 2004). To date, it is 
widely accepted that the molecular mechanism of APAP hepatotoxicity is initiated by the 
cytochrome P450-mediated bioactivation of APAP to the reactive metabolite NAPQI 
(Mitchell eta!., 1973b, Dahlin etal., 1984, Lee etal., 1996).
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At therapeutic doses, APAP primarily undergoes glucuronidation and sulfation metabolism 
prior to its excretion in the urine. NAPQI is also formed in small quantities (5 - 10 % APAP) 
mainly by CYP2E1 bioactivation and to a lesser extent by CYP1A2 and CYP3A4 (Dahlin et ol., 
1984, Raucy et al., 1989, Manyike et ai, 2000) but is spontaneously quenched through GSH 
conjugation and subsequently excreted in the urine as mercapturic acid or cysteine 
conjugate (Mitchell et al., 1973b). However, these detoxification pathways can be 
overwhelmed as a consequence of APAP overdose, resulting in large amounts of NAPQI 
being produced which cannot be efficiently detoxified as stated above. As a result, the 
cellular store of GSH becomes depleted enabling NAPQI to covalently bind to 
macromolecules and/or to generate ROS which consequently leads to hepatotoxicity 
(Jollow etai, 1973, Potter eto/., 1973).
The hepatotoxic effect of APAP is commonly associated with the administration of 
an acute toxic dose as observed in the clinic (Lee, 2004, Larson et al., 2005), and 
demonstrated in model systems (Kitteringham et al., 2000, Randle et al., 2008). However, 
there is evidence that prolonged exposure to APAP may lead to reduced sensitivity to 
hepatotoxicity. In a case study described by Shayiq et al., (1999), a physician who was 
addicted to oxycodone presented no sign of liver injury despite ingesting up to 36,000 
tablets for 2 years, equivalent to a daily dose of 65 g APAP. Similarly, a patient suffering 
from rheumatoid arthritis who took daily doses of 15 -20 g APAP as pain relief for 5 years 
showed no signs of APAP toxicity. In this particular study, the authors attributed this 
resistance to a combination of slow APAP absorption, enhanced detoxification and reduced 
drug bioactivation compared with normal volunteers (Tredger eto/., 1995).
Following from this, in vivo animal studies have been undertaken to simulate the 
cases described above and have reported similar findings. Shayiq et al. (1999) 
demonstrated that exposure of mice to incremental doses of APAP afforded these animals 
protection against a subsequent lethal dose. The protection was attributed to increased cell 
proliferation within the liver and reduced covalent binding as a result of a shift in the 
bioactivation of APAP from centrilobular to periportal regions, where CYP2E1 is not found 
and GSH is more abundant. In a further study by Aleksunes et al. (2008), the protective 
mechanism was reported to involve the induction of a member of the multidrug resistance- 
associated protein family, MRP4.
Whilst the precise mechanism underlying the adaptive change resulting in 
protection against hepatotoxicity following prolonged APAP exposure remains undefined,
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the possible explanations proposed point to a generalised up-regulation of cellular defence 
and a reduced capacity to bioactivate the drug. Furthermore, the enhanced cellular 
proliferation observed in the Shayiq study (1999) suggests that the liver is able to repair 
tissue damage more readily in the treated mice. Studies conducted within the department 
and elsewhere have identified Nrf2 as a regulator of both cellular defence and of cell 
viability. Several of the key mechanisms identified in the chronic studies described above, 
such as GSH synthesis, cytochrome P450 activity, cellular transport and cell proliferation are 
modulated by the Nrf2/ARE pathway. It is thus plausible that Nrf2 may be a principal 
regulator of the adaptive response induced by prolonged exposure to APAP. Consequently, 
the studies described in this chapter were designed to test the hypothesis that Nrf2 is 
essential in the adaptive response against acute and chronic exposure to chemical stress 
inducers. This hypothesis was tested by comparing the ability of Nrf2(+/+)and Nrf2('A)mice to 
adapt to APAP treatment following the dosing regimens summarised in Table 3.2. 
Furthermore, we investigated the underlying basis of this protection through a targeted 
metabolomic analysis focussing on the GSH system by selecting and monitoring 
perturbations of key metabolites in this system. Substantiation of this hypothesis raises the 
possibility that mice deficient in the Nrf2-driven cellular defence system could provide a 
valuable in vivo model of oxidative and drug-induced chemical stress.
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3.2 MATERIALS AND METHODS
3.2.1 Materials
All chemicals and reagents were purchased from Sigma Aldrich Chemical Co. (Poole, Dorset, 
UK) unless otherwise stated. Acetone and formic acid were purchased from VWR 
(Lutterworth, Leicestershire, UK). Sodium hydroxide and methanol were purchased from 
Fisher Scientific (Loughborough, Leicestershire, UK). Ophthalmic acid was purchased from 
Bachem (Weil am Rhein, Germany). Infinity ALT (GPT) liquid stable reagent was purchased 
from Thermo Scientific (Loughborough, Leicestershire, UK).
3.2.2 Animal dosing regimen
All animal experiments were undertaken in accordance with criteria outlined in a license 
granted under the Animals (Scientific Procedures) Act 1986, and approved by the Animal 
Ethics Committees of the University of Liverpool. The generation of the Nrf2('/') mice have 
been previously described (Itoh et a!., 1997, McMahon et al.t 2001). All animals were 
housed under 12-h light/dark cycles with room temperature maintained between 19 °C - 
23 °C. Animals had free access to food and water.
3.2.3 The effect of acute APAP treatment to the GSH system in wild type and 
Nrf2('/ > mice
Male C57BL/6 Nrf2t+/+) and Nrf2('/') mice were administered intraperitoneally (i.p.) with a 
sub-lethal dose of 350 mg/kg APAP in 0.9 % saline or vehicle (control). Animals were 
sacrificed at 0, 1, 3 and 5 h (Table 3.2) by carbon dioxide (C02) asphyxiation and cervical 
dislocation. Livers were removed and snap frozen immediately in liquid nitrogen and stored 
at -80 °C until further use. Serum was obtained by allowing the blood to clot at room 
temperature for 1 h followed by pulse centrifugation at 4000 rpm (Bio-Tek FL600 Vermont, 
USA).
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3.2.4 The effect of chronic APAP treatment at escalating doses to the GSH 
system in wild type and Nrf2|■/■, mice
Male C57BL/6 mice were administered with escalating doses of APAP (150 - 600 mg/kg) in 
0.9 % saline or vehicle (control; i.p.) for 8 consecutive days as shown in Table 3.2. Animals 
were killed 5 h after the last dose at day 8 by C02 asphyxiation and cervical dislocation. 
Sample collection and storage were as detailed in section 3.2.3.
3.2.5 The effect of chronic APAP treatment at escalating doses followed by a 
lethal dose to the GSH system in wild type and Nrf2^■/■, mice
Male C57BL/6 mice were administered escalating doses of APAP (150, 150, 300, 300, 450, 
450, 600 and 600 mg/kg) in 0.9 % saline or vehicle (control i.p.) for 8 consecutive days as 
shown in Table 3.2, followed by a 1000 mg/kg APAP dose in 0.9 % saline or vehicle (control) 
on day 9 for 5 h. Animals were killed by C02 asphyxiation and cervical dislocation. Sample 
collection and storage were as detailed in section 3.2.3.
Table 3.2. Summary of studies carried out in this chapter which were designed to test the 
hypothesis that Nrf2 is essential in the adaptive response against chemical stress. Unchallenged
refers to chronic treatment with APAP up to day 8, without the challenge dose of 1000 mg/kg APAP 
on day 9, whereas challenged refers to chronic treatment including day 9.
TYPE OF DOSING REGIMEN
STUDY
Acute 350 mg/kg APAP treatment for 0,1, 3 and 5 h.
Chronic Single ip dose/day (mg/kg)
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day8 Day 9
Unchallenged 150 150 300 300 450 450 600 600
Challenged 150 150 300 300 450 450 600 600 1000
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3.2.6 Determination of serum alanine transaminase (ALT) levels
Blood from the above animals (sections 3.2.3 - 3.2.5) were allowed to clot overnight at 4 °C 
and subsequently pulse centrifuged at 4000 rpm (Bio-Tek FL600 Vermont, USA) after which 
serum samples were collected. Determination of serum ALT was carried out using Infinity 
ALT (GPT) reagent (Thermo Scientific, Loughborough, UK) according to the manufacturer's 
instructions.
3.2.7 Determination of hepatic GSH content
Hepatic GSH was determined based on the method of (Vandeputte et al., 1994). Briefly, 
approximately 50 mg of tissue was homogenised in 5-sulfosalicyclic acid (SSA; 200 pi; 6.5 % 
w/v) and GSH stock buffer (800 pi; 143 mM NaH2P04, 6.3 mM EDTA), pH 7.4). Protein was 
precipitated on ice for 10 min prior to centrifugation (14000 rpm for 5 min). Total hepatic 
GSH content was measured (412 nm) according to the kinetic reaction between GSH and 
GSH reductase on a microtitre-plate reader (UV-visible absorbance MRX Dynatech 
Laboratories, Chantilly, VA).
3.2.8 Determination of protein concentration
Hepatic protein content was determined according to the method of Lowry (1951) as 
described in chapter 2, section 2.2.8.
3.2.9 Metabolite analysis by LC-MS-MS
3.2.9.1 Homogenisation of liver tissue
Liver tissue from each animal was weighed and homogenised in phosphate buffer (1:5; w/v) 
using a micropestle, followed by a freeze (- 80 °C for 1 h)/ thaw (room temperature) step 
and sonication (Soniprep 150, MSE London, UK, three times at ten second bursts) before 
centrifugation for 30 min at 4 °C. The supernatants were collected and stored at -80 °C until 
required.
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3.2.9.2 Preparation of metabolite standard stocks
Combined metabolite standards with a concentration range of 0 - 4 pM were prepared in 
0.1 % formic acid. A 1 ml solution of 10 mM internal standard (S-hexylglutathione) was 
prepared by firstly adding 450 pi 0.1 % formic acid and 50 pi 1 M NaOH to allow the S- 
hexylglutathione to dissolve to the correct pH. An additional 500 pi 0.1 % formic acid was 
added to give a concentration of 10 mM and was then further diluted to obtain a 5 pM 
stock.
3.2.9.3 Preparation of standard and sample mixtures for analysis.
A standard mixture was prepared by adding 10 pi metabolite standard, 10 pi 5 pM 5- 
hexylglutathione stock solution and 10 pi 30 mg/ml BSA {in dHzO) and made up to 50 p! 
with dH20. The sample mixture consisted of 10 pi liver homogenate or serum with 10 pi 5 
pM S-hexylglutathione and made up to 50 pi with dH20.
For the determination of cysteine, a derivatisation step was carried out with 
iodoacetamide to stabilise the sulfhydryl group within the cysteine molecule. Derivatised 
standard mixture consisted of 5 pi standard, 10 pi 5 pM S-hexylglutathione, 5 pi 30 mg/ml 
BSA (in dH20) and 30 pi 550 mM iodoacetamide (dissolved in 10 mM ammonium 
bicarbonate) and allowed to react at room temperature for 30 min. The derivatised sample 
mixture consisted of 5 pi liver homogenate or serum, 10 pi 5 pM S-hexylglutathione, 5 pi 
dH20 and 30 pi 550 mM iodoacetamide. Samples and standards were de-proteinated with 
200 pi ice-cold acetone at -20 °C for 1 h. Supernatants were obtained by centrifugation 
(Beckman GS-15R High Wycombe, Buckinghamshire, UK) for 10 mins at 4 °C. Acetone was 
removed by drying the supernatants down to approximately 50 pi in a Speed Vac 
(Eppendorf Concentrator 5301 Histon, Cambridge, UK) at 30 °C for 25 min. Samples were 
subsequently diluted with 200 pi 0.1 % formic acid and stored at 4 °C prior to analysis.
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3.2.9.4 LC-MS-MS
All LC-MS-MS experiments were performed using a Perkin Elmer SCIEX API 2000 LC-MS-MS 
system with a Perkin Elmer Series 200 Autosampler and HPLC Pump (Massachusetts, USA). 
Analytes were separated using a Prodigy C18 column 5 \x ODS (2), 150 x 4.6 mm length 
(Phenomenex Macclesfield, Cheshire, UK).
The flow-rate of 1 mL/min was achieved with an elution gradient composed of 
solvent A (0.1 % formic acid in dH20) and solvent B (100 % MeOH). The gradient started 
with a 12 min linear gradient from 100 % - 40 % solvent A, followed by an isocratic step of 
40 % solvent A for 2 min, a linear gradient from 40 % to 100 % solvent A for 8 min and then 
a final isocratic step of 100 % solvent A for 8 mins. The total analysis time and injection 
volume were 35 min and 50 \x\ respectively. The autosampler syringe was subjected to 
three times pre and post sample injection washes with solvent A. Analytes were detected in 
the positive ion mode using MS-MS with MRM which uses the unique fragmentation 
pattern of each metabolite for detection. Optimisation of the fragmentation pattern and 
quantification of metabolites were carried out using reference standards. Optimised MRM 
fragmentation patterns used to detect the metabolites are summarised in Table 3.3. 
Nebuliser, curtain and collision gases were set to 20, 10 and 8 respectively. Ionisation spray 
was set at 5.5 kV and the source temperature was 300 °C. System control and data 
acquisition were performed using Analyst Version 1.4 software.
Table 3.3 Optimised MRM transitions used for the detection and quantification of each analyte.
Compound Parent Ion (m/z) Fragment Ion (m/z)
Ophthalmic acid 290 58
GSSG 613 355.3
Methionine 149.66 104.3
Spermidine 146.109 71.9
Taurine 125.94 108.3
Cysteine 179.66 88.2
S-hexylglutathione 392.076 246.5
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3.2.10 Statistical analysis
All results are expressed as mean ± standard error of the mean (SEM). All values were 
analyzed for non-normality using the Shapiro-Wilk test. A student's unpaired t test or 
AIMOVA was used if normality was indicated. For non-normally distributed data a Mann 
Whitney U or a Kruskal Wallis tests was applied. Results were considered significant when 
p values were less than 0.05.
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3.3 RESULTS
3.3.1 Metabolic perturbations within the GSH system in response to an acute 
sub-lethal dose of APAP in Nrf2(+/+) and Nrf2('/") mice
To determine the role of Nrf2 in the adaptive response to APAP-induced stress, Nrf2(+/+) and 
Nrf2('A) mice were treated with an acute dose of 350 mg/kg APAP for 0, 1, 3 and 5 h. Liver 
and serum samples were collected and analysed for serum ALT levels as a measure of liver 
damage as well as metabolites within the GSH system to deteremine the relationship 
between Nrf2 and perturbations within the GSH system in response to APAP-induced 
stress. Serum ALT levels were also measured as detailed in section 3.2.6 to indicate liver 
injury and/or toxicity as a consequence of acute paracetamol treatment as described 
above.
3.3.1.1 Determination of hepatic injury by measurement of serum ALT
Serum ALT was measured to determine whether an acute dose of 350 mg/kg APAP leads to 
liver injury and/or toxicity in the Nrf2('A) mice compared with Nrf2{+/+) after a 5 h period 
post dose.
At 3 h post dose, serum ALT was detected to be significantly higher in both Nrf2(+/+) 
and Nrf2(A) mice (318.31 ± 199.17 and 215.15 ± 92.58 U/L respectively) compared with 
their corresponding control groups (25.46 ± 6.31 and 41.60 ± 19.46 U/L for Nrf2(+/+) and 
Nrf2("A) respectively) and the 0 h control animals (15.19 ± 2.77 and 13.95 ± 2.34 U/L for 
Nrf2(+/+) and Nrf2("A) respectively) (Figure 3.3-A and B respectively). After 5 h, the difference 
in ALT values was markedly higher in the treated Nrf2('A) animals (2019.93 ± 1315.93 U/L) 
compared with the time-matched control group (30.30 ± 14.48 U/L) and was determined to 
be significantly higher compared with ALT levels measured in the 0 h control group (13.95 ± 
2.34 U/L). On the other hand, ALT levels in the equivalent wild type group (234.47 ± 141.66 
U/L) were only marginally higher above baseline values (30.39 ± 14.49 U/L for time- 
matched control), but demonstrated significantly higher ALT when compared with the 0 h 
Nrf2(+/+) control group (15.19 ± 2.77 U/L). These data indicate a potential adaptive 
response induced by the Nrf2(+/+1 mice to the acute APAP treatment of 350 mg/kg allowing 
the attenuation of further liver injury at 5 h. On the other hand, the ability of the Nrf2( A)
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mice to launch an adaptive response may have been abrogated resulting in higher serum 
ALT at 5 h compared with time-matched control.
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Figure 3.3 Serum ALT activities in mice after treatment with an acute dose of APAP. Male C57BL/6 
Nrf2 + + (A) and Nrf2( 71 (B) mice were administered an acute dose of 350 mg/kg APAP ( H) or vehicle 
(□). Blood samples were collected at 0, 1, 3 and 5 h and serum extracted as detailed in section 3.2.3. 
Serum ALT activity was measured using the protocol detailed in section 3.2.6. Data from both A and 
B are presented as mean serum ALT activity (U/L) ± SEM (n = 4-6 animals).
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3.3.1.2 Metabolite analysis by LC-MS-MS
3.3.1.2.1 Metabolite profile of Nrf2{+/+} and Nrf2{‘/) mice in response to an 
acute dose of APAP
Figures 3.4 (hepatic) and 3.5 (serum) represent the effect of acute APAP treatment on the 
GSH system at the four time-points measured (0, 1, 3 and 5 h) in the Nrf2l+/+) and 
Nrf2('/')mice.
Acute treatment in the Nrf2(+/+) mice with 350 mg/kg APAP resulted in a significantly 
lower level of hepatic GSH at 1 h post dose (7.51 ± 2.27 nmol/mg protein) compared with 
time-matched control (32.83 ± 7.48 nmo!/mg protein). Although not determined to be 
significant, this trend was consistent at 3 and 5 h with hepatic GSH also lower in the Nrf2(+/+) 
APAP-treated groups (17.37 ± 4.56 and 36.88 ± 5.70 nmol/mg protein respectively) 
compared with their time-matched controls (28.04 ± 3.90 and 56.63 ± 13.07 nmol/mg 
protein respectively). However, hepatic GSH was observed to be generally higher in the 
Nrf2(+/+) APAP-treated animals at the later time-points of 3 and 5 h compared with those 
from the 1 h group potentially indicating GSH recovery.
Similar to observations made in the Nrf2{+/+)mice, hepatic GSH in the APAP-treated 
Nrf2(V') animals were significantly lower at 1, 3 and 5 h (9.28 ± 3.15, 4.94 ± 1.16 and 14.62 ± 
6.93 nmol/mg protein respectively) compared with time-matched control groups (38.13 ± 
7.31, 28.36 ± 2.42 and 33.69 ± 5.39 nmol/mg protein respectively). When comparing the 
level of hepatic GSH between the APAP-treated Nrf2(+/+,and Nrf2('A) at 3 and 5 h, GSH levels 
were generally higher in the Nrf2(+/+} animals (17.36 ± 4.56 and 36.88 ± 5.70 nmol/mg 
protein at 3 and 5 h respectively) compared with the Nrf2('A) mice (4.94 ± 1.16 and 14.62 ± 
6.93 nmol/mg protein at 3 and 5 h respectively). This difference could be indicative of the 
difference in which these two strains were able to up-regulate GSH synthesis. Furthermore, 
hepatic GSH in the Nrf2(+/+) control group at 0 h (30.05 ± 5.95 nmol/mg protein) was only 
significantly higher when compared with levels measured in the Nrf2(+/+) APAP-treated 
group at 1 h, whilst all Nrf2('A) APAP-treated groups at 1, 3 and 5 h were significantly lower 
compared with the Nrf2('A) control group at 0 h (42.65 ± 6.30 nmol/mg protein).
Similar to the pattern observed with hepatic GSH, GSSG in the liver was also lower 
at 1, 3 and 5 h in the Nrf2(+/+) APAP-treated groups (1.62 ± 0.40, 7.27 ± 2.25 and 11.79 ±
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1.82 nmol/mg protein respectively) compared with time-matched controls (15.03 ± 2.10, 
19.34 ± 3.80 and 23.09 ± 4.04 nmol/mg protein respectively). Furthermore, levels of hepatic 
GSSG in these animals were also significantly lower compared with the 0 h Nrf2(+/+) control 
group (23.06 ± 2.62 nmol/mg protein). However, a trend towards increasing levels of GSSG 
was observed in the Nrf2(+/+) APAP-treated groups over the 1, 3 and 5 h time points 
suggesting that the level of chemical stress may have started to subside at the later time 
points (3 and 5 h) allowing GSH levels to recover and become available for physiological 
oxidation reactions.
Hepatic GSSG was also markedly lower at 1, 3 and 5 h in the Nrf2('/") APAP-treated 
groups (3.32 ± 1.10, 1.91 ± 0.99 and 5.47 ± 1.72 nmol/mg protein respectively) compared 
with the 0 h control group (12.57 ± 2.53 nmol/mg protein) as well as their corresponding 
time-matched control groups, particularly at 1 and 3 h (10.55 ± 1.52 and 13.22 ± 1.58 
nmol/mg protein respectively). Hepatic GSSG was significantly lower in the Nrf2(’A) control 
group at 0 and 5 h (12.57 ± 2.53 and 9.18 ± 2.35 nmol/mg protein) compared with their 
Nrf2(+/+,counterparts (23.06 ± 2.62 and 23.09 ± 4.04 nmol/mg protein). This was also 
observed in the APAP-treated groups where the Nrf2(7-, animals at 5 h demonstrated 
significantly lower levels of hepatic GSSG (5.47 ± 1.72 nmol/mg protein) compared with this 
group's wild type counterpart (11.79 ± 1.82 nmol/mg protein).
GSSG in the serum of the Nrf2(+/+) APAP-treated animals at 1 and 3 h were 
significantly lower (1.89 ± 0.88 and 13.97 ± 5.83 pM respectively) compared with the 0 h 
wild type control (23.80 ± 8.68 pM). Furthermore, GSSG in the serum of the 1 h Nrf2(+/+) 
APAP-treated animals were significantly lower (1.89 ± 0.88) compared with the 
corresponding time-matched control group (9.80 ± 3.21 pM). Only serum GSSG measured 
in the Nrf2t/f) APAP-treated animals at 1 h (2.38 ± 2.75 pM) demonstrated a significant 
difference where it was lower compared with the 0 h Nrf2('/') control group (13.86 ± 5.25 
pM).
A time-dependent increase was observed in hepatic ophthalmic acid measured in 
the Nrf2(+/+) APAP-treated animals where average levels at 1, 3 and 5 h were significantly 
higher (0.30 ± 0.04, 0.37 ± 0.07 and 0.68 ± 0.20 nmol/mg protein respectively) compared 
with their time-matched controls (0.14 ± 0.01, 0.2 ± 0.08 and 0.21 ± 0.08 nmol/mg protein 
respectively). Furthermore, hepatic ophthalmic acid in the Nrf2(+/+) APAP-treated animals at 
1, 3 and 5 h were also significantly higher when compared with the Nrf2(+/+) 0 h control 
group (0.16 ± 0.01 nmol/mg protein). On the other hand, although hepatic ophthalmic acid
79
Chapter 3
in the APAP-treated Nrf2(‘/') were consistently higher compared with their time-matched 
controls, these differences were not determined to be significant. Interestingly, hepatic 
ophthalmic acid in the Nrf2(/') mice at 1 h (0.16 ± 0.03 nmol/mg/protein) was significantly 
lower compared with its wild type equivalent (2.12 ± 0.61 nmol/mg/protein).
Ophthalmic acid levels in the serum of APAP-treated Nrf2(+/+}mice were significantly 
higher at 3 and 5 h (6.24 ± 1.12 and 9.01 + 2.4 pM respectively) compared with their time- 
matched controls (1.01 ± 0.17 and 0.44 ± 0.25 pM respectively) and the 0 h Nrf2(+/+, control 
group (2,08 ± 0.41 pM). Only at 3 h was there a significant difference observed in the levels 
of serum ophthalmic acid in the Nrf2('/') animals between the APAP-treated (3.98 ± 1.16 pM) 
and time-matched control (1.19 ± 0.36 pM) groups.
Significant differences in hepatic cysteine were only observed at the 3 h timepoint. 
APAP-treated IMrf2(+/+) (0.11 ± 0.03 nmol/mg protein) and the 3 h Nrf2(V') control animals 
(0.08 ± 0.01 nmol/mg protein) demonstrated significantly lower hepatic cysteine levels 
compared with the 3 h wild type control group (0.26 ± 0.05 nmol/mg protein).
Significant differences were also observed in serum methionine levels. Serum 
methionine in the Nrf2t'A) control group at 0 h (9.01 ± 0.86 pM) was significantly lower 
compared with its wild type counterpart (37.20 ± 8.00 pM) and the Nrf2l'A) control groups 
at 1, 3 and 5 h (20.33 ± 8.68,19.35 ± 5.77 and 33.47 ± 12.29 pM respectively). No significant 
differences were observed in hepatic spermidine and taurine levels as well as serum 
spermidine. However, serum taurine in the Nrf2<'A) animals at 0 h was significantly lower 
(199.14 ± 20.45 pM) compared with its wild type counterpart (271.90 ± 8.10 pM).
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3.3.2 Assessing metabolite perturbations in the GSH system upon chronic 
treatment of IMrf2(+/+) and Nrf2t'/') mice with escalating doses of APAP (150 - 600 
mg/kg)
Nrf2(+/+) and Nrf2('A) were administered escalating doses (150 - 600 mg/kg) of APAP for 8 
days as illustrated in Table 3.2 and described in section 3.2.4. All samples were analysed for 
the selected metabolites within the GSH system as described in section 3.2.9. Serum ALT 
levels were also measured as detailed in section 3.2.6 to indicate liver injury and/or toxicity 
as a consequence of chronic paracetamol treatment as described above.
3.3.2.1 Determination of hepatic injury by serum alanine transferase 
measurement
Minimal increase in serum ALT was observed in the Nrf2(+/+) APAP-treated group (51.13 ± 
8.05 U/L) compared with control (17.66 ± 1.99 U/L) (Figure 3.6). In contrast, the Nrf2('A) 
APAP-treated animals had a mean ALT of 721.21 ± 373.33 U/L compared with 41.95 ± 12.91 
U/L in the corresponding controls. These data show that chronic treatment of Nrf2(+/+> mice 
with escalating doses of APAP ranging from sub-toxic to toxic levels results in a marked 
ability to withstand what would represent a toxic challenge of APAP in acutely challenged 
mice. Nrf2(V‘) mice, whilst showing a reduced hepatotoxic response compared with an 
untreated mouse did nevertheless, show enhanced liver injury/toxicity as assessed by ALT 
compared with the wild type.
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Figure 3.6 Serum ALT activity in mice after chronic treatment with escalating doses of APAP. Male 
C57BL/6 Nrf2 ( □ ) and Nrf2( 7 ’ ( ■ ) mice were administered with escalating doses (150 - 600 
mg/kg) of APAP or saline over an 8 day period (3.2.4). Blood samples were collected and analysed for 
ALT activity as detailed in 3.2.6. Data are presented as mean serum ALT activity (U/L) (± SEM), n = 4 
animals.
3.3.2.2 Metabolite profile of Nrf2(+/+) and Nrf2('/‘) mice in response to chronic 
treatment with escalating doses of APAP
Glutathione and metabolites (GSSG, methionine, cysteine, taurine, spermidine and 
ophthalmic acid) associated with the glutathione biosynthetic pathway were measured in 
the liver and serum of Nrf2(+/+) and Nrf2(7 ’ mice administered with escalating doses of 
APAP or saline (control) for 8 consecutive days to determine perturbations within the GSH 
system and whether these were or were not Nrf2-mediated. Figures 3.7 (hepatic) and 3.8 
(serum) represent the effect of APAP on the GSH system under the treatment described 
above in the Nrf2(+/+) and Nrf2('/ )mice.
A treatment regimen of increasing APAP dose had no significant effect on the 
majority of metabolites measured in the liver and serum between APAP and saline-treated 
mice of both strains.
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Numerically, hepatic GSH in the Nrf2,+/+) control animals was higher (70.9 ± 4.90 nmol/mg 
protein) compared with the Nrf2('A) control group (52.5 ± 4.50 nmol/mg protein). 
Interestingly, an increase in hepatic GSH was observed in both Nrf2(+/+) and Nrf2l'/') APAP- 
treated animals (81.20 ± 3.30 and 80.00 ± 12.80 nmol/mg protein) compared with their 
respective controls but this difference was more prominent in the Nrf2(V'> animals.
No difference in hepatic ophthalmic acid was observed between the APAP (0.60 ± 
0.28 nmol/mg protein) and saline-treated (0.63 ± 0.36 nmol/mg protein) Nrf2(+/+) animals. 
However, although not determined to be significant, a marked increase in hepatic 
ophthalmic acid was observed in the APAP-treated Nrf2lv') mice (0.98 ± 0.34 nmoi/mg 
protein) compared with control (0.16 ± 0.03 nmol/mg protein). Interestingly, hepatic 
ophthalmic acid was higher in the saline-treated Nrf2(+^animals compared with their Nrf2'‘ 
^counterparts, whilst the opposite was observed in the APAP-treated groups.
Serum levels of ophthalmic acid were lower in the APAP-treated animais of both 
strains (1.49 ± 0.43 and 0.95 ± 0.21 pM for Nrf2l+/+,and Nrf2('A) respectively) compared with 
their respective controls (3.71 ± 2.02 and 1.21 ± 0.53 pM for Nrf2(+/+) and Nrf2(V') 
respectively) but were not determined to be statistically significant. Serum ophthalmic acid 
in the Nrf2('/') animals of both treatment groups were consistently lower when compared 
with their wild type counterparts.
Levels of hepatic GSSG were lower in the Nrf2(+/+) APAP-treated animals (44.63 + 
13.77 nmol/mg protein) compared with the control group (76.74 ± 17.16 nmol/mg protein). 
In contrast, an increase in hepatic GSSG was observed in the Nrf2('A) APAP-treated animals 
(78.97 ± 22.00 nmol/mg protein) compared with control (45.73 ± 2.07 nmol/mg protein). 
When comparing between Nrf2(+/+) and Nrf2('A), hepatic GSSG was lower in the Nrf2('A) 
saline-treated animals whilst levels were higher in the Nrf2('A) APAP-treated groups in 
comparison to their wild type counterparts.
Interestingly, serum GSSG was lower in the APAP-treated groups of both strains 
(10.45 ± 3.79 and 2.77 ± 1.24 |iM for Nrf2*+A^and Nrf2AA* respectively) compared with their 
respective controls (18.86 ± 18.86 and 26.39 ± 17.02 pM for Nrf2(+/+) and Nrf2('A) 
respectively). When comparing between Nrf2(+/+)and Nrf2('A), serum GSSG was higher in the 
Nrf2('A) saline-treated animals whilst levels were lower in the Nrf2('A) APAP-treated groups in 
comparison with their wild type counterparts.
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Hepatic spermidine was lower in both APAP-treated strains (0.02 ± 0.01 nmol/mg protein 
for both Nrf2(+/+}and Nrf2('A1) compared with their respective controls (0.09 ± 0.08 and 0.08 
± 0.06 nmol/mg protein for Nrf2{+/+) and Nrf2(V') respectively). No notable differences were 
observed in hepatic and serum spermidine levels between the two strains in response to 
either saline or APAP treatment.
No notable differences were observed in hepatic methionine of both strains under 
the two treatment groups. However, Nrf2,+/+) APAP-treated animals demonstrated a 
significantly lower level of serum methionine (37.54 ± 2.45 pM) compared with control 
(52.71 ± 3.33 pM). Serum methionine in Nrf2("/'> saline-treated animals were also 
significantly lower (43 + 1.96 pM) compared with their wild type counterparts (52.71 pM). 
In contrast, a higher level of serum methionine was measured from Nrf2(V') APAP-treated 
animals (47.46 ± 6.85 pM) compared with its wild type counterpart (37.54 ± 2.45 pM).
A significant increase in hepatic taurine was observed in the Nrf2('A) APAP-treated 
animals (27.79 ± 1.46 nmol/mg protein) compared with the control group (19.51 ± 2.38 
nmol/mg protein), and was also higher when compared with the Nrf2(+/+) APAP-treated 
group (17.14 ± 2.45 nmol/mg protein). No other notable changes in liver and serum taurine 
were observed.
Hepatic cysteine was determined to be higher in the Nrf2(+/+) APAP-treated animals 
(0.32 ± 0.11 nmol/mg protein) compared with control (0.18 ± 0.03 nmol/mg protein) and 
levels of hepatic cysteine in the wild type were in general higher under both treatments 
when compared with the THLE-Nulls (0.14 ± 0.03 and 0.17 ± 0.01 nmol/mg protein for Nrf2{' 
A)saline and APAP-treated animals respectively).
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Chapter 3
3.3.3 Metabolite perturbations in the GSH system upon chronic treatment of 
Nrf2(+/+) and Nrf2('/‘) mice with escalating doses of APAP (150 - 600 mg/kg) for 8 
days followed by a lethal dose of 1000 mg/kg APAP on day 9
The ability of mice to withstand a hepatotoxic dose of APAP following pretreatment with 
increasing doses (150 - 600 mg/kg) over an 8-day treatment regimen (Table 3.2) was 
assessed in both Nrf2(+/+) and Nrf2('/'> animals by administration with a final toxic dose 
challenge of 1000 mg/kg APAP on day 9. A summary of all the treatment groups during this 
investigation is summarised in Table 3.4.
Table 3.4 Abbreviations used to denote the different treatment groups:
Abbreviation Dosing regimen
55 Mice dosed with 0.9 % saline for 9 consecutive days.
SA Mice treated with 0.9 % saline for 8 consecutive days followed by a 
lethal dose of 1000 mg/kg APAP on day 9.
AS Mice treated with escalating doses of APAP for 8 consecutive days 
followed by a dose of 0.9 % saline on day 9.
AA Mice treated with escalating doses of APAP for 8 consecutive days 
followed by a lethal dose of 1000 mg/kg APAP on day 9.
3.3.3.1 Determination of hepatic injury by measurement of serum ALT
Serum ALT was measured to determine whether chronic treatment with escalating doses of 
APAP can provide protection from a subsequent toxic dose in mice and whether the 
deletion of the Nrf2 gene has made the Nrf2('A) animals more susceptible to APAP-mediated 
toxicity compared with Nrf2(+/+).
Following the 1000 mg/kg challenge dose, serum ALT in the Nrf2(+/+1SA group was 
significantly higher (3263.2 ± 823.49 U/L) compared with the control group, Nrf2(+/+)SS 
(25.64 ± 5.31 U/L) (Figure 3.9-A). In the wild type mice pretreated with APAP (Nrf2(+/+)AA), a 
smaller though significant increase in serum ALT was also observed (993.84 ± 317.85 U/L) 
compared with its corresponding control group, Nrf2(+/+)AS (141.98 ± 79.17 U/L). Although
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both Nrf2(+/+,SA and Nrf2(+/+)AA had significantly higher serum ALT compared with their 
respective controls, the Nrf2(+/+)SA group was more susceptible to APAP-induced hepatic 
injury compared with the Nrf2(+/+)AA group. Furthermore, these data suggest that 
pretreatment with escalating doses of APAP may have afforded the wild type animals 
protection against a toxic dose challenge.
Although a similar pattern in serum ALT to the wild type was also observed in the 
Nrf2('/') animals {Figure 3.9-A), serum ALT levels measured in the Nrf2('/'1 animals were only 
from those that survived. As shown by the survival data in Figure 3.9-B, chronic treatment 
with saline followed by a toxic dose challenge of APAP (SA) was 100 % lethal to the Nrf2('A) 
animals. This was also demonstrated in the Nrf2('/') animals that were pretreated and 
subsequently challenged with APAP {Nrf2,v')AA), although the number of deaths in this 
group was marginally smaller compared with the Nrf2('/‘)SA group. The difference observed 
between these two groups suggests an important role of Nrf2 in the adaptive response of 
mice to chemical stress.
Measurement of serum ALT revealed a significant increase in the Nrf2l*/')SA group 
(1484.62 ± 435.46 U/L) compared with the Nrf2(V")SS group {18.52 ± 2.45 U/L). Similarly, 
although not significant, serum ALT in the Nrf2('/')AA group (468.09 ± 318.96 U/L) was 
higher compared with control, Nrf2,'A>AS (153.31 ± 64.13 U/L). The serum ALT data in the 
Nrf2l'A) animals suggest that the saline pretreated group challenged with a lethal dose of 
APAP (SA) was more susceptible to APAP-induced toxicity in comparison to the APAP 
pretreated group (AA). Furthermore, based on a clinical chemistry endpoint, as this data 
was consistent with that observed in the Nrf2(+/+) animals, the absence of the Nrf2 gene in 
the IMrf2('AI animals did not enhance the susceptibility of the Nrf2('A) animals to APAP- 
induced toxicity. Observations in the serum ALT of both the Nrf2(+/+> and Nrf2l'A) animals 
were therefore APAP-mediated.
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Figure 3.9 Serum ALT activity and survival rate in mice pretreated with escalating doses of APAP 
and subsequently challenged with a toxic dose. Male C57BL/6 Nrf2(+/+) ( □) and Nrf2('/) (■ ) mice 
were administered with escalating doses of APAP (150 - 600 mg/kg) or saline over an 8 day period 
and then challenged with a 1000 mg/kg APAP or saline on day 9 for 5 h. Blood samples were 
collected and analysed for serum ALT activity (A) as detailed in 3.2.6 and survival rate across the 
duration of the treatment (B). Data are presented as mean serum ALT activity (U/L) (± SEM) or 
percentage of survival rate, n = 4-8 animals).
91
Chapter 3
3.3.3.2 Metabolite analysis by LC-MS-MS
Figures 3.10 (hepatic) and 3.11 (serum) represent the effect of APAP treatment at 
escalating doses for 8 days and then challenged with a toxic dose on day 9 on the GSH 
system in the liver and serum of the Nrf2(+/+) and Nrf2('/')mice.
3.3.3.2.1 Comparison between Nrf2(+/+SS, Nrf2t'/ )SS, Nrf2(+/+)SA and Nrf2( / )SA
treatment groups
Mean GSH, GSSG and methionine levels were significantly lower in the livers of both 
Nrf2(+/+)SA (2.98 ± 0.77,1.01 ± 0.11 and 0.86 ± 0.07 nmol/mg protein respectively) and Nrf2(' 
^’SA (3.07 ± 0.84, 1.27 ± 0.18 and 1.05 ± 0.18 nmol/mg protein) in comparison to levels 
observed in their respective controls, Nrf2<+/+)SS (74.62 ± 2.04, 57.59 ± 15.35 and 1.81 ± 0.13 
nmol/mg protein respectively) and Nrf2(V"1SS (37.46 ± 1.89, 34.69 ± 5.18 and 2.37 ± 0.17 
nmol/mg protein) groups.
In contrast, mean hepatic ophthalmic acid and cysteine levels within the Nrf2(+/+)SA 
groups (0.58 ± 0.14 and 0.12 ± 0.02 nmol/mg protein respectively) were significantly higher 
in comparison to the Nrf2(+/+)SS group (0.11 ± 0.02 and 0.05 ± 0.00 nmol/mg protein 
respectively). This was also observed in the equivalent Nrf2('/') animals where hepatic 
ophthalmic acid and cysteine were determined to be 0.68 ± 0.11 and 0.14 ± 0.02 nmol/mg 
protein respectively in the Nrf2('/')SA animals compared with 0.063 ± 0.02 and 0.023 ± 0.00 
nmol/mg protein respectively in the Nrf2(V')SS animals but only the difference in ophthalmic 
acid was determined to be significant. A noticeably higher level of hepatic spermidine was 
also observed in both the Nrf2(+/+)SA and Nrf2(V')SA groups (0.07 ± 0.04 and 0.18 ± 0.11 
nmol/mg protein respectively) in comparison to control (0.02 ± 0.01 nmol/mg protein for 
both strains) but were also not determined to be significant.
Similar to that observed in the liver, significantly higher ophthalmic acid (3.10 ± 
0.46 and 2.29 ± 0.33 p.M respectively) was also observed in the serum of both Nrf2(+/+)SA 
and Nrf2('/'1SA groups in comparison to their respective controls (0.51 ± 0.08 and 0.26 ± 0.05 
pM for Nrf2t+/+)SS and Nrf2(V')SS respectively). Consistent with hepatic levels, serum GSSG 
was also lower in the Nrf2{+/+)SA group (0.25 ±0.25 pM) compared with control (15.33 ± 4.03 
pM for Nrf2(+/+,SS). Furthermore, no serum GSSG was detected in the Nrf2( A)SA, whilst 7.81 
± 3.12 pM was measured in the serum of the control group Nrf2('/‘)SS. Spermidine in the
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serum was also higher in the Nrf2(+/+)SA (1.3 + 0.32 \xM) and Nrf2('/')SA (1.21 + 0.47 \xM) 
groups compared with their respective controls (0.41 ± 0.12 and 0.72 ± 0.43 |iM for 
Nrf2t+/+1SS and Nrf2('/',SS respectively). Methionine on the other hand only demonstrated a 
significant difference in the Nrf2(A) animals where it was lower in the Nrf2(V')SA animals 
(31.14 ± 4.51 pM) compared with the Nrf2(V )SS group (51.40 ± 2.13 pM).
Although no notable change was observed in hepatic taurine levels in both SA and 
SS treatment groups of both strains, taurine measured in the serum of Nrf2(+/+,SA (251.72 ± 
20.71 pM) and Nrf2*/)SA (228.42 ± 16.39 pM) animals were significantly lower compared 
with their respective controls (336.93 ± 22.72 and 331.45 ± 6.69 pM for Nrf2(+/+)SS and 
Nrf2('/',SS respectively).
3.3.3.2.2 Comparison between Nrf2(+/+)AS, Nrf2(/}AS , Nrf2(+/+,AA and
Nrf2(/)AA
Significantly lower levels of GSH (4.23 ± 1.09 and 8.06 ± 2.54 nmol/mg protein), GSSG (1.74 
± 0.49 and 5.00 ± 3.02 nmol/mg protein), as well as a marked but not significant decrease in 
methionine (0.93 ± 0.00 and 0.74 ± 0.11 nmol/mg protein) and cysteine (0.08 ± 0.02 and 
0.15 ± 0.04 nmol/mg protein) were observed in the liver of Nrf2(+/+)AA and Nrf2(V',AA groups 
respectively, in comparison to their corresponding controls, Nrf2,+/+)AS (44.02 ± 12.06, 
25.08 ± 2.63, 1.83 and 0.19 ± 0.07 nmol/mg protein respectively) and Nrf2('/',AS (35.01 ± 
8.16, 19.03 ± 1.38, 2.24 ± 0.44 and 0.19 ± 0.02 nmol/mg protein). Interestingly, hepatic 
methionine was significantly higher in the Nrf2(V')AS group (2.24 ± 0.44 nmol/mg protein) 
compared with its wild type counterpart (1.83 ± 0.20 nmol/mg protein)
Consistent with that observed in the liver, GSSG levels in the serum of the 
Nrf2(+/+,AA group (0.22 ± 0.22 pM respectively) was significantly lower in comparison to the 
Nrf2(+/+)AS group (20.32 ± 6.14 pM). GSSG in the serum of Nrf2(V‘,AA group was not 
detected whilst 3.14 ± 2.06 pM was observed in the control (Nrf2('/")AS). This was in 
agreement with that observed in the liver although to a lesser extent as hepatic GSSG were 
at detectable levels in all treatment groups.
On the other hand, ophthalmic acid in the liver and serum of the Nrf2(+/+,AA and Nrf2(V')AA 
groups (2.81 ± 0.38 and 2.86 ± 0.79 nmol/mg protein in the liver and 18.99 ± 7.47 and 6.03 
± 1.03 pM in the serum) were significantly higher in comparison to the Nrf2l+/+,AS and
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Nrf2('/')AS groups (0.28 ± 0.09 and 0.21 ± 0.06 nmol/mg protein in the liver and 1.02 ± 0.22 
and 0.45 ± 0.13 pM in the serum), consistent with the GSH depletion observed from the 
same animals.
Hepatic spermidine in the Nrf2('/')AA animals (0.03 ± 0.00 nmol/mg protein) was 
significantly lower compared with the control group, Nrf2(V'>AS (0.09 ± 0.04 nmol/mg 
protein). Similar to the saline pretreated animals, higher levels of hepatic spermidine in the 
Nrf2(+/+)AA animals (0.04 ± 0.01 nmol/mg protein) were detected in comparison to the 
Nrf2(+/+)AS group (0.02 ± 0.01 nmol/mg protein). This was in contrast to what was observed 
in the serum where spermidine in the Nrf2(+/+)AA group was lower (0.15 ± 0.10 pM) 
compared with the control Nrf2(+/+)AS animals (0.51 ± 0.15 pM).
In contrast to the unaltered levels of hepatic taurine, a significant decrease was 
observed in the serum of Nrf2(+/+)AA and Nrf2,'/'>AA groups (174.48 ± 15.44 and 170.97 ± 
9.11 pM respectively) compared with the control groups (265.05 ± 12.55 and 209.75 ± 9.64 
pM), consistent with that observed in the serum of the saline pretreated animals. 
Furthermore, taurine levels in the serum of the Nrf2(V')AS animals were significantly lower 
compared with its wild type counterpart.
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Chapter 3
3.4 DISCUSSION
The purpose of the studies described in this chapter was to investigate the utility of the 
Nrf2('/') mouse as a model of chemical stress within the context of the GSH system. Ail 
studies were carried out using the Nrf2(+/+) mouse as a comparator and APAP as the 
chemical stress-inducer. To address the role of Nrf2 in the immediate response of the 
mouse to chemical stress, both Nrf2l+/+) and Nrf2(V') were administered an acute sub-toxic 
dose of APAP over a 5 h period. Serum ALT as an indicator of liver injury/toxicity and 
selected metabolites that represent pathways in the GSH system as detailed in chapter 1 
were measured. Further to this, the role of Nrf2 in the adaptive response of the mouse to 
chemical stress was also investigated through chronic dosing with escalating doses (0-600 
mg/kg) of APAP as a means of preconditioning these animals to an APAP-mediated 
environment. To gain insight into modulations within the GSH system if any, as one 
potential mechanism of adaptation to chronic APAP treatment and to determine whether 
this treatment was toxic, the same parameters to those measured in the acute study were 
also taken at the end of the 8-day APAP treatment described here. To determine if this 
preconditioning period has provided protection against a subsequent toxic dose challenge 
of APAP, another set of Nrf2(+/+)and Nrf2(’/'> mice were also preconditioned with escalating 
doses of APAP for 8 days as above and were this time challenged with a toxic dose of 1000 
mg/kg APAP on day 9. The same parameters as stated above were also measured in these 
animals.
3.4.1 Acute time-course study with 350 mg/kg APAP
As mentioned above, the aim of this experiment was to elucidate the role of Nrf2 in the 
immediate response of the mouse within the context of the GSH system after exposure to 
an acute sub-toxic dose (350 mg/kg) of APAP. The significant increases in serum ALT at 3 
and 5 h indicated liver injury as a consequence of APAP-treatment in both Nrf2(+/+) and 
Nrf2('A) mice (Figure 3.3). At closer inspection, the effect of this treatment was the same to 
both strains at 3 h, but only progressed to a more notable increase in serum ALT in the 
Nrf2('A) animals at 5 h whilst levels remained the same in the Nrf2(+/+) demonstrating a 
higher susceptibility of the Nrf2('/'> mice to APAP-induced toxicity at doses that are tolerated 
by their wild type counterparts. This is consistent with findings by other groups who have 
also shown enhanced susceptibility of Nrf2 deficient mice to APAP-induced toxicity (Chan et
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ol., 2001, Enomoto et al., 2001) and to other hepatotoxicants including alcohol (Lamle et 
ol., 2008), pentachlorophenol (Umemura etal., 2006), carbon tetrachloride (Xu etal., 2008) 
and arsenic (Jiang et al., 2009). The attenuation of further liver injury in the APAP-treated 
Nrf2(+/+) mice may be an indication of an adaptive response induced in the wild type mice 
therefore providing protection . On the other hand, this ability to adapt to APAP-induced 
stress may have been abrogated in the Nrf2(V') mice as a consequence of Nrf2 deletion 
resulting in a further increase in serum ALT at 5 h.
The differences in serum ALT levels between the Nrf2,'/') and Nrf2(+/+) mice are 
supported by the trend in hepatic GSH levels observed in the same animals (Figures 3.4 and 
3.5). Immediate significant depletion of hepatic GSH at 1 h was observed in both strains, 
indicative of the overwhelming level of APAP-induced chemical stress as a consequence of 
APAP bioactivation (Mitchell et al., 1973a). However, this was followed by a consistent 
time-dependent increase in hepatic GSH in the Nrf2(+/+) APAP-treated animals where levels 
were almost comparable to the control group at 5 h. On the other hand, an attempt to 
restore hepatic GSH to normal levels by the Nrf2tv') APAP-treated animals was only 
observed at 5 h where the difference in GSH levels between the Nrf2(+/+1 and Nrf2(V') 
animals was not determined to be significant, a contrast to what was observed at 1 and 3 h. 
This may in part explain the difference in serum ALT observed between the two strains, as 
the inability of the Nrf2("/') animals to up-regulate GSH synthesis readily may have led to 
continued liver damage and therefore leakage of hepatic ALT into the circulation. On the 
other hand, the ability of the Nrf2(+/+> animals to up-regulate GSH synthesis more readily 
may have allowed the detoxification of reactive species and restore redox balance much 
quicker. Liver damage was therefore less severe and hence no further increase in serum 
ALT was seen at 5 h. As such, Nrf2 up-regulation of GSH synthesis (Chan and Kwong, 2000, 
Chan et al., 2001, Enomoto et al., 2001) plays an important role in the response to acute 
chemical stress as demonstrated by the GSH data presented here. The decrease in hepatic 
GSH seen following APAP treatment was mirrored by levels of GSSG in the serum and liver 
of both strains potentially as a consequence of the GSH redox cycling pathway as described 
in chapter 1, indicating the lack of GSH available for this process as a consequence of APAP 
treatment.
Increasing levels of ophthalmic acid in the liver and serum were observed in both 
strains in response to APAP treatment, however in comparison to their respective controls, 
this trend was more prominent in the Nrf2(+/+) animals compared with the Nrf2('A) animals 
(Figure 3.4). This is consistent in terms of the similarities in the synthesis of GSH and
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ophthalmic acid (Chapter 1, Figure 1.8), both of which share the same enzymes and 
precursors, apart from cysteine which is used in GSH synthesis and is replaced with 2-AB in 
the synthesis of ophthalmic acid. Although GCL, the enzyme responsible for the rate 
limiting step of GSH synthesis, has a higher affinity for cysteine (Km reported as 0.3 mM, 
Seelig and Meister, 1985) than 2-AB (Km reported as 1.0 mM, Seelig and Meister, 1985), the 
switch in GCL activity to ophthalmic acid synthesis is clearly demonstrated at 1 h when 
hepatic GSH was markedly depleted in response to APAP-induced chemical stress. This 
observation makes ophthalmic acid a potential biomarker of GSH consumption. However, 
at later time points, ophthalmic acid levels continue to rise despite recovering levels of 
hepatic GSH, possible explanations of which are discussed in chapter 4. For the purpose of 
our objectives in this current work, the less prominent rise in ophthalmic acid in the Nrf2(V') 
animals demonstrates the abrogated ability of these animals to up-regulate GCL activity for 
the synthesis of either ophthalmic acid or GSH.
Levels of methionine and taurine in the serum of Nrf2('/') control animals at 0 h 
were significantly lower compared with their wild type counterparts (Figure 3.5). This could 
be an indication of an adaptive mechanism employed by the Nrf2('/') animals to protect 
against cellular stress. As this difference was not seen in the liver, the decrease in the 
serum of these metabolites could be a method of conserving/maintaining hepatic levels 
which would be highly significant given the importance of both methionine and taurine in 
cell defence.
Although significant changes in metabolite levels were observed in both Nrf2 wild 
type and null animals in response to APAP treatment, the response is very similar between 
the two strains indicating that both employed similar cellular defence mechanisms in 
response to acute APAP treatment. The difference however is the level of response which is 
generally higher in the wild type compared with the Nrf2 nulls. This suggests that Nrf2 does 
play a role in the response of mice to acute APAP-induced stress in addition to other 
adaptive mechanisms.
3.4.2 Chronic study with escalating doses of (150-600 mg/kg) APAP
Work described in this section was carried out to determine: 1) if the mouse is able to 
adapt to chemical-induced stress; 2) if this adaptation is Nrf2-mediated; and, 3) if this 
adaptation involved modulations within the GSH system.
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Escalating doses of AFAR over an eight-day treatment regimen resulted in only a mild/no 
ALT response, despite the final dose of 600 mg/kg being invariably toxic when administered 
acutely. Although not determined to be statistically significant, the marked increase in 
serum ALT of the Nrf2('/') animals compared with the Nrf2(+/+) in response to chronic AFAR 
treatment (Figure 3.6) is consistent with results presented in the acute study (Figures 3.3) 
as well as reports in the literature (Chan and Kwong, 2000, Chan et al., 2001, Enomoto et 
ai, 2001) further demonstrating the enhanced susceptibility of the Nrf2(V') animals to 
chemical stress. In addition, the Nrf2(+/+) animals were able to adapt to this APAP dosing 
regimen as demonstrated by the lack of increase in serum ALT at the end of the treatment 
indicating no or minimal liver injury. As this was not observed in the equivalent Nrf2('A) 
animals, this effect is at least in part, Nrf2 mediated.
The subtle changes observed in the majority of metabolites monitored in the GSH 
system of both Nrf2(+/+) and Nrf2(V') animals could be indicative of a limited role of the GSH 
system with regards to chronic APAP treatment. However, it may also be these subtle 
changes that are key in the adaptation of the Nrf2(+/+) animals at least, to chronic APAP 
treatment. Although these differences in metabolite levels between APAP treated and 
control groups were also observed in the Nrf2(V') animals, the inability of the Nrf2('A) APAP- 
treated group to attenuate the increase in serum ALT suggests that other factors in addition 
to modulation in metabolites within the GSH system are required for 
attenuation/protection from APAP-induced liver injury.
A number of metabolites were significantly altered in response to APAP treatment, 
however these differences were not comparable between the Nrf2(+/+) and Nrf2('/') animals. 
Interestingly, the difference between Nrf2(+/+} and Nrf2(V') mice may explain part of the 
protective mechanism employed by the Nrf2(+/+1 mice and why this was not observed in the 
Nrf2(V') mice.
The significant decrease in serum methionine in the APAP-treated Nrf2{+/+) mice, 
which was not observed in the equivalent Nrf2 nulls could be indicative of a conservation 
mechanism for hepatic methionine, through modulation in methionine transport, for 
example, employed by the Nrf2(+/+) animals. This could have a significant impact on the 
ability of these animals to adapt to high levels of chemical stress as a consequence of APAP 
treatment, considering the role of methionine as an essential source of methyl groups and 
sulphur atoms, both of which are essential in sustaining physiological maintenance and 
defence of the cell (Finkelstein, 1998, Varela-Moreiras, 2001, Martinez-Chantar et o/., 2002,
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Mato et al, 2002). With regards to the GSH system, methionine is an essential source of 
cysteine and 2-AB, precursors of GSH and ophthalmic acid syntheses, respectively 
(Finkelstein, 1998). Given this role, the un-altered levels of both GSH and ophthalmic acid in 
these animals may therefore be in part due to the maintained levels of methionine, which 
may have subsequently led to the consistent supply of cysteine and 2-AB. The significance 
of methionine conservation in the liver could also be explained by the fact that it is an 
essential amino acid, therefore the inability of the body to synthetically up-regulate 
methionine levels may partly explain the decrease in serum methionine. The absence of 
this observation in the equivalent Nrf2('A1 animals suggests that this response is Nrf2- 
mediated and is consistent with the difference in serum ALT between the treated Nrf2(+/+1 
and Nrf2('A) animals.
However, serum methionine in the Nrf2('A) control group was significantly lower 
compared with levels from the equivalent wild type group consistent with that observed in 
the serum of the control groups of both strains at 0 h in the acute AFAR study. The Nrf2AA) 
may have therefore also employed the same mechanism as the wild type to conserve 
hepatic methionine levels, but as described above, this mechanism of maintaining hepatic 
methionine may not have been up-regulated more readily compared with the Nrf2('A) 
animals. This response is therefore Nrf2-mediated. This may be an adaptive mechanism 
employed by the Nrf2 nulls as a consequence of Nrf2 deletion, as although it's purpose as a 
source for cysteine may not be of significant use for GSH synthesis as the enzymes involved 
in this reaction, GCL and GS are under Nrf2 transcriptional regulation, cysteine is an 
antioxidant in its own right and would therefore still be used for cellular defence.
The significant increase in hepatic taurine of the Nrf2l~A) APAP-treated animals 
compared with the Nrf2('A) control and equivalent wild type APAP-treated groups could be a 
defence mechanism adopted by these animals in response to chronic APAP treatment, 
taurine being known to possess a number of cytoprotective properties including 
antioxidant activity (Gordon et al., 1986, Chen, 1993, Wang et al., 1996, Lourenco and 
Camilo, 2002) and modulation of calcium homeostasis (Huxtable, 1992, Wangeto/., 1996). 
In particular, treatment with a pharmacological dose of taurine, prior to, simultaneously or 
1 h after an acute toxic dose of APAP were shown to significantly attenuate liver injury 
(Waters et al., 2001). Furthermore, the inability of the Nrf2('A) animals to utilise cysteine for 
the up-regulation of GSH synthesis may have led to higher levels of cysteine oxidation, a 
process in which taurine is a product, therefore contributing to the high levels of hepatic 
taurine observed.
101
Chapter 3
No other significant changes were observed in the metabolites monitored in this study. As 
mentioned at the beginning of this section, subtle changes and not necessarily only 
significant ones that contribute to potential adaptaion of these animals to chemical stress, 
however, in addition to modulations within the GSH system, other mechanisms could also 
be in play that may have allowed these animals to an APAP-induced environment as will be 
discussed in chapter 6.
3.4.3 Chronic study with escalating (150-600 mg/kg) doses of APAP and 
subsequently challenged with a lethal dose
Work discussed in this section was carried out to establish whether chronic APAP 
treatment, employed as a form of preconditioning, affords mice protection from a 
subsequent toxic dose of APAP. The role of Nrf2 in APAP autoprotection within the GSH 
system was also investigated by comparing the response of both Nrf2(+/+) and Nrf2l*/') 
mice. For clarification, four treatment regimens were employed in this experiment as 
summarised in Table 3.4.
Saline pretreatment did not afford protection to either strain against the toxic dose 
of APAP as demonstrated by the significant increase in serum ALT in the challenged animals 
(Nrf2(+/+>SA and Nrf2(‘A)SA). Although to a lesser extent, this was also observed in the APAP 
pretreated groups of both strains that were also challenged with a toxic dose of APAP 
(Nrf2l+/+)AA and Nrf2(‘A)AA). This demonstrates that the significant increase in serum ALT 
observed in the saline pretreated groups (Nrf2(+/+)SA and Nrf2('/')SA) was to some extent 
attenuated in the equivalent APAP pretreated groups {Nrf2(+/+) AA and Nrf2('A)AA) indicating 
autoprotection and consistency with reports in the literature (Tredger etal., 1995, Shayiq et 
ai, 1999, Aleksunes et al., 2008). As this attenuation in serum ALT increase was observed in 
both the Nrf2(+/+) and Nrf2l'/‘1 APAP pretreated animals, autoprotection from APAP-induced 
stress pretreatment is not Nrf2-mediated.
The consistently lower levels of serum ALT in the Nrf2l'/')SA and Nrf2(V',AA groups 
compared with the equivalent Nrf2(+/+) animals do not an accurately represent the relative 
toxicity in the Nrf2('/') and Nrf2(+/+) animals, as the average serum ALT presented here were 
only from those that survived. Treatment with a toxic dose of APAP in these groups 
resulted in deaths (Figure 3.9-B) indicating a high mortality rate in the Nrf2l"A) animals 
compared with the Nrf2(+/+>. As such, although Nrf2 is not the sole determinant of
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autoprotection, it is clearly an important factor in the defence system of a mouse to 
combat against APAP-induced toxicity.
The increase in serum ALT observed in both the SA and AA groups of both strains 
was supported by the significant decrease in hepatic GSH, indicating APAP-induced stress 
(Figure 3.10). However in contrast to the attenuation in serum ALT increase in the AA 
groups, the degree of GSH depletion was comparable between the SA and AA groups of 
both strains. Within the context of the GSH system, autoprotection may have therefore 
been in part afforded from modulations within the GSH system as discussed in section 3.4.2 
during APAP pretreatment but not from an up-regulation of GSH synthesis in response to 
the toxic APAP dose. In particular, modulations in serum methionine and hepatic taurine in 
the Nrf2(+/+,A as well as taurine and ophthalmic acid in the Nrf2(V')A may have enhanced the 
defence mechanism of these animals therefore allowing them to respond to the APAP 
challenge better. Consistent with its role in the GSH redox cycle, the depletion in hepatic 
GSH also led to the significant depletion in GSSG in the AS and AA groups of Nrf2(+/+) and 
Nrf2(V') animals (Figure 3.10).
The increase in hepatic cysteine observed in both Nrf2(+/+) and Nrf2('/‘,SA groups 
could be indicative of the demand for cysteine for use in cellular defence such as GSH 
synthesis, in response to APAP toxicity. However, this increase was not reflected in the 
corresponding hepatic GSH data being a precursor for GSH as GSH recovery was not 
observed. This may be due to several factors including the rate of GCL and GS activities, 
which may have been subjected to oxidation and/or covalent binding given the high level of 
APAP-mediated stress present, therefore reducing or even abrogating GCL and/or GS 
activities. However, ophthalmic acid levels indicate that both GCL and GS are still fully 
active in the SA groups of both strains. This provides further support for a potential switch 
mechanism in the substrate affinity of GCL from cysteine to 2-AB, hence the significant 
increase in hepatic and serum OA in these animals. As the intact activity in GCL and GS are 
evident for OA synthesis in both strains, the proposed switch in substrate affinity of GCL is 
not likely to be Nrf2-mediated. Furthermore, this also suggests that this switching 
mechanism is carried out by existing hepatic GCL particularly in the Nrf2('/'1animals. In the 
Nrf2(+/+), this switch may have been carried out by a combination of existing and newly 
synthesised GCL. This increase in hepatic and serum ophthalmic acid was also evident in 
the APAP pretreated and challenged groups (AA) of both strains indicating that irrespective 
of pretreatment, the extremely toxic conditions posed by the challenge dose at day 9 (1000 
mg/kg) may have led to all groups employing the same defence pathway to combat and
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therefore survive these toxic conditions. In such situations, it would therefore be difficult to 
differentiate between the Nrf2{/) and Nrf2(+/+) with regards to their response. Alternatively, 
cysteine in its own right is an antioxidant, as demonstrated by the use of N-acetylcysteine 
as an antidote to APAP self-poisoning in the clinic. Therefore, although the significant 
increase in hepatic cysteine in the SA group was not reflected in an increase in hepatic GSH, 
it may have been utilised as a direct antioxidant for the detoxification of reactive species in 
the cell.
The significant decrease in hepatic methionine in the SA and AA groups of both 
strains indicate the high demand of methyl groups and sulphur atoms by various metabolic 
pathways including those in the GSH system during chemical stress. This, however was only 
reflected in the serum of the SA group of the Nrf2(V') animals (Figure 3.11) whilst levels in 
other groups were comparable with their respective controls. This difference in methionine 
levels in the Nrf2('/')SA group between the liver and serum may be indicative of the demand 
for methionine in extrahepatic tissues, hence the decrease in serum, whilst the unaltered 
levels in the liver may be indicative of the abrogated ability of the Nrf2(V‘) animals to up- 
regulate GSH synthesis. As such, there is less demand for methionine in the liver.
Taurine levels in the liver were unaltered in all groups of both Nrf2(+/+) and Nrf2('A) 
mice. However consistent decreases in the serum SA and AA groups of both Nrf2(+/+) and 
Nrf2(V') mice indicate a response to APAP treatment. As taurine has been reported to 
possess cytoprotective properties, its decrease in serum may reflect the demand by various 
tissues including the liver to combat against APAP toxicity. Absorption of taurine from the 
circulation therefore supports the unaltered levels observed in the liver of all groups. 
However, taurine may also be formed through cysteine oxidation and therefore the 
maintenance of hepatic taurine may be a combination of both mechanisms.
3.4.4 Overall conclusion
Under the three dosing regimens employed in this chapter, the Nrf2(V') animals were 
demonstrated to be more susceptible to APAP-induced stress compared with the Nrf2*+^. 
This difference was more prominent in the serum ALT data rather than in the selected 
metabolites measured in the GSH system. This suggests that perturbations within the GSH 
system do not indicate toxicity or demonstrate the effect of Nrf2 deletion in the Nrf2('/') 
animals, as observed throughout the three studies. Instead, what the studies have shown is
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that the response of both strains to the three APAP dosing regimens were very similar. As 
discussed in section 3.4.1, both strains responded similarly up to a certain threshold of 
chemical stress. When levels of stress goes beyond this threshold and therefore requires 
up-regulation of Nrf2-mediated defence pathways, differences between the strains are 
then observed. However, monitoring metabolites in the GSH pathway does not 
demonstrate significant effects, if any, of deleting the Nrf2 gene. As such, other pathways 
are worth investigating to further characterise the effect of Nrf2 deletion in mice.
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Chapter 4
Qualification of ophthalmic acid as a potential biomarker of chemical
stress in vitro and in vivo
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4.1 INTRODUCTION
Current research and clinical practice rely on the use of biomarkers to differentiate the 
pathology of the diseased state versus normal, as well as to characterise the response of 
the body to therapeutic interventions. In particular, research in DILI uses a plethora of 
biomarkers to indicate the window of efficacy to toxicity caused by drugs (Ozer et a!., 
2008). However, despite the significant role in the study of DILI, the discovery of a 
biomarker that fulfils all the desired attributes described in chapter 1 has to this day proven 
a challenge. In response to this, many groups continue to expend considerable effort into 
the discovery and development of new {and existing) biomarkers to maintain a standard of 
high quality in research, including that of DILI, with the ultimate aim of benefiting public 
health.
Alanine amino transaminase (ALT) is one such biomarker that has been extensively 
used as a marker of liver injury (Amacher, 1998, Amacher, 2002). Its role as a marker for 
DILI has been attributed to its high hepatic expression (Sherman, 1991, Dufour et al., 
2000b, Dufour et al., 2000a) compared with its low abundance in extrahepatic tissues both 
in rodents and human (Boyd, 1983). As such, significant elevations in serum ALT activity 
have been correlated with its leakage from the liver into the circulation during liver injury. 
Furthermore, its sensitivity to DILI where its levels are highly elevated in serum makes it an 
amenable biomarker in practise. However, its specificity is dampened by its distribution in 
extraheptic tissues and elevation in serum even in the absence of DILI (Edgar et al., 1998, 
Thulin etai, 2008).
Glutathione is another marker that has been invaluable in the study of DILI. It has 
an extensive list of functions both in basic cellular processes (Meister, 1983, Wu et al., 
2004, Townsend, 2007) and in cell defence (Meister, 1988, DeLeve and Kaplowitz, 1991, 
Fernandez-Checa et al., 1992) under physiological conditions and during cellular stress. 
This, along with its high abundance in the liver, demonstrates its relevance and therefore 
usefulness as a marker of oxidative stress. Indeed, a number of well known hepatotoxicants 
including carbon tetrachloride (CCI4) (Recknagel et al., 1989), APAP (Hinson et al., 1981), 
bromobenzene (Jollow et al., 1974) and furosemide (Williams et al., 2007) are also known 
to perturb the hepatic GSH store. However, despite all these, its utility is limited to 
preclinical research as a consequence of its chemical instability as detailed in the chapter 1. 
As such, a stable and accessible biomarker that directly indicates perturbations in hepatic
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GSH could prove highly valuable in the study of DILI, particularly in the clinic where the 
measurement of hepatic GSH is rarely, if ever, an option.
In a recent metabolomics study that looked at the hepatic metabolic profile of mice 
treated with APAP, ophthalmic acid, an analogue of GSH, was observed to increase 
significantly in the liver and serum as GSH was depleted. As such, ophthalmic acid was 
proposed to be a direct biomarker of GSH consumption (Soga et ai, 2006). Furthermore, 
the same group also demonstrated similar results in mice treated with two other 
modulators of GSH, diethyl maleate (DEM), which directly binds to the thiol group of GSH 
(Zalups and Lash, 1997) and buthionine sulfoximine (BSO), which inhibits the enzyme 
responsible for the rate-limiting step of GSH synthesis (Griffith and Meister, 1979). 
Ophthalmic acid utilises the same synthetic enzymes responsible for GSH biosynthesis, 
glutamate cysteine ligase (GCL) and glutathione synthetase (GS), however, GSH and 
ophthalmic acid are chemically different in that the thiol-containing precursor, cysteine, 
required for GSH synthesis is replaced by 2-aminobutyrate (2-AB) during ophthalmic acid 
synthesis, 2-AB being an amino acid that shares a similar structure to cysteine but with the 
thiol group replaced with a methyl group instead (Figure 1.8). Based on these experiments, 
Soga et al (2006) suggested that the elevation in ophthalmic acid both in the liver and 
serum of APAP-treated mice may be due to a combination of cysteine/GSH depletion and 
subsequent activation of glutamate cysteine ligase (GCL), the enzyme responsible for the 
rate-limiting step of GSH synthesis, towards the ophthalmic acid biosynthetic route.
Whilst no research has been done to specifically elucidate the function of 
ophthalmic acid, it has been extensively used to investigate the significance of the thiol 
group of GSH in its various functions, with most studies predominantly focussed on GSH- 
mediated transport (Ballatori and Dutczak, 1994, Leslie etal., 2001, Leslie etal.f 2003, Leslie 
et al., 2004, Circu et al., 2009). As such, work described in this chapter was aimed at 
evaluating the extent to which ophthalmic acid qualifies as a surrogate for GSH 
consumption and consequently represents a potential biomarker of oxidative stress. This 
was investigated in both in vivo and in vitro settings using mouse, rat and human model 
systems as well as a variety of GSH modulating agents including APAP, its reactive 
metabolite NAPQJ and DEM. Ophthalmic acid and GSH were measured in order to elucidate 
the relationship between these two metabolites during cellular stress. ALT and 
mitochondrial activities were also measured to indicate toxicity where appropriate. 
Experiments described in this chapter were therefore carried out to address the following: 
1) Is ophthalmic acid a direct biomarker of GSH consumption or a general biomarker of
109
Chapter 4
oxidative stress? and 2) Can ophthalmic acid be used as a biomarker of oxidative stress 
across species in a variety of in vitro and in vivo model systems?
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4.2 MATERIALS AND METHODS
4.2.1 Materials
All chemicals and reagents were purchased from Sigma-Aldrich (Poole, Dorset, UK) unless 
otherwise stated. Ophthalmic acid (OA) was purchased from Bachem (Weil am Rhein, 
Germany). Solvents were obtained from either VWR (Lutterworth, Leicestershire UK) or 
Fischer Scientific (Loughborough, Leicestershire, UK). THLE cells and chemicals used in 
sections 4.2.7 and 4.2.8 are detailed in chapter 2 section 2.2. Hepalclc? was purchased 
from ATCC-LGC Standards (Teddington, Middlesex, UK). Infinity ALT (GPT) liquid stable 
reagent was purchased from Thermo Scientific (Loughborough, Leicestershire, UK).
4.2.2 Animals
Adult male Wistar rats and adult male C57BL/6 mice were obtained from Charles River 
Laboratories (Margate, Kent, UK). All animal experiments were undertaken in accordance 
with criteria outlined in a license granted under the Animals (Scientific Procedures) Act 
1986, and approved by the Animal Ethics Committee of the University of Liverpool. All 
animals were housed under 12-h light/dark cycles with room temperature maintained 
between 19 - 23 °C. Animals had free access to food and water.
4.2.3 APAP treatment of mice and its effect on ophthalmic acid levels
Male C57BL/6 mice (20 - 25 g) were administered with 530 mg/kg APAP in 0.9 % saline or 
vehicle (control) i.p. for 0, 1, 2, 4, 6 and 24 h and sacrificed at each time point by C02 
asphyxiation. Livers were removed and snap frozen in liquid nitrogen. Serum samples were 
prepared by allowing blood samples collected to clot overnight at 2 - 4 °C followed by pulse 
centrifugation at 4000 rpm. All samples were stored at -80 °C until analysis.
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4.2.4 DEM treatment of rats and its effect on ophthalmic acid levels
Male Wistar rats {200 - 300 g) were anaesthetised (1.4 g/ml urethane in saline dosed at 1.0 
ml/kg i.p) and cannulated via the trachea and carotid artery fed with heparin containing 
saline (250 U/mi). A 3 cm incision in the abdomen was also made, and covered with saline 
soaked gauze to allow access and collection of liver sections during sampling. Blood 
(including pre-dose) and liver samples were collected simultaneously at 15 minute intervals 
up to and including the 2 h time point. Blood samples which contained heparin were 
centrifuged at 10, 000 rpm for 5 min to allow the isolation of serum. Liver and serum 
samples were immediately snap frozen in liquid nitrogen and stored at -80 °C until analysis.
4.2.5 Culture of Hepalclc? cells
The mouse hepatoma cell line Hepa-lclc? was maintained in Dulbecco's modified Eagle's 
medium (cDMEM) supplemented with L-glutamine (584 mg/L), foetal bovine serum (FBS; 
10%), penicillin (100 U/mL) and streptomycin (100 pg/mL) in a humidified chamber at 37 °C 
under 5 % C02. For drug preparation and incubations, un-supplemented media (DMEM) 
was used.
Cells were grown in a T75 Nunclon A culture flask (75 cm2) and routinely passaged 
when growth reached 80 % confluency. Briefly, cDMEM was removed and the cells were 
washed with DMEM to remove the majority of protein from the growth media. The cells 
were detached from the surface of the culture flask by the addition of 3 mL trypsin and 
incubation for 5 min at 37 °C. The detached cells were resuspended in 10 mL cDMEM and 
pelleted by centrifugation at 1000 rpm for 5 min at room temperature. The trypsin/cDMEM 
supernatant was carefully removed and the cells were resuspended in fresh 10 mL cDMEM. 
Cell clumps were broken up by passing the cell suspension through a 21-gauge needle using 
a 5 mL syringe. For future experiments, the cells were re-seeded at a ratio of 1:4 
(cells:cDMEM). Cells used were between 1-12 passages.
Accurate seeding of cells for a particular experiment was achieved by making a 
mixture of cell suspension (40 pi) as described above and Trypan Blue (0.4 % w/v; 10 pi) and 
counting 10 pi of this mixture using a haemocytometer and a light microscope (Wilovert 
D6330) at 20X magnification. Viable cells (Trypan Blue positive) within the central 5x5 
square (0.1 mm3) were counted and calculated as follows:
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Number of cells x 1.1 (to correct for dilution of cell suspension) (40 pi) with Trypon Blue (10 
pi) = cells per 0.1 mm3 x 10,000 = cells/1 cm3 = cells/1 mL
4.2.6 Treatment of Hepalclc? cells with NAPQI and its effect on ophthalmic acid 
levels
Hepalc cells were seeded (250 x 103 cells/well) onto Nunclon A 6-well plates (culture area 
of 9.6 cm2/well) in a total volume of 2 ml cDMEM and left to grow for 24 h. Prior to drug 
treatment, the growth media was removed and the cells were washed with HBSS to remove 
the remaining protein from the growth media. The cells were subsequently treated with 
increasing concentrations (0 - 300 pM in 0.1 % DMSO) of NAPQI and incubated for 1 or 24 h 
in a humidified chamber at 37 °C under 5 % C02. After incubation, the treatment media was 
removed and the cells were washed with HBSS. The cells were lysed by four freeze-thaw 
cycles in 300 pi 0.1 % formic acid, collected in eppendorf tubes and stored at -80 °C until 
analysis.
4.2.7 DEM treatment of THLE-2E1 and THLE-Null cells and its effect on 
ophthalmic acid level
THLE-Null and THLE-2E1 cells were seeded (450 x 103 cells/well) in a Biocoat™ 6-well plate 
for 24 h in complete Basal PMFR-4 media (CM; prepared as detailed in chapter 2, section 
2.2 ). Each cell line was treated with increasing concentrations of DEM (0 - 1000 pM 
prepared in serum free Basal PMFR-4 media (SFM) prepared as detailed in chapter 2, 
section 2.2 in triplicate and left to incubate for 1 h in a humidified chamber at 37 °C under 5 
% C02. Treatment media was discarded and the cells were washed with HBSS (-Ca2+/-Mg2+). 
To each well, 0.1 % formic acid (250 pi) was added and subsequently subjected to four 
freeze-thaw cycles. Samples were collected in eppendorf tubes and stored at -80 °C until 
analysis.
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4.2.8 APAP treatment of THLE-2E1 and THLE-Null cells and its effect on 
ophthalmic acid levels
Cell lysates obtained from chapter 2, section 2.2 for both THLE-Null and THLE-2E1 were also 
analysed for ophthalmic acid levels as detailed in section 4.2.11.
4.2.9 Determination of protein content
Protein content of liver homogenates prepared in sections 4.2.3 and 4.2.4 were measured 
following the method of Lowry et af. (1951) as detailed in chapter 2 section 2.2. Protein 
content in both THLE and Hepalclc? cell lysates treated with DEM or NAPQI were 
measured following the method of Bradford (1976) as detailed in chapter 2 section 2.2 . 
Treatment of the THLE cells with APAP resulted in very low protein content at higher APAP 
concentrations and longer incubation periods, therefore protein content was measured 
following the protocol of Lowry et al. (1951) as detailed in chapter 2 section 2.2.
4.2.10 Determination of GSH content
Hepatic GSH from the in vivo studies were determined following the method of Vandeputte 
et al. (1994) as detailed in chapter 3 section 3.2.
4.2.11 Determination of ophthalmic acid by LC-MS-MS
Serum and liver homogenate samples from the in vivo studies were obtained, prepared and 
analysed as detailed in chapter 3 section 3.2. Cytosolic extracts from the in vitro studies 
were analysed using the same LC-MS-MS conditions employed in chapter 3.
4.2.12 Statistical analysis
Where applicable, all data were expressed as mean ± standard error of the mean (SEM). 
Values to be compared were analysed for non-normality using a Shapiro-Wilk test. 
Unpaired t-tests or one-way ANOVA was used when normality was indicated. A Mann- 
Whitney U or Kruskall-Wallis test was used for non-parametric data. All calculations were
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performed using StatsDirect statistical software and results were considered to be 
significant when p < 0.05.
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4.3 RESULTS
4.3.1 Correlation between GSH and ophthalmic acid in APAP-treated mice
Glutathione and ophthalmic acid levels in the liver and serum of C57BL/6 mice 
administered a toxic dose of APAP (530 mg/kg) were measured by LC-MS-MS to validate 
the proposed potential role of ophthalmic acid as an indicator of GSH consumption. ALT 
activity was also measured as an independent marker of toxicity.
Significant hepatic GSH depletion was observed in the APAP-treated animals 
compared with their respective time-matched controls up to and including the 4 h group. A 
similar trend was also observed with the 6 h group although the difference was not 
determined to be statistically significant. In contrast, comparable levels of hepatic GSH 
were observed between the treated and control animals in the 24 h group (Figure 4.1 C).
The significant difference in the levels of serum ALT at 6 and 24 h in the APAP- 
treated animals compared with their respective time-matched controls indicated APAP- 
induced toxicity (Figure 4.1 D). Furthermore, this demonstrated serum ALT as a late marker 
of liver toxicity.
In contrast to the significant depletion observed in hepatic GSH, hepatic ophthalmic 
acid was significantly higher in the APAP-treated animals compared with control in the 1, 2 
and 6 h groups whilst comparable levels were observed in the 0 and 24 h groups. 
Interestingly, the trend observed in hepatic ophthalmic acid was not directly reflected in 
the serum as only the APAP-treated animals in the 4 and 6 h groups presented significantly 
higher levels of ophthalmic acid in serum compared with their respective time-matched 
controls (Figure 4.1 A and B).
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Figure 4.1 The effect of APAP-mediated chemical stress in mouse liver and serum. C57BL/6 male 
mice were administered 530 mg/kg APAP in 0.9 % saline ( ■) or an equivalent amount of vehicle as 
control ( □) i.p. for 0, 1, 2, 4, 6 and 24 h. Animals from each group were sacrificed at the end of their 
designated treatment periods by C02 asphyxiation. Ophthalmic acid levels were measured both in 
the liver (A) and serum (B) samples. Hepatic GSH (C) and serum ALT activity (D) were also measured 
to identify APAP-induced oxidative stress and toxicity respectively. * p < 0.05, ** p < 0.01 and *** p < 
0.001 against time-matched control. Each column represents the mean of four animals (n=4) and the 
bars indicate the standard error of mean (SEM).
4.3.2. Correlation between GSH and ophthalmic acid in DEM-treated rats
To determine whether the inverse correlation between GSH and ophthalmic acid in the 
APAP-treated mice (Figure 4.1) also applies to other chemical modulators of GSH in other 
species, male Wistar rats were treated with 150 mg/kg DEM and measured for both GSH 
and ophthalmic acid in the liver and blood samples collected at pre-dose and 15 minute 
intervals post-dose up to and including the 2 h time-point.
As demonstrated in Figure 4.2, hepatic GSH was significantly depleted at all time 
points measured compared with the pre-dose value. Although not determined to be 
significant, an increasing trend in ophthalmic acid both in the liver and serum of each 
animal was observed, with increases in ophthalmic acid seen to be higher in the serum than 
in the liver.
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Figure 4.2 Ophthalmic acid and GSH levels DEM-treated rats. Male Wistar rats were administered 
150 mg/kg DEM. Blood and liver snips were collected simultaneously at pre-dose and at 15 minutes 
intervals from 0 minute post-dose up to and including 120 minutes. Ophthalmic acid levels in both 
liver ( A ) and serum ( —B^>as well as hepatic GSH ( Q) were measured. Data presented are 
percentage of the corresponding pre-dose value. Error bars represent the standard error of mean 
(SEM), n = 4. *** p< 0.001 against the pre-dose group.
4.3.3 Correlation between GSH and ophthalmic acid In Hepalclc? mouse cells 
treated with DEM
Hepalclc? hepatocarcinoma cells were treated with increasing concentrations (0 - 1000 
pM) of DEM and were analysed for both GSH and ophthalmic acid levels to determine 
whether observations made in vivo as demonstrated in sections 4.3.1 and 4.3.2 could be 
modelled in vitro. A concentration-dependent decrease in GSH compared with control was 
observed, with significantly lower levels in cells treated with DEM at concentrations 
between 250 to 1000 pM. On the other hand, no significant change was observed in 
ophthalmic acid in the same DEM-treated cells compared with control (Figure 4.3).
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Figure 4.3 Glutathione and ophthalmic acid levels in mouse Hepalclc? cells treated with DEM.
Hepalclc? cells were treated with increasing concentrations of DEM (0 - 1000 pM) in triplicate for 1
h. Cells were harvested and analysed for GSH ( □) and ophthalmic acid (----- ). Data presented are
percentage of pre-treatment levels (0 h). Error bars represent the standard error of mean (SEM) of 
three independent experiments (n = 3). *** p < 0.001 compared with pre-treatment (0 h).
4.3.4 Correlation between GSH and ophthalmic acid in Hepalclc? mouse cells 
treated with NAPQI
Hepalclc? mouse cells were treated with the APAP reactive metabolite, NAPQI, to 
determine whether the correlation made between GSH and ophthalmic acid in the APAP- 
treated mice in section 4.3.1 could be modelled in vitro.
GSH levels measured (Figure 4.4) in cells with 300 pM NAPQI for 1 h demonstrated 
significant GSH depletion compared with control. Ophthalmic acid levels in these cells 
however did not demonstrate a significant change. In contrast, no significant difference in 
GSH levels was observed between control cells and those treated with NAPQI for 24 h. 
However, ophthalmic acid was significantly higher at 300 pM compared with control. This 
may be indicative of a potential alternative mechanism of ophthalmic acid increase in 
addition to or instead of GSH depletion.
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Figure 4.4 Glutathione and ophthalmic acid levels in Heplclc? cells treated with NAPQI.
Hepalclc? cells were treated with increasing concentrations of NAPQI (0 - 300 pM) for 1 (A) or 24 
(B) h in triplicate. After treatment, cells were harvested and analysed for GSH ( □ ) and ophthalmic 
acid (^“) levels. Data presented are percentage of control (0 h). Error bars represent the standard 
error of mean of three independent experiments (n =3). * and @ represent p < 0.05 for GSH and 
ophthalmic acid respectively against corresponding controls.
4.3.5 Correlation between GSH and ophthalmic acid in THLE human liver cells 
treated with DEM
Ophthalmic acid levels were also investigated in the human liver epithelial cell lines, THLE- 
Null and THLE-2E1 to evaluate the transferability of ophthalmic acid as a biomarker across 
species in pre-clinical studies as an early indicator of potential toxicity in drug discovery. 
Treatment with DEM demonstrated significant GSH depletion in both cell lines (Figure 4.5).
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Interestingly, this depletion in GSH was complemented by a trend towards increasing 
ophthalmic acid levels at increasing concentrations of DEM in the THLE-Null cell line (Figure 
4.5 A). This however was not observed in the THLE-2E1 cells as no significant change was 
observed in ophthalmic acid despite the significant decrease in GSH at 500 and 1000 pM 
DEM (Figure 4.5 B).
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Figure 4.5 Glutathione and ophthalmic acid levels in THLE-Null and THLE-CYP2E1 cells treated with 
DEM. THLE-Null and THLE-CYP2E1 cells were treated with increasing concentrations of DEM (0 - 
1000 pM) for 1 h in triplicate. After treatment, cells were harvested and analysed for GSH and 
ophthalmic acid levels. A represents GSH (^fc-) and ophthalmic acid ( -■-) levels in the THLE-Null 
cells whilst B represents both metabolites in the THLE-2E1 cells. C and D are comparisons of 
ophthalmic acid and GSH respectively in the THLE-Null ( — } and THLE-2E1 ( — -) cells. Data
presented are percentage of control (0 pM). Error bars represent the standard error of mean of 
three independent experiments (n = 3). * p < 0.05, ** p < 0.01 and *** p < 0.001.
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4.3.6 Correlation between GSH and ophthalmic acid in THLE cells treated with 
APAP
THLE-Null and THLE-2E1 cells were treated with increasing doses of APAP (0 - 25 mM) for 
24,48 and 72 h and were analysed for GSH and ophthalmic acid levels.
APAP treatment of THLE-Null and THLE-2E1 cells resulted in a concentration- 
dependent decrease in GSH with marked GSH depletion observed in the THLE-2E1 at all 
three time points but was only apparent in the THLE-Null cells at 48 and 72 h (Figure 4.6).
No trend was observed in ophthalmic acid levels both in the THLE-Null and THLE- 
2E1 cells at 24 h (Figure 4.6). However, ophthalmic acid in THLE-Null cells treated with 25 
mM APAP for 48 and 72 h were markedly decreased which is in contrast with that observed 
in the THLE-2E1 where levels were increased. This contrast in observation may be indicative 
of the role of CYP2E1 in the toxicity and GSH depletion observed in the THLE-2E1 cells as 
presented in chapter 2 which would not be the reason for the toxicity and GSH depletion 
observed in the THLE-Null cells.
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4.4 DISCUSSION
The discovery and development of biomarkers is essential for the advancement of drug 
safety science. With respect to DILI, the usefulness of a biomarker that reflects GSH 
consumption is evident through its role not only in cell defence (Hayes and Pulford, 1995, 
Reed, 2004), but also in other fundamental cellular processes such as protein synthesis and 
cell proliferation (Meister, 1983, Wu et ai, 2004, Townsend, 2007). As such, and based on 
recent findings, this chapter focussed on the qualification of ophthalmic acid as a potential 
biomarker of GSH consumption (Soga etal., 2006). Initial work in mice administered a toxic 
dose of APAP was carried out to verify findings by another group of the potential role of 
ophthalmic acid as a biomarker of GSH consumption (Soga et ai, 2006). Upon confirmation 
of this, ophthalmic acid was also measured in the rat treated with another GSH depleting 
agent, DEM, to elucidate whether ophthalmic acid can be used as a biomarker across a 
variety of experimental models in vivo and a range of GSH modulators. This was followed by 
work in the mouse hepatoma cell line, Hepalclc and human epithelial liver cell lines THLE- 
Null and THLE-2E1, using APAP or its reactive metabolite, NAPQJ, as the GSH modulating 
agents to determine if ophthalmic acid can be employed as a biomarker of oxidative stress 
in vitro.
Administration of an acute toxic dose of APAP in mice resulted in the immediate 
depletion of hepatic GSH (Figure 4.1-C). In parallel to this but not a direct reflection of 
hepatic GSH depletion was the significant increase in hepatic ophthalmic acid (Figure 4.1- 
A). Furthermore, and of paramount interest with respect to biomarker development, this 
increase in hepatic ophthalmic acid was also observed in the serum (Figure 4.1-B). These 
initial results are in broad agreement with findings reported by Soga and colleagues (2006) 
and confirm the potential of ophthalmic acid as a biomarker of GSH consumption. However, 
upon closer inspection of our results (Figure 4.1), whilst hepatic GSH depletion occurred 
almost immediately, the increase in ophthalmic acid both in the liver and serum were more 
prominent at the later time points, demonstrating a delay in ophthalmic acid response to 
GSH depletion. As such, although there is a genuine correlation between GSH depletion and 
ophthalmic acid increase during xenobiotic-induced stress, as demonstrated in our lab, 
ophthalmic acid is not a direct marker of hepatic GSH consumption. Despite this, the 
ophthalmic acid response that has been consistently observed in this chapter and in the 
work described in chapter 3, and in other laboratories (Soga et a!., 2006) in response to 
xenobiotic-induced stress suggests that ophthalmic acid may still prove useful, as a general
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biomarker of xenobiotic-induced stress either individually or when used as part of a panel. 
Further work to investigate the mechanism of this response observed in ophthalmic acid 
could be valuable in determining its specificity as a marker of oxidative stress.
What seemed like a delayed response in ophthalmic acid in our study compared 
with that reported in the literature may be accounted for by certain differences in the 
experimental protocols employed. In particular, whilst animals used in our study were not 
subjected to dietary restrictions, animals used by Soga and colleagues (2006) were starved 
overnight. Considering the similarities in the synthesis of ophthalmic acid and GSH (Figure 
1.8) with regards to precursors and enzymes, diet may have been an important factor in the 
levels of GSH and ophthalmic acid. Indeed, in rats that were fed an 8 % casein diet 
supplemented with 3 % methionine (a precursor of cysteine and 2-aminobutyrate (2-AB)}, 
GSH and 2-AB levels were observed to have increased whilst ophthalmic acid levels 
decreased (Takanori Kasai and KlRiYAMA, 1989a). This study also demonstrated that GCL 
has a higher affinity for the substrate cysteine compared with 2-AB, both of which are 
products of methionine metabolism, with Km values reported to be 0.3 and 1.0 mM for 
cysteine and 2-AB respectively (Seelig and Meister, 1985). As such, due to the consistent 
availability of cysteine in our animals, GCL activity would have been primarily involved in 
the synthesis of GSH. However, when cysteine supply is exhausted, not just for GSH 
synthesis but also for its antioxidant activity during xenobiotic-induced oxidative stress such 
as with APAP, GCL activity may have diverted to the synthesis of ophthalmic acid where 2- 
AB supply is plentiful, hence the later maximal peak of this metabolite. On the other hand, 
fasting of animals overnight prior to APAP administration (Soga et at., 2006) may have 
provided enough time for GCL activity to adapt to such conditions which may 
consist/involve low methionine levels and may have consequently directed GCL and GS 
activities for ophthalmic acid synthesis as 2-AB is also a product of other metabolic 
pathways such as in the threonine metabolic pathway. Indeed, it has been reported that in 
starved animals, although threonine dehydrogenase, the dominant enzyme responsible for 
the metabolism of threonine to 2-ketobutyrate (another precursor of 2-AB) is inhibited, an 
alternative and less common pathway catalysed by threonine dehydratase is up-regulated 
accounting for a similar level of total hepatic threonine catabolic activity (77 - 86 %) to that 
of threonine dehydrogenase (87 %) (Bird and Nunn, 1983). The maintained supply of 2-AB 
may have therefore, in part, accounted for the earlier maximal peak of ophthalmic acid 
previously reported in starved animals (Soga etal., 2006).
125
Chapter 4
Administration of DEM to rats resulted in a significant time-dependent decrease in hepatic 
GSH with a concurrent, but non-significant increase, in ophthalmic acid both in the liver and 
serum (Figure 4.2). These findings are in support of the results in the mouse in vivo work 
with APAP (Figure 4.1) as it also demonstrates that ophthalmic acid is not a direct marker of 
GSH consumption. However, the trend towards increasing levels of ophthalmic acid as GSH 
is depleted also provides further support for the role of ophthalmic acid during oxidative 
stress. As this increase in ophthalmic acid was not determined to be significant, this 
suggests that other factors may be involved that influence this increase. Possible 
determining factors could be a certain threshold of GSH/ROS levels or the effect of 
oxidative stress resulting from GSH consumption on metabolic pathways that influence the 
synthesis of ophthalmic acid. It is also possible that GSH itself is not the determining factor 
in the GSH synthetic pathway that results in ophthalmic acid increase. Instead, it could be 
levels of the precursors involved. In particular, cysteine could be a potential candidate as it 
is the likely molecule to be affected during chemical stress. Its depletion may therefore be a 
more crucial factor for ophthalmic acid synthesis.
The increase in ALT in the APAP-treated mice, which is in practice used as a marker 
of toxicity in research and in the clinic, may have a role in the rise in ophthalmic acid 
increase as its catalytic activity results in the production of glutamate. Due to the nature of 
the study in rats with DEM, ALT could not be analysed as blood was collected every 15 
minutes for 2 h from each animal. Sample volume was limited, allowing only the analysis of 
ophthalmic acid. It would be interesting to see if the correlation made between ALT and 
ophthalmic acid in mice treated with APAP can also be seen in the rat treated with DEM as 
this could provide further insight into the mechanism of ophthalmic acid increase, which is 
clearly not entirely if at all GSH-mediated. To investigate the correlation, if any, between 
ALT and ophthalmic acid, preliminary work would have to be carried out to determine 
when ALT levels are increased under this treatment regimen in rats with DEM. This will 
therefore aid in determining when to measure ophthalmic acid, GSH and ALT and make all 
the appropriate correlations.
In vitro studies carried out in the liver cell lines mouse HepalclcT (Figure 4.3) and 
human THLE-Null and THLE-2E1 (Figure 4.5) with DEM, were in agreement with the in vivo 
rat study, as a dose-dependent decrease in GSH with no significant change in ophthalmic 
acid levels were also observed. This further supports our previous suggestion of a multi­
factorial mechanism of ophthalmic acid increase.
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The trend towards increasing ophthalmic acid in the THLE-Null cells, in response to DEM 
treatment, which was not observed in the THLE-2E1 cells may be due to the difference in 
CYP2E1 expression between these two cell lines. As discussed in chapter 2, CYP2E1 
overexpression leads to an increase in ROS production due to its loose coupling with the 
enzyme CPR {Gorsky et al.r 1984, Ekstrom and Ingelman-Sundberg, 1989). The THLE-2E1 
cells (Mari and Cederbaum, 2000) are therefore already exposed to higher levels of 
oxidative stress compared with the THLE-Nulls resulting in the enhancement of defence 
mechanisms in the THLE-2E1 cells allowing them to survive better upon exposure to DEM 
compared with THLE-Null. This data also suggests that the trigger for the increase in 
ophthalmic acid is not or is only partly due to GSH depletion, but certainly involves the 
inability to up-reguiate other cell defence pathways as in the THLE-2E1, these defence 
pathways would have already been up-regulated due to the higher levels of oxidative stress 
these cells are already exposed to prior to DEM treatment.
Treatment of Hepalclc? with NAPQI demonstrated no noticeable change in GSH 
levels except for cells treated with 300 pM for 1 h (Figure 4.4). Furthermore, no change in 
ophthalmic acid levels was observed under all the treatment conditions used. Work within 
our group has previously demonstrated NAPQI to be a potent GSH depleter, with significant 
GSH depletion already demonstrated in Hepalclc? cells after treatment with 3 pM NAPQI 
for 1 h compared with control (Copple et ai, 2008a). Such reactivity of NAPQI is evidently 
lacking in the present study and may have been due to degradation resulting in low 
reactivity of the NAPQI used. Due to time constraints, this could not be investigated further 
or repeated. However, where there was significant GSH depletion observed (cells treated 
with 300 pM for Ih, Figure 4.4 A), there was no corresponding increase in ophthalmic acid. 
Instead, ophthalmic acid was significantly elevated in cells treated with 300 pM NAPQI but 
24 h later, when GSH was at control levels (Figure 4.4 B). Although this particular 
experiment requires repeating, the results indicated that ophthalmic acid is not a direct 
marker of GSH depletion.
Preliminary work carried out in the THLE cells with APAP (Figure 4.6) indicated GSH 
depletion in the THLE-2E1 cells compared with THLE-Null at 24 h. This difference is more 
prominent at 48 and 72 h with GSH depletion already observed at 15 mM APAP at these 
timepoints but was only apparent at 25 mM APAP at 24 h in the THLE-2E1 cell line. At the 
same time, a trend towards increasing ophthalmic acid was observed. These results, 
although preliminary, further suggests that other factors are involved that triggers the 
increase in ophthalmic acid.
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Work presented in this chapter has demonstrated that ophthalmic acid is not a direct 
marker of GSH consumption in in vitro models but may still prove useful as a marker of 
oxidative stress when used in conjunction with other biomarkers. The disparity in 
ophthalmic acid response between the in vitro and in vivo experiments described in this 
chapter may be due to the model systems themselves. As cell lines are isolated systems, 
other extracellular factors or perhaps signalling between cell types are involved in the 
increase in ophthalmic acid. It is also possible that a different cell type to the cell lines 
employed here are responsible for the increase in ophthalmic acid synthesis, therefore in 
vitro studies would have to specifically use a certain cell type. The mechanism that triggers 
the increase in ophthalmic acid deserves further investigation as the consistent response in 
ophthalmic acid levels during chemically-induced oxidative stress may have biological 
significance that the cell employs to survive under such stress.
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Chapter 5
Investigating the potential of ophthalmic acid as a translatable 
biomarker of chemical stress in the clinic
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5,1 INTRODUCTION
Potential biomarkers should satisfy a set of criteria that will determine whether they qualify 
as markers of a particular health condition or drug effect. Ideally, a biomarker should be 
organ specific, have strong correlation with other already existing well-defined markers of a 
specific injury, be sensitive in terms of timing (i.e. promptly indicative after an insult to 
allow physicians to intervene by withdrawing or introducing medication{s) for example, but 
also return to normal once the insult has been removed or the damage repaired) and 
detection (i.e. low but detectable basal levels with easily detectable increases), not subject 
to diurnal variation or diet-induced, adaptable for high throughput screening assays, 
detectable in biological matrices that can be accessed non-invasively (blood and/or urine), 
increase in levels and transferable across pre-clinical and clinical applications (Boone et al., 
2005, Ramaiah, 2007, Ozer et al., 2008, Laverty et al., 2010). However, a biomarker of 
chemical stress possessing ail these attributes is yet to be discovered.
The work described in chapter 4 clearly indicates that ophthalmic acid is a potential 
biomarker of chemical stress. It was also markedly elevated in mouse liver following 
exposure to both acute and chronic treatment with APAP (chapter 3) and more 
importantly, this was reflected by a similar increase in serum, suggesting its utility as a 
minimally invasive marker of chemical stress. Similar results have been demonstrated in 
other laboratories (Soga et al., 2006) where they also showed that the depletion of GSH by 
DEM produced the same increase in both hepatic and serum ophthalmic acid. 
Administration of BSO, an inhibitor of GCL, in contrast, resulted in a decrease in both 
hepatic and serum ophthalmic acid and GSH, demonstrating the similarities in their 
synthesis.
As such, the work described in this chapter explored the potential utility of 
ophthalmic acid as a translational clinical biomarker by establishing whether it is detectable 
and quantifiable in the serum of healthy individuals. Furthermore, this study also 
determined the intra- and inter-individual variation of ophthalmic acid and the effect this 
has on the potential of ophthalmic acid as a chemical stress biomarker. Ultimately, the aim 
was to explore the possibility of progressing ophthalmic acid as a clinical biomarker of 
chemical stress.
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5.2 MATERIALS AND METHODS
5.2.1 Materials
Ophthalmic acid was purchased from Bachem (Weil am Rhein, Germany). Acetone 
(Normapur) and Formic Acid (AnalR NormaPur 99-100%) were both purchased from VWR 
(Lutterworth, Leicestershire, UK). Bovine Serum Albumin (BSA) and 5-hexylglutathione were 
both purchased from Sigma Aldrich Chemical Co. (Poole, Dorset, UK). Methanol (HPLC 
Grade) and Infinity ALT (GPT) liquid stable reagent were purchased from Thermo Scientific 
(Loughborough, Leicestershire, UK).
5.2.2 Volunteers
The protocol employed for sample collection (section 5.2.3) and consent forms used for this 
study are under the approval of the Capenhurst Independent Research Ethics Committee 
(CIREC). The study group consisted of 5 male healthy volunteers with ages ranging between 
20 and 54 years old, with an average age of 38 (± 11.56 SD). Characteristics of the 
volunteers are given in Table 5.1. This study aimed to determine the extent of normal ALT 
and ophthalmic acid variation therefore the volunteers were not subjected to any dietary 
restrictions such as alcohol consumption.
Table 5.1 Volunteer details
Volunteer Age Gender Ethnicity Smoker
Dietary
limitations
1 46 Male Caucasian No None
2 34 Male Caucasian No None
3 28 Male Caucasian No None
4 28 Male Chinese No None
5 54 Male Caucasian No None
5.2.3 Serum sample collection
Blood samples were collected from five male healthy volunteers for five consecutive days 
(days 1-5) and followed up with one collection per week for the next three weeks (days 8,
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15 and 22). Blood samples were consistently taken at the same time on each day of 
collection. The blood samples were left to clot at room temperature for 30 minutes and 
centrifuged at 2600 g (SANYO MSB Harrier 15/80, Loughborough, Leicestershire, UK) for 20 
minutes. Serum samples were carefully transferred into cryovials and stored at -80°C until 
required for analysis.
5.2.4 Ophthalmic acid analysis 
5.2.4.1 Sample preparation
Each serum sample (10 ^il) was spiked with 10 pi 5 pM 5-hexylglutathione and made up to 
50 pi with dH20. For the standards, 10 pi standard (to make final concentrations of up to 1 
pM), 10 pi 5 pM S-hexylglutathione and 10 pi 30 mg/ml BSA were added together and 
made up to 50 pi with dH20. The internal standard S-hexylglutathione was prepared by 
making 1 mL of a 10 mM solution by firstly adding 450 pi 0.1 % formic acid and 50 pi 1 M 
NaOH to allow the S-hexylglutathione to dissolve into solution. A further 500 pi 0.1 % 
formic acid was added to give a concentration of 10 mM. Further dilutions to obtain 5 pM 
S-hexylglutathione were carried out with 0.1 % formic acid.
Samples and standards were de-proteinated with 200 pi ice-cold acetone, vortexed 
and left to precipitate at -20 °C for 1 hour. After de-proteination, the samples were 
centrifuged (Beckman GS-15R, High Wycombe, UK) for 10 minutes at 4 °C and the 
supernatants collected. Acetone used for de-proteination was removed by drying the 
supernatants down to approximately 50 pi in a speed vac (Eppendorf Concentrator 5301, 
Cambridge, UK) at 30 °C for 25 minutes. The concentrated standards were further diluted 
with 200 pi 0.1 % formic acid. Both neat serum samples and diluted standards were stored 
at4 °C prior to analysis.
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5.2.4.2 LC-MS-MS analysis
Samples were analysed on a QTRAP®5500 hybrid triple-quadrupole/linear ion trap 
instrument with Turbolon V™ Ion source (Applied Biosystems, UK) and were delivered into 
the instrument by automated in-line LC (Ultimate 3000 (Dionex, UK)), Gemini CIS, 3 |am, 
2.1 x 100 mm column (Phenomenex, UK)). A gradient from H2O/0.1% Formic Acid (FA) v/v 
to 100% Acetonitrile/0.1% FA v/v in 15 min was applied at a flow rate of 200 \xl min’1. 
The QXRAP®5500 was operated in positive ESI mode with the following parameters 
optimised; ionspray potential 5500 V; nebuliser gas (GAS1) 50 psi; auxiliary gas (GAS2) 60 
psi; ion spray heater to 700°C and medium collision gas. Two MRM transitions were 
monitored for both ophthalmic acid (290/58 and 290/161.1) and the internal standard (5- 
hexylGlutathione - 0/247.1 and 0/162.1) with a 100 ms dwell time. The declustering 
potential, focusing potential, collision energy, cell entrance potential and cell exit potential 
were optimised for each MRM transition.
5.2.5 ALT activity assay
Serum samples were collected and prepared as described in sections 5.2.2 - 3 and ALT 
levels were determined using Infinity ALT (GPT) reagent (Thermo Scientific, Loughborough, 
Leicestershire, UK) according to the manufacturer's instructions. Samples analysed for ALT 
activity were the same samples analysed for basal ophthalmic acid levels.
5.2.6 Statistics
Intra- and inter individual variation of ophthalmic acid level and ALT activity were analysed 
by calculating the mean concentration/activity, standard deviation (SD) and coefficient of 
variation (%). Low SD and CV values relative to the relevant data set were determined to 
have low dispersion of data points and high reproducibility, and vice versa.
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5.3 RESULTS
5.3.1 Detection and quantification of basal ophthalmic acid in human serum
In order to compare the relative concentration of ophthalmic acid in rodent and human 
blood, serum samples from mouse, rat and man were analysed by mass spectrometry using 
both the in-house instrumentation described in chapter 2 and using a state-of-the-art triple 
quadrupole ion-trap instrument (AB Sciex QTrap 5500} in the laboratory of AB Sciex. Whilst 
mouse and rat plasma ophthalmic acid was measurable using the API3000 mass 
spectrometer, no ophthalmic acid was detectable in human serum under the same 
conditions. However, it was possible to detect and quantify ophthalmic acid in human 
samples using the QTRAP5500. Comparative basal ophthalmic acid levels for the three 
species are shown in Table 5.2 and the MRM mass spectra for each is given in Figure 5.1. It 
can be seen from Table 5.2 that the resting plasma levels of ophthalmic acid are 
approximately 20 - 30 times lower in man than in mouse, necessitating the use of a highly 
sensitive mass spectrometer for detection. The basal value obtained in rat (0.007 nM) was 
intermediate between man and mouse. No differences in the levels of ophthalmic acid 
were observed between male and female mice, nor when C57BL/6 mice were compared 
with levels in CD1.
Table 5.2 Basal ophthalmic acid levels in the serum of mouse, rat and man.
Sample ID Sample type Ophthalmic acid (nM)
A Human - Maie 0.002
B Mouse - Male C57BL/6 0.054
C Mouse - Female C57BL/6 0.060
D Mouse - Male CD1 0.045
E Rat - Male Wistar rat 0.007
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Figure 5.1 Basal ophthalmic acid in male (A) C57BI6 mouse, (B)Wistar rat and (C) human serum 
using the AB Sciex QTrap 5500 LC-MS-MS system. The spectra show the MRM peaks for ophthalmic 
acid in equivalent amounts of each serum sample. Note the difference in ion count scale on the Y- 
axis, indicating the low levels found in human relative to rodent samples. Mean values derived from 
the analysis are given in Table 5.2.
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5.3.2 Intra-individual variation of basal ophthalmic acid and ALT activity in 
human serum
In order to define the inter- and intra-individual variation in basal ophthalmic acid levels, 
serum was collected from five volunteers at specified times up to four weeks (Figure 5.2) 
and both ophthalmic acid and ALT levels were measured. The mean concentration of basal 
ophthalmic acid from each volunteer ranged between 0.37 nM to 1.17 nM, with the lowest 
value observed from volunteer 1 and highest from volunteer 3. This range in mean 
concentration extended to a maximum of 3.81 nM when data from volunteer 4, day 8 
(V4:8) was included since this was measured at about 10 times greater than all other 
values, and was thus considered an atypical value (Figures 5.2 A and C).
The SD (nM) was calculated for each volunteer in order to determine the profile of 
ophthalmic acid concentration across the 8 days. The SD values ranged between 0.21 nM - 
0.56 nM, or up to 7.84 nM when including V4:8. These values indicate that ophthalmic acid 
levels vary between individual and within an individual (Figure 5.2 C).
In order to assess if the degree of variation is similar between volunteers, the CV 
{%) was calculated. The CV values ranged between 34.89 % - 88.11 %, or up to 205.92 % 
when including V4:8. Volunteers 1-3 shared a similar degree of variation (34.89 % - 39.07 
%) in ophthalmic acid levels around their respective mean concentrations. Levels from 
volunteers 4 (53.47 %) and 5 (88.11 %) tended to be more variable, especially when data 
from V4:8 (205.92% for volunteer 4, Figure 5.2 C) was taken into account.
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■ Day 2
■ Day8
■ DayB
■ Day 15
■ Day 4
■ Day 22
Volunteer Mean (nM) SD (nM) CV (%)
1 0.54 0.21 39.07
2 1.17 0.41 34.89
3 1.11 0.42 37.44
4 1.04 0.56 53.47
4° 3.81 7.84 205.92
5 0.37 0.33 88.11
Figure 5.2 Intra-individual variation of basal ophthalmic acid in the serum of 5 male healthy 
volunteers. Blood samples were collected for 5 consecutive days (days 1-5) and followed up by one 
day per week for the next three weeks (days 8, 15 and 22). Serum was collected from each blood 
sample as detailed in sections 5.2.2-3 and analysed for ophthalmic acid by LC-MS-MS as described in 
section 5.2.4. A represents ophthalmic acid data including V4:8, an outlier highlighted as 4° in C. B 
represents ophthalmic acid data excluding the outlier (4°). C summarises the mean concentration 
(nM), standard deviation (SD nM) and coefficient of variation (CV %) of ophthalmic acid 
concentrations of all 8 visits from each volunteer.
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ALT activity was measured at each time point and is presented in Figure 5.3. Every value in 
all the volunteers was below the upper limit of normal (defined as 40 U/L), however, 
considerable variation was observed between individuals. Volunteer 1 consistently had 
values that were just below the ULN whereas in volunteer 4, ALT activity could only be 
detected at day 15. Overall, whilst considerable inter-individual variation is observed, 
values within an individual were relatively consistent.
The CV values for ALT activity ranged between 15.2 % - 62.9 %, with the lowest 
value observed from volunteer 1 and the highest from volunteer 3. Only one ALT value was 
obtained from volunteer 4, consequently no estimate of variance was possible.
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■ Day 5 ■ Day8 ■ Day 15 ■ Day 22
Volunteer Mean (U/L) SD (U/L) CV (%)
1 31.76 4.81 15.15
2 3.33 1.04 31.26
3 1.48 0.93 62.86
4 4.83 N.D. N.D.
5 8.69 3.22 37.03
Figure 5.3 Intra-individual variation of ALT activity in the serum of 5 male healthy volunteers.
Blood samples were collected for 5 consecutive days (days 1-5) and followed up by one day per week 
for the next three weeks (days 8, 15 and 22). Serum was collected from each blood sample as 
detailed in sections 5.2.2-3 and analysed for ALT as described in section 5.2.5. A represents ALT 
activity levels (U/L). B summarises the mean concentration, standard deviation (SD) and coefficient 
of variation (CV) of ALT activity levels in all 8 visits for each volunteer.
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5.3.3 Inter-individual variation of ophthalmic acid and ALT activity in basal 
human serum
The mean concentration range of ophthalmic acid across all five volunteers was between 
0.55 nM - 1.29 nM. However, the maximum concentration extended to 5.42 nM when all 
data from volunteer 4 were taken into account (Figures 5.4 A - B).
SD values were also calculated in order to determine the spread of ophthalmic acid 
concentration from each day. The SD values ranged between 0.2 nM - 0.85 nM, or up to 
9.92 nM from V4:8 (Figure 5.4 C), very similar to observations made from the intra- 
individual variation analysis.
The mean ALT activity range was between 7.19 (day 8) - 11.30 (day 1) U/L, which 
again was below the ULN of 40 U/L. SD values were calculated with the least varied 
observed on day 5 (9.6 U/L) and the most varied observed on day 1 (16.36 U/L). The CV 
values that ranged between 115.17 % -167.71 %, were in general of high values but were 
comparable between visits with the least variable set of data observed on day 15 and the 
most variable observed on day 22. The high CV values observed from this analysis 
demonstrated the high degree of variability in ALT activity between individuals (Figures 5.5 
A-B).
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Visit (Day) Mean (nM) SD (nM) CV (%)
1 0.55 0.30 53.90
2 0.67 0.20 29.92
3 0.98 0.68 69.10
4 0.69 0.40 57.99
5 0.70 0.41 59.06
8 0.79 0.51 57.99
8° 5.42 9.92 183.09
15 0.89 0.42 47.08
22 1.29 0.85 65.61
Figure 5.4 Inter-individual variation of basal ophthalmic acid in the serum of 5 male healthy 
volunteers. Blood samples were collected for 5 consecutive days (days 1-5) and followed up by 
one day per week for the next three weeks (days 8,15 and 22). Serum was collected from each blood 
sample as detailed in sections 5.2.2-3 and analysed for ophthalmic acid by LC-MS-MS as described in 
section 5.2.4. A represents inter-individual variation of ophthalmic acid concentration including 
V4:8, an outlier highlighted as 8° in C. B represents the same data to A, excluding 8° C summarises 
the mean concentration, standard deviation (SD) and coefficient of variation (CV) of ophthalmic acid 
concentration between the five volunteers.
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2 9.72 14.69 151.20
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4 8.83 11.96 135.37
5 7.54 9.60 127.32
6 7.19 11.59 161.06
7 10.72 12.35 115.17
8 8.64 14.49 167.72
Figure 5.5 Inter-individual variation of ALT activity in the serum of 5 male healthy volunteers.
Blood samples were collected for 5 consecutive days (days 1-5) and followed up by one day per 
week for the next three weeks (days 8, 15 and 22) (Table 5.1). Serum was collected from each blood 
sample as detailed in sections 5.2.2-3 and analysed for ALT as described in section 5.2.5. A 
represents ALT activity levels (U/L). B summarises the mean concentration, standard deviation (SD) 
and coefficient of variation (CV) of ALT activity levels between the five volunteers.
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5.4 DISCUSSION
At present, many biomarkers are in use for preclinical and clinical applications despite 
shortcomings with regards to their specificity, accessibility and transferability (for a review 
on liver biomarkers, please refer to Ozer (2008). ALT for instance is widely used as a 
principal biomarker for liver injury although elevations have been reported in cases other 
than (Muller et oi, 2000), or with no evidence of, liver injury (Jackson et at. 2008). 
Furthermore, intrinsic factors such as gender, age and body mass index (BMI) (Kariv et al. 
2006) as well as polymorphic differences (Yuan et al. 2008) have been shown to influence 
serum ALT levels. As such, there is a pressing need for new biomarkers to support the 
current panel by further substantiating toxicity profiles used to characterise various liver 
conditions. Presently, the discovery of a number of potentially useful liver biomarkers that 
have been reported in the literature, a list of which is summarised in chapter 1, Table 1.6 
merit further investigation. These include a-glutathione-S-transferase (MacGregor 2003), 
cytochrome c (Miller et al. 2008), regucalcin (Yamaguchi et al. 2002), arginase 1 (Ashamiss 
et al, 2004, Murayama et al. 2008), ornithine carbamyl transferase (Amacher 2002, 
Murayama et al. 2008), paraoxonase (Amacher et al. 2005), ALT isoforms (Miyazaki 2009), 
calpain (Limaye et al. 2003), sPLA2 (Bhave et al. 2008), HMGB1 (Antoine et o/., 2009) and 
liver-specific isoforms of ALP (Amacher et al. 1987), all of which are potentially useful as 
markers of hepatotoxicity.
The study presented in this chapter explores the potential of ophthalmic acid as a 
biomarker for chemical stress in the clinic. Interest in ophthalmic acid arose from 
observations made initially by Soga et al. (2006) and subsequently repeated in our own 
laboratory (chapter 4), where ophthalmic acid levels were significantly elevated in the liver 
and serum of APAP-treated mice in parallel to a significant depletion in hepatic GSH. This 
correlation has brought attention to the potential role of ophthalmic acid as a surrogate 
marker of GSH consumption in response to chemical stress, which is of significance given 
the important role of GSH in the detoxification of both electrophiles and reactive oxygen 
species during cellular stress (chapter 1). GSH itself does not have the potential to be a non- 
invasive biomarker of chemical stress, an important feature of a clinical biomarker, since its 
stability outside the cell is low due to the instantaneous degradation of GSH through the 
activity of gamma-glutamyl transpeptidases, allowing reabsorption of the amino acid 
constituents of GSH in tissues for various cellular processes (Meister and Anderson 1983; 
Meister 1984). Furthermore, although it is routinely used as a chemical stress biomarker in
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preclinical studies, the oxidative susceptibility of the thiol group of GSH does not make it 
amenable to adapt to current clinical protocols and would require careful consideration 
with regards to sample handling if accurate measurements were to be achieved. The nature 
of its function as a detoxification molecule, directly or indirectly, during chemical stress 
leads to its depletion which could affect the level of sensitivity in which it could be 
measured. On the other hand, a biomarker such as ophthalmic acid which does not only 
demonstrate a potentially important function but is also more chemically stable, at least 
during measurement in the laboratory, due to the replacement of the sulphydryl-containing 
cysteine in the GSH molecule with 2-AB where the sulphydryl group is replaced by a methyl 
group, deserves further investigation in both preclinical and clinical applications. Unlike 
GSH, an increase in ophthalmic acid levels can be measured in response to cellular stress 
indicating a potentially sensitive marker of GSH consumption.
As demonstrated in the results section of this chapter, the detection and 
quantification of basal ophthalmic acid in human serum was established through the use of 
a highly sensitive LC-MS-MS system. This present study along with that carried out by 
Kombu et al. (2009), where they investigated the rate of 2H labelling of GSH, GSSG and 
ophthalmic acid from 2H-enriched body water, are the first to report the presence of 
ophthalmic acid in human serum. Furthermore, the concentrations observed, with 0.14 nM 
being the lowest concentration detected across all the serum samples, are within the ideal 
concentration range of a serum biomarker at basal level, with the exception of one 
determination. As such, the presence of ophthalmic acid in human serum and the capability 
to detect and quantify it provides a platform to further investigate the translatability of 
ophthalmic acid as a clinical biomarker of chemical stress. However, although this has 
provided positive results, only a small sample size was used to carry out this study 
therefore an extension of this work using a larger population size is required.
The intra- and inter-individual variability of ophthalmic acid was also investigated 
from the same sample group. The degree of inter- and intra-individual variation of 
ophthalmic acid differed amongst the participants. However, apart from a sample collected 
from volunteer 4 on day 8, all ophthalmic acid concentrations measured were below 2 nM. 
The ALT activity levels were also analysed from the same samples as a comparator 
biomarker. Similar to observations made with ophthalmic acid, there were also differing 
degrees of inter- and intra-individual variation in ALT activity amongst the participants 
however, all values were below the ULN. This suggests that under normal physiological 
conditions, there will always be intrinsic and extrinsic differences in ophthalmic acid
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concentration and ALT activity levels within and between healthy individuals. With regards 
to ophthalmic acid, the key is to determine the absolute maximum level in human serum 
that is indicative of a healthy individual, similar to how the ULN was determined for ALT 
activity (Hy's Law) {Zimmerman, 1968, Zimmerman, 1978, Senior, 2009) which is at present, 
routinely used as guidance for diagnosing hepatotoxicity in the clinic.
Data from volunteer 4 displayed the highest concentration of ophthalmic acid in 
this study which was interestingly followed a week later by the only ALT measurement 
obtained from this volunteer on day 15. All participants were assumed to be healthy at the 
start and throughout the course of this study. However, it should be noted that they were 
not restricted to a particular lifestyle such as following a set diet regimen as the aim of this 
study was to encapsulate the degree of variability of ophthalmic acid in a healthy 
population with differing lifestyles. As such, the high ophthalmic acid level on day 8 and the 
ALT activity measured on day 15 from volunteer 4 may have been triggered by a change in 
the lifestyle activity of volunteer 4. For example, a change in alcohol intake, vigorous 
exercise or new medication could account for the above changes despite the absence of 
overt liver injury. Furthermore, volunteer 4 was the only volunteer from a different ethnic 
background which may reflect genetic differences between ethnic populations. Intrinsic 
factors such as gender and polymorphic differences have been demonstrated to affect 
basal ALT levels (Kariv et al., 2006, Yuan et al., 2008), and this would be expected for other 
potential markers, such as ophthalmic acid. It is therefore likely that the above factors may 
have the potential to perturb levels of biomarkers such as ophthalmic acid.
Although the above observation was only made from one individual, this could be 
indicative of a correlation between ophthalmic acid and ALT. As the increase in ophthalmic 
acid preceded the observed increase in ALT, this may suggest that ophthalmic acid is an 
early biomarker of chemical stress. This follows a similar trend to that observed in chapters 
3 and 4 in the serum of mice treated with APAP where the increase in ophthalmic acid also 
preceded the increase in serum ALT. The sensitivity of this correlation was demonstrated by 
the change in both ophthalmic acid and serum ALT in an individual who was assumed to be 
healthy as there was no report of any change in this person's health throughout the study. 
This observation is critical in the design of future experiments, in particular when 
investigating whether observations made in chapters 3 and 4 and by Soga et al. (2006) in 
mice can also be demonstrated in humans. For this work, it is important to determine the 
effects of APAP both at therapeutic and toxic levels in order to determine the degree of 
change in ophthalmic acid.
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Biomarkers are known to be influenced by several factors which may influence the basal 
and inducible levels of a biomarker, as well as the degree of response observed in a 
biomarker following a given stimulus. Such factors include gender, age, BMI and 
polymorphic differences, all of which have been shown to affect plasma ALT activity (Kariv 
et al. 2006; Yuan et al. 2008). Investigating the variability of basal ophthalmic acid with 
regards to such factors, in addition to those discussed earlier, would therefore be of benefit 
in establishing whether a standardised basal concentration can be used as a point of 
reference by all future users, or whether such standard concentrations should be set 
categorically depending on certain variables that have been previously shown to have an 
impact on other biomarkers. Indeed as mentioned earlier, difference in ethnic background 
may be an influencing factor in ophthalmic acid levels as volunteer 4 who is from a 
different ethnic background compared with the other volunteers displayed the highest 
ophthalmic acid measured in the study.
Several studies have also explored the distribution of ophthalmic acid in different 
species (Waley, 1958, Reddy et al., 1966, Takanori Kasai and KIRIYAMA, 1989a, Takanori 
KASAI and KIRIYAMA, 1989b, Soga et al., 2006). However, as the function of ophthalmic acid 
is unknown, the physiological significance of variability in tissue distribution and abundance 
across species is not yet understood. Interestingly, not all previous distribution studies have 
reported ophthalmic acid to be detected in the liver. This suggests highly varied levels of 
hepatic ophthalmic acid among species even down to the extreme of undetectable levels. 
However, this variability in hepatic ophthalmic acid may reflect a lack of sensitivity in the 
assay. The presence of hepatic ophthalmic acid across preclinical models and in humans 
would be of great significance as the liver is a major site of drug metabolism and is 
therefore also a major target for xenobiotic-induced stress and toxicity.
Although the distribution and abundance of ophthalmic acid has been established 
in several tissues, only a few groups have reported the presence and concentration of basal 
ophthalmic acid in serum (Kombu et al. 2009; Soga et al. 2006). This chapter describes basal 
levels of ophthalmic acid in mouse, rat and human serum. Ophthalmic acid was found to be 
most abundant in mouse followed by rat and then human sera (Figure 5.2). Preliminary 
work was also carried out in the department to determine whether ophthalmic acid levels 
were influenced by diurnal variation in rodents (data not shown), however, no effect of the 
time of sampling within a 24 h period was observed. As discussed earlier, the accessibility of 
a biomarker, especially in biofluids, is crucial in assessing the transferability of a biomarker 
from preclinical to clinical use. Although basal serum ophthalmic acid levels are different
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amongst species, its consistent presence in the serum advances its potential role as a 
transferable biomarker for chemical stress. Similar findings were observed in current 
biomarkers such as ALT where basal levels differ between species and organ sources 
(Lindblom et al. 2007; Miyazaki 2009; Rajamohan et al. 2006). As such, in order for 
ophthalmic acid to be used as a sensitive biomarker of chemical stress in preclinical and 
clinical applications, differences in its basal concentration between models systems should 
be determined.
In summary, the experiments detailed in this chapter, which represent the first 
systematic attempt to define ophthalmic acid baseline characterisation in man, suggest that 
ophthalmic acid may have potential for clinical use. The serum concentrations of 
ophthalmic acid at basal levels are very low in man, compared with mice which whilst a 
desirable property, poses problems bioanalyticaily. Ophthalmic acid was only detectable 
using the AB Sciex 5500 QTRAP mass spectrometer which is currently one of the most 
sensitive instruments on the market. Quantification of analytes at levels approaching the 
lower limit of detection is likely to lead to loss of precision through analytical error. 
Nevertheless, the work described in this chapter indicates that ophthalmic acid levels are 
generally stable within a given individual and that variation between individuals is similar to 
that observed with the established biomarker of liver damage, ALT. Furthermore, the high 
level of ophthalmic acid detected in a single sample from one of the volunteers (V4:8), 
whilst unexplained, does suggest a significant dynamic range for ophthalmic acid in 
response to a stress stimulus. Overall, the data described here are supportive of further 
investigation of ophthalmic acid as a clinically applicable biomarker of chemical stress in 
larger volunteer cohorts. Subsequently, its qualification as a biomarker should be assessed 
in patients exposed to a known chemotoxic stimulus, such as APAP overdose.
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6. FINAL DISCUSSION
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6.1 Introduction
Today, public health is heavily dependent on the use of drugs for the cure and management 
of a wide array of health conditions. Ironically however, they may also pose threat to public 
health when administered incorrectly or due to an idiosyncratic reaction. Such threats can 
be a consequence of inadequacies in the research of a drug as further work is often 
hampered by the unavailability of appropriate tools as well as the complexity of the 
pharmacology of a drug.
Research tools that are able to accurately simulate the pharmacology of a drug in a 
human system would be highly advantageous for the investigation of the mechanistic basis 
of ADRs and as preclinical screening systems for the assessment of toxicological potential. 
As such, a great deal of research is in progress for the development of better model 
systems in an attempt to reduce the high attrition rate of new drug candidates. The work 
carried out during this PhD project was aimed at the identification of development of new 
model systems for investigating the consequences of chemical stress in the liver. The 
development of such model systems will allow the investigation of both the toxicological 
consequences of drug-induced stress and also the adaptive responses that have evolved 
within mammalian systems to provide defence against noxious chemical stimuli. Ultimately, 
a better understanding of these processes afforded by the use of these model systems 
should result in the identification of new biomarkers of value as preclinical tools or 
translational indices of chemical stress.
Two independent models were characterised: first, the use of a cell line expressing 
cytochrome P450 shown to generate oxidative stress, and secondly, a transgenic mouse 
model deficient in a major regulator of the stress defence response, Nrf2. In addition, the 
GSH analogue, ophthalmic acid, levels of which have been demonstrated to increase, in 
concurrent with GSH depletion, was assessed for its potential as an oxidative stress 
biomarker.
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6.2 Exploiting the cytochrome P450 enzyme family as models of chemical 
stress.
As detailed in chapter 1, the CYP450 enzyme family plays an important role during phase ! 
metabolism. Consequently, they are also responsible for the bioactivation and subsequent 
accumulation of reactive species that may overwhelm cellular defence system potentially 
leading to adverse drug reactions. Furthermore, polymorphisms in these enzymes may 
influence an individual's susceptibility to such reactions (Morgan et a!., 1984, Aivan et al., 
1990, Pirmohamed and Park, 2001, Nakamura, 2008). As such, exploitation of this enzyme 
family in understanding xenobiotic-induced stress has been well exercised through the 
employment of various methods such as the manipulation of CYP450 protein expression in 
both in vitro (Mace et al., 1998, Bull et ai, 2001, Dambach et al., 2005) and in vivo 
(Gonzalez, 2002, Cheung and Gonzalez, 2008) systems. The establishment of such systems 
have in turn been applied in drug metabolism studies as well as for understanding the 
biological consequences of altered protein expression, which in turn provides insight into 
the metabolic fate of a drug under these conditions.
Although the use of primary hepatocytes is the preferred method for studying 
drug-induced chemical stress, limitations of this model as detailed in chapter 1, particularly 
in its (rapid) loss of metabolic capacity soon after isolation impedes its practical use in 
research. As such, immortalised cell lines which have been manipulated to overexpress 
individual CYP450 isoforms have been adopted as surrogates of primary hepatocytes. Many 
such cell lines already exist (Dai et al., 1993, Bull et al., 2001) however, the THLE CYP450 
over-expressing cells are the first to be developed as a panel of cell lines originating from 
one parental source providing direct comparators for a given study (Pfeifer et al., 1993, 
Mace et al., 1998, Dambach et al., 2005). As part of this PhD project, the THLE-2E1 cell line 
was characterised and investigated for its utility as a model of chemical stress due to the 
CYP2E1 protein's metabolic role in the bioactivation of a number of clinically relevant 
drugs/compounds with APAP (Morgan et al., 1983, Raucy et al., 1989, Lee et al., 1996, 
Zaher et al., 1998, Manyike et al., 2000) and ethanol (Lieber et al., 1970, Koop et al., 1982, 
Ryan et al., 1986, Bradford et al., 2005) being well known examples, and due to the 
generation of ROS through its interaction with the CPR enzyme (Gorsky et al., 1984, 
Ekstrom and Ingelman-Sundberg, 1989, Dai etal., 1993, Mari and Cederbaum, 2000, Gong 
and Cederbaum, 2006).
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Work carried out in the THLE-2E1 cells demonstrated CYP2E1 overexpression that was 
comparable with an equivalent amount of cryopreserved primary human hepatocytes. 
Furthermore, this CYP2E1 protein over-expression correlated with a distinct CYP2E1 
metabolic activity that was assessed and demonstrated through the use of two well known 
CYP2E1 substrates, APAP and chlorzoxazone. As such, this demonstrates that from a 
metabolism point of view, the THLE-2E1 cells could be useful in metabolism studies of new 
and existing drugs. However, further validation of this utility would have to be carried out 
through full metabolic characterisation of other well established drugs known to be 
principally metabolised by the CYP2E1 enzyme.
The ability of CYP2E1 to produce high levels of ROS species due to its loose coupling 
with CPR has been reported in a number of model systems (Gorsky et ol.t 1984, Ekstrom 
and Ingelman-Sundberg, 1989, Dai et o/., 1993, Mari and Cederbaum, 2000, Gong and 
Cederbaum, 2006). Through the measurement of GSH where levels were elevated in 
untreated THLE-CYP2E1 cells compared with the THLE-Null, also demonstrated higher levels 
of oxidative stress in the THLE-CYP2E1 cells at least in comparison to the THLE-Null cells, 
indicating the potential role of the THLE-2E1 cell line as a model of oxidative stress. Further 
insight into the adaptation mechanisms employed by the THLE-2E1, which could potentially 
indicate adaptative mechanisms in the liver during oxidative stress, could be obtained 
through further research. In particular, the increased GSH level in these cells suggests a role 
of the transcription factor Nrf2, being a transcriptional regulator of GSH synthesis, in the 
adaptation of the THLE-2E1 cells to oxidative stress. Indeed this was demonstrated in 
another CYP2E1 overexpressing cell line, HepG2-2El where the authors associated this 
increase in GSH with Nrf2 up-regulation. This therefore opens the possible role of Nrf2 in 
adaptation to oxidative stress not just in the GSH synthetic pathway, but also in other 
pathways in which other cy to protective genes that it regulates are involved in. This could 
be further explored by measurement of Nrf2 levels in the THLE-2E1 cells versus the THLE- 
Null as well as target genes that Nrf2 has been reported to regulate. As GSH levels are 
clearly higher in the THLE-2E1 compared with the THLE-Nulls, measurement of GCL and GS 
protein and activity levels would be a good starting point for this further work.
Within the remit of the aims in this PhD project, the utility of the THLE-2E1 cell line may be 
limited to drug metabolism and basal oxidative stress studies, as chemical-induced toxicity 
was not detected under the experimental conditions used with APAP. This as discussed in 
chapter 2, could be a consequence of the adaptation of this cell line in response to higher 
levels of basal oxidative stress compared with the THLE-Nulls. The suggested role of Nrf2 in
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this adaptation in the previous paragraph based on higher GSH levels in the THLE-2E1 cells 
compared with the THLE-Null may also mean up-regulation of other cytoprotective genes 
such as GSTs (Itoh et ai, 1997, Hayes et aL, 2000, Reisman et oi, 2009d) and MRPs (Maher 
etal., 2005, Maher et ai, 2007). Various defence mechanisms may therefore be in play to 
defend basal and chemical-induced stress. As such, it would be difficult to study drug- 
toxicity in these cells particularly when defence systems may have already been up- 
regulated prior to treatment. Furthermore, although CYP2E1 activity was observed in the 
THLE-2E1 cells and not in the THLE-Nulls, this level of activity when compared with CYP2E1 
activity in primary human hepatocytes as reported by Lahoz (2007) does not demonstrate 
the same magnitude of increase in activity as has been reported in the other CYP450 
overexpressing THLE cell lines. As this is a comparison between two independent 
experiments from two independent laboratories, it would be ideal to carry out direct 
comparisons with regards to CYP450 activity in each of the CYP450 overexpressing cell 
lines, the THLE-Null cells and primary human hepatocytes to have a more accurate 
indication in the difference in CYP450 activities between these systems. However, based on 
this current comparison, although the THLE-2E1 may have a higher CYP2E1 activity when 
compared with what was reported by Lahoz (2007) in primary human heptocytes, this may 
not be sufficient to cause toxicity. Indeed, in normal APAP metabolism, only a small amount 
of the reactive metabolite NAPQI is produced, which is subsequently detoxified through 
GSH reaction. A certain amount of NAPQI is required for APAP-induced toxicity to take 
place, but this was not observed in our studies despite using a concentration of up to 25 
mM APAP, demonstrating that CYP2E1 activity in these cells are insufficient to produce 
enough NAPQI to cause toxicity. This, in addition to the potentially enhanced defence 
system in the THLE-2E1 cells impede the utility of this cell line for imvestigating chemical- 
induced liver toxicity. Furthermore, despite the convenience of immortalised cell lines such 
as the THLE-2E1, care should be exercised when using models such as this as their 
establishment as immortalised cells and manipulated systems no longer reflect the 
physiological characteristics of an intact liver.
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6.3 The role of Nrf2 in the GSH system: The utility of the Nrf2 knockout mouse 
as a model of chemical stress
As detailed in chapter 1, the regulatory role of Nrf2 in the basal and inducible transcription 
of a wide array of cytoprotective genes, including GCL, the enzyme responsible for the rate 
limiting step in GSH synthesis, brings Nrf2 to the forefront of cellular defence. As the GSH 
synthetic pathway is closely linked to several other metabolic pathways, referred to in this 
PhD project as the GSH system (chapter 1), the roie of Nrf2 within the GSH system was 
investigated in response to chemical-induced stress. In particular, treatment of Nrf2(+/+) and 
Nrf2('/') animals with three different dosing regimens of APAP was carried out and 
investigated for the role of Nrf2 on the GSH system. In brief, Nrf2(+/',', and Nrf2(‘A) mice were 
administered with either: 1) an acute sub-toxic dose of 350 mg/kg across a 5 h time point; 
2) escalating doses (0 - 600 mg/kg) over an 8 day period; or 3) escalating doses (0 - 600 
mg/kg) over an 8 day period followed by a toxic dose challenge of 1000 mg/kg on day 9. In 
parallel, serum ALT activity was also measured in these animals to determine toxicity and to 
elucidate whether correlations can be established between toxicity and perturbations 
within the GSH system as a result of APAP treatment and Nrf2 deletion.
The use of the Nrf2('/') mouse in various laboratories has revealed the importance of 
this transcription factor in cell defence. In particular, the enhanced susceptibility of this 
model to chemical stress in comparison to its wild type counterpart has been well 
established with a variety of chemical stress inducers as detailed in chapter 1 (Chan et ai, 
2001, Enomoto et al., 2001, Umemura et al.t 2006, Xu et ai, 2008, Jiang et ai, 2009). As 
such, the work carried out in this project was performed to elucidate whether this 
susceptibility was due to Nrf2 deletion, which may have in turn affected the GSH system. 
Indeed findings by our group are consistent with reports in the literature of a 20 - 30 % 
decrease in hepatic GSH in the Nrf2('/'1 animals basally (Kitteringham et ai, 2010). The aim 
was to explore this further by also measuring perturbations within the GSH system, in 
addition to the decrease already observed in the basal GSH content of the Nrf2('/', animals.
Interestingly, the acute APAP study indicated that up to a certain level of chemical 
stress, both strains responded in a similar manner as demonstrated by the level of serum 
ALT up to and including the 3 h time point (chapter 3, Figure 3.3) observed. However, at 5 
h, a distinct difference in response was observed as a further increase in serum ALT was 
observed in the IMrf2(/') APAP-treated animals but not in the wild type equivalents, when 
compared with their respective control groups. This suggests that the effect of Nrf2
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deletion is only apparent when a certain threshold of chemical stress is reached. This 
agrees with the corresponding GSH data where recovery of hepatic GSH back to basal levels 
was more apparent in the Nrf2(+/+) animals than in the equivalent Nrf2 nulls. The ability to 
up-reguiate GSH synthesis is therefore one factor that may have allowed the Nrf2(+/+} 
animals to attenuate further liver injury demonstrating the difference in response between 
the two strains.
Treatment with escalating doses of APAP (0 - 600 mg/kg) led to an increase in serum 
ALT in the Nrf2(^ animals whilst levels in the equivalent wild type remained comparable 
with their corresponding control further demonstrating the enhanced susceptibility of the 
Nrf2('A) animals to xenobiotic-induced stressed. It is interesting that although the dose 
range of APAP used during this treatment reached up to 600 mg/kg; a dose considered to 
be toxic to wild type animals when administered acutely, the wild type animals did not 
demonstrate toxicity in response to this treatment. Furthermore, although a marked 
increase in serum ALT was observed in the equivalent Nrf2(V') animals, the level of increase 
only indicated minimal hepatotoxicity. This demonstrates that although there is a distinct 
difference in response between the Nrf2(+/+) and Nrf2('/'> animals to this treatment with 
regards to serum ALT, both strains were to some degree able to attenuate toxicity. This 
difference also suggests a role of Nrf2 in protection from such treatment, however, the lack 
of significant changes in the metabolites monitored within the GSH system suggests that 
this role does not necessarily involve modulations within the GSH system. Instead, other 
mechanisms could also be in play that have afforded both the wild type and Nrf2{'A) animals 
protection from chronic APAP treatment, as will be discussed below.
Serum ALT and survival rate data for both Nrf2(+/+) and Nrf2('A) animals that were 
pretreated with saline or escalating doses of APAP and subsequently challenged with a toxic 
APAP dose (SA and AA groups respectively) further demonstrated the enhanced 
susceptibility of the Nrf2( A) animals to xenobiotic induced stress compared with the wild 
type. Interestingly, the AA group of both strains demonstrated a lower increase in serum 
ALT and better survival rate than the SA groups when compared with their respective 
controls. This suggests that paracetamol pretreatment afforded both strains protection 
against the toxic dose on day 9, the only difference being the Nrf2('A) animals were not able 
to afford the same level of protection as the wild type animals suggesting that this 
protection is in part Nrf2--mediated. However, similarities in response of both strains to the 
three treatment regimens with APAP indicate that Nrf2 is not the only factor involved in the 
attenuation and/or protection from xenobiotic-induced liver injury. Certainly with regards
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to the two chronic dosing regimens, other factors could be involved as demonstrated by 
Shayiq and colleagues (1999) whereby they investigated the effect of chronic APAP 
treatment to a toxic dose challenge in mice. In this study, they reported autoprotection 
afforded by the APAP-pretreated animals against a subsequent toxic dose. This they 
reported to be due to a down-regulation in CYP2E1 and CYP1A2 activities, an increase in 
cell proliferation and therefore damage repair and a shift in APAP bioactivation from 
centrilobular to periportal regions where CYP2E1 was not found and where GSH was more 
abundant. As such, in addition to the role of Nrf2 by up-regulation of cell defence, 
particularly in GSH synthesis as discussed below, other adaptive mechanisms as reported by 
Shayiq and co-workers may have also been employed by both strains which could explain 
why similarities in response have been observed.
Perturbations within the GSH system observed in both strains under the three 
treatment regimens were generally comparable. Significant changes were consistently 
observed in GSH, GSSG and ophthalmic acid levels suggesting that these metabolites are 
the main players within the GSH system that respond to APAP treatment, although the 
other pathways in their own right are also important in cell defence. Although comparable 
patterns in metabolite levels were observed between the Nrf2(+/+) and Nrf2(V') animals, a 
delay in both GSH and ophthalmic acid synthesis was evident in the Nrf2('A) animals 
suggesting that the role of Nrf2 within the GSH system is focussed on the GSH and 
ophthalmic acid synthetic pathways, which agrees with the role of Nrf2 as an important 
transcriptional regulator of GCL and GS, both of which are involved in GSH and ophthalmic 
acid synthesis. However, as Nrf2 is involved in the regulation of a vast number of cell 
defence genes in addition to GCL and GS, other pathways in which these cytoprotective 
genes are involved in may be modulated differently in the Nrf2(V'> animals in response to 
chemically-induced stress compared with the Nrf2l+/+). Further investigation in this area 
could therefore provide further insight into the role of Nrf2 in cell defence. Indeed, through 
a global proteomic approach, we have shown that in addition to cell defence proteins, 
those involved in the synthesis and metabolism of fatty acids and other lipids were 
markedly modulated in the liver of the Nrf2('/') mouse compared with its wild type 
counterpart (Kitteringham et al, 2010).
Therefore, in conclusion the Nrf2(/') mouse provides an excellent model for exploring 
the toxicological and physiological response to chemical stress, since there are clear 
differences in the susceptibility of these animals to APAP hepatotoxicity, both following an 
acute dose and chronic administration. The results suggest that the consequences of Nrf2
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deletion manifest at two levels: first, there is a constitutive loss of cellular defence, which is 
reflected by the enhanced sensitivity of the Nrf2(V‘) at early time points after APAP 
administration. Second, there is a clear evidence of an abrogated ability to initiate an 
adaptive up-regulation in cell defence, since at the later time points, the toxicological 
response is attenuated in Nrf2,+/+) mice compared with Nrf2(V"). The chronic studies do, 
however, indicate that Nrf2 is not the sole arbiter of toxicological sensitivity since both 
Nrf2{+/+) and Nrf2("A) mice showed markedly reduced sensitivity to APAP hepatotoxicity 
following a pre-conditioning treatment regime with increasing doses of APAP. Thus, the 
Nrf2('/') mouse model has great potential value for exploring the drug-induced chemical 
toxicity in the liver and other organs, but equally may provide a rich source of candidate 
biomarker for both preclinical and translational application.
6.4 Is there a need for new biomarkers?
At present, several biomarkers are already used in research and in the clinic. However, the 
drive for the discovery and development of new biomarkers should still be encouraged as 
current ones do not fulfil all the attributes of an ideal biomarker. For example, although 
serum ALT has been historically used as a marker of liver injury, elevated levels of this 
protein have also been reported in conditions where no histopathological evidence of liver 
damage was observed (Edgar et a!., 1998, Muller et al., 2000, Jackson et a/., 2008, Thulin et 
a!., 2008). As such, part of this PhD project was to investigate the GSH analogue, 
ophthalmic acid and its potential as a biomarker of oxidative stress.
Interest in ophthalmic acid has stemmed from findings by another group 
demonstrating significant elevations in liver and serum ophthalmic acid in parallel to a 
significant depletion in hepatic GSH in mice that were treated with either APAP, BSO or 
DEM (Soga et al., 2006). Based on these results, this group concluded that this increase was 
a consequence of a combination of GSH and cysteine depletion in response to chemical 
stress. Subsequently, this group proposed ophthalmic acid as a potential biomarker of GSH 
consumption hence oxidative stress. Such a role could prove advantageous in research and 
in the clinic given the importance of GSH in redox homeostasis, cell defence and in the 
limitations of GSH itself as an index of oxidative stress. As such and as mentioned above, 
the purpose of the work discussed here was to further investigate this proposed function of 
ophthalmic acid particularly in its transferability across in vitro and in vivo experimental
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systems. Furthermore, initial work was carried out, as described in chapter 5, to assess the 
potential of ophthalmic acid as a clinical biomarker as no amenable method of measuring 
hepatic GSH is currently available for clinical use.
Results from work carried out in chapter 4 on mice treated with APAP was in broad 
agreement with findings reported in the literature, as elevations in liver and serum 
ophthalmic acid were also observed in our study during which hepatic GSH levels 
decreased. Similar results were also observed in the Nrf2(+/+, and NrfZ^ animals that were 
investigated in chapter 3 indicating the consistent response of ophthalmic acid to APAP- 
induced stress. However, in contrast to the literature, the observed increase in liver and 
serum ophthalmic acid both in chapters 3 and 4 were later than the immediate decrease in 
hepatic GSH, suggesting that ophthalmic acid is not a direct marker of GSH consumption. As 
discussed in chapter 4, this may have been due to several factors, in particular diet, as an 
important influencing factor as both GSH and ophthalmic acid rely on methionine, an 
essential amino acid, as source for cysteine and 2-AB, precursors in GSH and ophthalmic 
acid syntheses respectively. Animals used in our study were given free access to food 
whilst Soga and colleagues (2006) used starved animals in their study. As such and 
considering the importance of diet in both GSH and ophthalmic acid syntheses, the 
differences in experimental approach employed by both groups may have also led to the 
difference in results observed. However, regardless of these differences, as our results 
demonstrated that ophthalmic acid levels can be influenced by other factors other than 
GSH depletion, it can be concluded that ophthalmic acid does not directly reflect GSH 
consumption.
In support of this conclusion, work carried out in rats treated with DEM demonstrated 
a dose-dependent decrease in hepatic GSH but no significant increase in ophthalmic acid. In 
vitro work on the mouse cell line Hepalclc treated with NAPQI as well as the human THLE- 
Null and THLE-2E1 cel! lines treated with APAP were also in agreement with this, as 
although GSH depletion was observed, no concurrent increase in ophthalmic acid took 
place. The disparity between the in vivo and in vitro results however could be due to 
intrinsic differences between the experimental models themselves. The increase in 
ophthalmic acid may rely on cell signalling between different cell types therefore limiting 
the use of cell lines in monitoring ophthalmic acid response to chemical stress. Ophthalmic 
acid could also be synthesised by a particular cell type therefore in vitro studies are 
dependent on identifying and using that particular cell type. Interestingly, the late increase 
in ophthalmic acid has been consistent with liver toxicity measured as an increase in serum
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ALT activity in vivo. This correlation is worth investigating further especially as the exact 
role of ophthalmic acid basally or during chemical stress is yet unknown. On other hand, as 
ophthalmic acid synthesis relies on the activity of GCL, it is possible that the trigger that 
leads to the up-regulation of ophthalmic acid synthesis is the availability of the precursor 
cysteine. As discussed in chapter 4, GCL has a higher affinity for cysteine than 2-AB 
therefore it is possible that cysteine depletion is the trigger for the up-regulation of 
ophthalmic acid and not GSH. This could be further investigated by repeating the 
experiments discussed in the section with the addition of monitoring for cysteine levels.
In parallel to the work described in chapter 4 where the utility of ophthalmic acid as a 
marker of oxidative stress in vivo and in vitro was investigated, work described in chapter 5 
was undertaken to further evaluate the breadth of utility of ophthalmic acid, in particular, 
for its potential use in a clinical setting. As such, preliminary work was carried out in 
chapter 5 where attempts were made to detect and quantify ophthalmic acid in the serum 
of healthy volunteers. The significance of this work is due to the fact that hepatic GSH in 
man is highly inaccessible. A marker that could directly indicate perturbation in the GSH 
content of the liver of an individual would therefore be an enormous advantage. 
Measurement of ophthalmic acid in serum was achieved only when using a highly sensitive 
mass spectrometer the QTRAP5500. Thus, whilst we have the capability to detect basal 
ophthalmic acid in human serum, a highly important factor in the development of a 
biomarker particularly for clinical use, this currently requires expensive, high specification 
instrumentation that will not be generally amenable. Serum ALT was used as a biomarker 
comparator in this study. From this, we have demonstrated that both ALT and ophthalmic 
acid are subject to intra- and inter-individual variation. Although only using a small cohort, 
this suggests that there will always be intrinsic intra- and inter-individual variability in 
ophthalmic acid level however, with regards to its development as a clinical biomarker, 
determination of a threshold that indicates its purpose is the key message, as determined 
for ALT using Hy's Law {Zimmerman, 1968, Zimmerman, 1978, Senior, 2009). Interestingly, 
one volunteer from whom only one ALT measurement was detected from all samples 
collected in the study also exhibited the highest level of ophthalmic acid in a different 
serum sample. This provides further support in the correlation previously observed 
between ophthalmic acid and ALT in chapter 5 and therefore merits further investigation.
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6.5 Conclusion and future directions
The work carried out in this PhD project aimed to contribute to the effort in developing 
model systems to facilitate better research in drug safety. The THLE-2E1 cell line, the 
Nrf2(/) mouse and the GSH analogue ophthalmic acid all in their own right have the 
potential as useful tools in the study of chemical stress. However, as demonstrated in this 
project, the development of a model system or biomarker that bears all attributes required 
to directly reflect the fate of a drug in the human body to allow accurate prediction of its 
efficacy and safety is still a major challenge. Furthermore, even with the existence of 
excellent models of a particular health condition for example, caution should be taken 
when extrapolating results in the laboratory to the clinic as these are isolated systems and 
are therefore under conditions that are different in the human body.
Whilst the studies performed during this project have confirmed that each of the 
models investigated has potential for use in the preclinical evaluation of chemical stress, 
none provide all the attributes needed to address all toxicological issues. Thus, further 
developmental work is required to both identify new models and to enhance the 
application of existing ones. The procedures established during this course of my studies 
should help to provide a framework for the future optimisation of both preclinical and 
translational models for investigating drug-induced toxicity.
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Appendix 1: The methionine cycle
S-adenosyl-methionine
Methionine S-adenosyl-homocysteine
(SAH)
Adenosine
Homocysteine
Adenosyl
homocysteinase
Methionine adenosyl 
transferase (MAT)
Methionine 
synthase (MS) or 
Betaine:homocytein 
e methyltransferase 
(BHMT)
TRANSSULFURATION
PATHWAY
Appendix 1. The methionine cycle. Methionine is an essential sulphur-containing amino acid that is 
required in a variety of fundamental biological processes, particularly during protein synthesis. The 
methionine cycle comprises both trans- and remethylation reactions. Through the catalytic activity 
of methionine adenosyl transferase (MAT), methionine is converted to the active S-adenosyl 
methionine (SAM) which is capable of donating its methyl group to an acceptor to produce S- 
adenosyl homocysteine (SAH). SAH is then hydrolysed to homocysteine and adenosine by SAH 
hydrolase. At this point, homocysteine may be remethylated back to methionine by methionine 
synthase (MS) and/or by betaine:homocysteine methyltransferase (BHMT), where the entire 
methionine cycle starts again. Alternatively, homocysteine may be utilised as the initial substrate 
that enters the transsulfuration pathway (Figure 1.8), providing the link to GSH synthesis.
162
Appendix
Appendix 2: The transsulfuration pathway
METHIONINE CYCLE
Cystathionine
P-synthase
Homocysteine
Serine
y-Cystathionase
a-a m i nobutyrate-pyruvate 
aminotransferase
Cystathionine 2-Ketobutyrate
Cysteine
i ]
CYSTEINE SULFINATE GSH SYNTHETIC
PATHWAY PATHWAY
OPHTHALMIC ACID 
PATHWAY
Appendix 2 The transsulfuration pathway. This is the major route of cysteine biosynthesis and is 
considered to be redox sensitive (Deplancke and Gaskins, 2002, Vitvitsky et a!., 2003, Banerjee 
and Zou, 2005). This pathway is initiated by a condensation reaction between homocysteine and 
serine to form cystathionine, catalysed by cystathionine p-synthase (CBS). Subsequent hydroxylation 
of cystathionine by y-cystathionase (y-Cys) leads to the production of cysteine and a-ketobutyrate. 
Cysteine may then be used as a substrate for GSH synthesis (Figure 1.5) amongst many other cellular 
activities in which it is involved (Jessop et al., 2004), whilst a-ketobutyrate is utilised for ophthalmic 
acid synthesis (Figure 1.11) (Cliffe and Waley, 1958, Cliffe and Waley, 1961). At excess quantities, 
cysteine may undergo a series of oxidation reactions to form taurine or inorganic sulphates (Figure 
1.10) (Stipanuk and Rotter, 1984, Bagley and Stipanuk, 1994, Bagley and Stipanuk, 1995, Bella and 
Stipanuk, 1995, Stipanuk, 2004, Stipanuk et al., 2004, Dominy et al., 2006).
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Appendix 4: The cysteine sulfinate pathway
TRANSSULFURATION
PATHWAY
▼
Cysteine
Cysteine dioxygenase 
(CDO)
Cysteine sulfinate
GSH SYNTHETIC 
PATHWAY
Cysteine sulfinate 
decarboxylase (CSD)
^r
Hypotaurine
▼
Taurine
Appendix 4. The cysteine sulfinate pathway. This is the primary source of taurine, through the 
oxidation of cysteine to cysteine sulfinate by cysteine dioxygenase (CDO) and the decarboxylation of 
cysteine sulfinate by cysteine sulfinate decarboxylase (CSD). This pathway depends upon the 
expression level and regulation of both CDO and CSD, as well as the availability of cysteine and 
methionine (Stipanuk and Rotter, 1984, Bagley and Stipanuk, 1994, Bagley and Stipanuk, 1995, Bella 
and Stipanuk, 1995, Stipanuk, 2004, Stipanuk et ai, 2004, Dominy et a!., 2006). Transport of taurine 
may also contribute to its intracellular concentration which may depend upon the expression level 
and regulation of a taurine transporter (TauT) as well as the extracellular concentration of this 
molecule. Taurine is present at high concentrations in the body (5 - 50 mM) and is implicated in a 
wide array of cytoprotective mechanisms including antioxidant effects, modulation of intracellular 
calcium level and ion channel activity as well as membrane and protein stabilisation (Geggel et al., 
1985, Rana and Sanders, 1986, Huxtable, 1992, Chen, 1993, Redmond etal., 1996, Wang etal., 1996, 
Waters etal., 2001, McCarty, 2004, Manna etal., 2008, Manna etal., 2009).
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